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Abstract 
Oral cancer in early stages (I and II) may be curable by surgery or radiation therapy 
alone but advanced stage disease (III and IV) has a relatively low survival rate. The 
pathogenic pathways that contribute to Oral Squamous Cell Carcinoma (OSCC) 
remain poorly characterised and the critical factor in the lack of prognostic 
improvement is that a significant proportion of cancers initially are asymptomatic 
lesions and are not diagnosed or treated until they reach an advanced stage. Hence, a 
clinically applicable gene expression signature is in high demand and improved 
characterization of the OSCC gene expression profile would constitute substantial 
progress. For OSCC, possible themes that might be addressed using microarray data 
include distinguishing the disease from normal at the molecular  level; determining 
whether specific biomarkers or profiles are predictive for tumour behaviour; and  
identifying  biologic pathways necessarily altered in tumourigenesis, potentially 
illuminating novel therapeutic targets. However, OSCC is a heterogeneous disease, 
making diagnostic biomarker development difficult. Although this phenotypic 
variation is striking when one compares OSCC from different geographic locales, 
little is known about the underpinning biological mechanisms. 
Cancer may be accompanied by the production and release of a substantial number of 
proteins, metabolites and/or hormones into the blood, saliva, and other body fluids 
that could also serve as useful markers for assessing prognosis, metastasis, 
monitoring treatment, and detecting malignant disease at an early stage.  
The primary aim of this thesis is to investigate metabolomic and transcriptomic 
profiles using multiple bioinformatics approaches and biological annotation tools in 
an attempt to identify specific biomarkers and prediction models for OSCC from 
each profile as well as from the interface outcomes of integrating the two platforms. 
Additional aims of the thesis go further to identify the mechanisms underlying the 
biological changes during tumorigenic transformation of OSCC, as well as to 
determine biological processes underpinning the heterogeneity of the disease among 
populations.  
 
  xx 
Two review studies were carried out in this thesis. The review study of published 
transcriptomic profiles of OSCC specified several genes and pathways exhibiting 
substantially altered expression in cancerous versus noncancerous states across 
studies. However, the result of the review suggests not relying on the final set of 
genes published by the individual studies, but to access the raw data of each study 
and start subsequent analysis from that stage using unified bioinformatics approaches 
to acquire useful and complete understanding of the systems biology. The other 
review study focused on the metabolic profiles of OSCC and revealed a systemic 
metabolic response to cancer, which bears great potential for biomarker development 
and diagnosis of oral cancer. However, the metabolic signature still needs to improve 
specificity for OSCC from other types of cancer. 
In an attempt to detect a robust gene signature of OSCC overcoming the limitation of 
the transcriptomic review in accessing the raw data from the previous works, four 
public microarray raw datasets (comprising 365 tumour and normal samples) of 
OSCC were successfully integrated using ComBat data integration method in R 
software, determining the common set of genes, biomarkers, and the relative 
regulatory pathways possibly accountable for tumour transformation and growth in 
OSCC. Examination of the meta-analysis datasets showed several discriminating 
gene expression signatures for OSCC relative to normal oral mucosa; with a 
signature of 8 genes (MMP1, LAMC2, PTHLH, TPBG, GPD1L, MAL, 
TMPRSS11B, and SLC27A6) exhibiting the best discriminating performance and 
show potential as a diagnostic biomarker set. In addition, 32 biomarkers specific to 
OSCC and HNSCC were identified with the majority involved in extracellular matrix 
(ECM), interleukins, and peptidase activity where around 2/3 of them are located in 
the extracellular space and plasma membrane. 
Additionally, investigation of the interactive network created by merging metabolic 
and transcriptomic profiles highlighted the significant molecular and cellular 
biofunctions, pathways, and biomarkers distinguishing OSCC from normal oral 
mucosa. The results highlighted interactions of significantly altered expression of D-
glucose, ethanol, glutathione, GABA, taurine, choline, creatinine, and pyruvate 
metabolites with the expressed PTGS2, IL1B, IL8, IL6, MMP1, MMP3, MMP9, 
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SERPINE1, COL1A1, COL4A1, LAMC2, POSTN, ADAM12, CDKN2A, PDPN, 
TGM3, SPINK5, TIMP4, KRT19, and CRYAB biomarkers of OSCC. Such a pattern 
may represent a clinically useful surrogate for the presence of OSCC which might 
help in deciphering some of the obscure multifaceted mechanisms underlying 
carcinogenesis of OSCC which emerged from dysregulated genetic and metabolic 
system of the body.       
In an attempt to define pathways of importance in two phenotypically different forms 
of OSCC, transcriptomic analysis of OSCC from UK and Sri Lankan patients was 
undertaken. The development of OSCCs in UK and Sri Lankan populations appears 
largely mediated by similar biological pathways despite the differences related to 
race, ethnicity, lifestyle, and/or exposure to environmental carcinogens. However, 
results revealed a highly activated “Cell-mediated Immune Response” in Sri Lankan 
tumour and normal samples relative to UK cohorts which may reflects a role in 
resistance of patients to invasiveness, metastasis, and mortality observed in Sri 
Lankan relative to UK patients. 
In conclusion, multiple molecular profiles were able to identify a unique 
transcriptomic profile for OSCC and could further discriminate the tumour from 
normal oral mucosa on the basis of 8 genes. Altered expression of several metabolic 
and transcriptomic biomarkers specific for OSCC were identified, along with several 
dysregulated pathways and molecular processes found common in patient with oral 
cancer. Integrating both metabolomic and transcriptomic signatures revealed a 
promising strategy in analysing the concurrent perturbation in both genetic and 
metabolic systems of the body. Additional results revealed possible impact of 
specific supplementary dietary components in boosting the immune system of the 
body against invasion, progression, and metastasis of the disease. Further clinical 
studies are required to confirm and validate the current results. 
 
  Chapter 1 
1 
 
Chapter 1: Introduction 
1.1 Oral cancer: Disease and diagnosis 
Oral squamous cell carcinoma (OSCC) is a sub-site of HNSCC. Tumour of the oral 
cavity consists 30% of all head and neck cancers. It includes carcinoma arising from 
the soft mucosal lining of the lips and all intra-oral sites corresponding to the ICD9 
codes 140 (lip), 141 (tongue), 143 (gum), 144 (floor of mouth) and 145 (other non-
specific sites), but excludes sites 142 (major salivary glands), 146 (oropharynx), 147 
(nasopharynx), 148 (hypopharynx) and 149 (ill-defined oral/oropharynx) (Who, 
1995). Approximately 90% of oral cancers are primary squamous cell carcinomas 
arising from the lining mucosa of the mouth, most commonly the tongue and the 
floor of the mouth (Severino et al., 2008). Tongue cancer is the most frequently 
reported in the oral cavity with no strong barrier to stop the tumour from spreading. 
In addition, comparing to another head and neck anatomic sites, the vascular and 
lymphatic systems of the tongue are well-developed and thus, the rate of cervical 
lymph node metastasis is high (Ho et al., 1992, Lopes, 2007). 
Early stage (I and II) oral cancer may be curable by surgery or radiation therapy 
alone but advanced cancers (stage III and IV) are generally treated by surgery 
followed by radiation therapy (Harrison et al., 1999). Using multimodal protocols 
that combine surgery with pre-operative or post-operative radiotherapy and/or 
adjuvant chemotherapy, the 2-year and 5-year survival rates for advanced cancers 
were as low as 20% and 12%, respectively (Reichard et al., 1993). The survival of 
progressive–stage patients rarely exceed 30 months, even for those that initially 
achieve complete clinical remission (Hill and Price, 1994). 
A critical factor in the lack of prognostic improvement is that significant proportions 
of cancers initially are asymptomatic lesions and are not diagnosed or treated until 
they reach an advanced stage. Early detection of cancer is the most effective means 
to reduce death from this disease. 
While oral cancer is quite often discovered in a patient during dental treatment, no 
specific tumour markers that enable the effective and simple detection and diagnosis 
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of oral cancer are available. In many cases of suspected cancer, a prompt diagnosis at 
the primary medical institution is not made, and patients are referred for examination 
to specialists only after the disease has developed to an advanced stage. The result of 
this delay in diagnosis is a missed opportunity for early treatment that forces the 
patient to undergo extended treatment (Katakura et al., 2007). 
The World Health Organization has clearly identified prevention and preliminary 
detection as major objectives in the control of oral cancer burden worldwide. 
Currently, screening of oral cancer and its pre-invasive intra-epithelial stages, as well 
as its early detection, is still largely based on visual examination of the mouth. A 
strong available evidence suggest that sight inspection of the oral mucosa is effective 
in reducing mortality from oral cancer in individuals exposed to risk factors (Fedele, 
2009). 
Simple visual examination, however, is limited by subjective interpretation and by 
the potential, albeit rare, occurrence of dysplasia and early OSCC within areas of 
normal-looking oral mucosa. As a consequence, adjunctive techniques have been 
suggested to increase ability to differentiate between benign abnormalities and 
dysplastic/malignant changes as well as to identify areas of dysplasia/preliminary 
OSCC invisible to naked eye. These include exfoliative cytology, the use of toluidine 
blue, brush biopsy, chemiluminescence and tissue auto fluorescence (Fedele, 2009). 
However, intrinsic differences in the optical properties of tissue can be due to 
changes in absorbance(Piazza et al., 2008) , scatter (Sharwani et al., 2006), or 
fluorescence (Fedele, 2009), (Roblyer et al., 2008, Pavlova et al., 2008, Schwarz et 
al., 2008, Mallia et al., 2008), and these changes can result from inflammation, 
increased cellularity, alter cellular anatomy (e.g., cell shape and nuclear volume), 
appearance of stromal, and biochemical differences associated with cellular 
proliferation and tissue reorganization. Even in auto fluorescence screening method, 
imaging tools based on tissue auto fluorescence cannot reveal the molecular basis of 
neoplasia with the specificity needed for guiding molecularly targeted drug 
interventions (Kelloff et al., 2009). Saliva containing exfoliated cells combined with 
cytospin may be a good approach; however, no specific marker can be used 
universally for the detection of oral cancer (Kao et al., 2009). 
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Histopathological examination itself shows weak points in cancer detection and 
classification, which require searching for more subtle and accurate method for early 
detection and stage evaluation of oral cancer. The anticipated biologic behaviour of 
squamous cell carcinoma of the head and neck region has been traditionally 
estimated by a qualitative system of grading initiated by Broders (Broders, 1926), 
based on the extent to which the neoplasm resembles the tissue of origin. Now, 
additional parameters, such as nuclear pleomorphism and the number of mitosis, 
enter this subjective determination of differentiation. This classification is usually 
simplified into three categories: poorly differentiated, moderately differentiated, and 
well-differentiated tumours. The association between the preceding classification and 
prognosis has proven little significance in squamous cell carcinoma of the head and 
neck region. A semi quantitative assessment of several histologic parameters would 
render a higher point value than would result from the degree of differentiation alone 
(Anneroth et al., 1987, Bryne et al., 1989). Leemans group have shown that about 
15% to 30% of stage III and IV patients with histopathologically tumour-free 
resection margins have recurrence (Leemans et al., 1994). The results of Chen group 
demonstrated that differentiation, invasion depth, perineural invasion, and lymph 
vascular permeation significantly affect nodal metastasis in tongue cancer. Therefore, 
patients in early stages I or II with such pathologic covariates may need more 
appropriate early neck treatment (Chen et al., 2008b). Moreover, the invasive nature 
of a biopsy makes histopathology unsuitable for cancer screening in high-risk 
populations (Li et al., 2004a). 
Given the recent progress in the field of molecular biology, the potential exists for 
finding molecular markers that aid in the early diagnosis and the prediction of 
prognosis. However, because of the diversity of anatomic sites, as well as genetic, 
ethnic, and geographic factors, it is unlikely that any universal biological marker will 
be appointed for squamous cell carcinoma of the head and neck region (Rose et al., 
2000). Exploration will be more efficient and successful if appropriate rules of 
evidence are applied to direct that exploration and determine when results can 
support strong claims and high expectations (Ransohoff, 2005). 
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1.2 Oral cancer pathology (development and 
metastasis) 
Oral cancer is considered the result of a multi-hit process, which involves a number 
of aberrant genetic events. Multiple oncogenes, regulatory factors, and tumour 
suppressor genes play a key role in the development and progression of this cancer 
(Vora et al., 2003). Deregulation of many genes like oncogenes and tumour 
suppressor genes has been associated with oral carcinogenesis (Spandidos et al., 
1985). The exact affected nature of each molecule in oral carcinogenesis remains 
largely elusive (Tsai et al., 2004).    
Some genetic alterations can be detected in tissue that appears normal by histological 
assessment (Jonason et al., 1996, Deng et al., 1996). Conversely extensive genetic 
changes can be seen at premalignant stages of human tumour development in many 
tissues (Rehman et al., 1994, Gong et al., 2001, Shaaban et al., 2002). The crucial 
determinant of progression may be the accumulation of specific combinations of 
genetic alterations or the occurrence of the mutations in a particular subset of target 
cells that has higher propensity for malignant progression (Brown et al., 1998).  
Metastasis is the process by which cancers spread to distinct sites in the body. It is 
the principal cause of death in individuals suffering from cancer. For some types of 
cancer, early detection of metastasis at lymph nodes close to the site of the primary 
tumour is pivotal for appropriate treatment. Because it can be difficult to detect 
lymph node metastases reliably, many individuals currently receive inappropriate 
treatment (Roepman et al., 2005). Improving our understanding of cancer and 
developing theoretical models will require an increased knowledge of the 
contributions of and interactions between the numerous components contributed to 
tumour formation and progression (Figure 1.1). 
 




Figure 1.1: Numerous components must be integrated to study the molecular basis of 
human cancer 
Several host factors contribute to tumourigenesis in humans, including diet, environmental factors, 
polymorphisms and mutations in susceptibility genes, age and immunity. Cells undergo genomic 
changes (DNA mutations and repair, methylation, amplification, deletions and rearrangements), 
leading to tumourigenesis. Tumour development also depends on factors in the microenvironment — 
some of these are produced locally, whereas others are produced systemically (growth factors, 
infiltrating cells and cytokines). Reciprocal interactions between the premalignant and malignant cells, 
stromal cells, extracellular-matrix components, various inflammatory cells and a range of soluble 
mediators therefore contribute to tumour development and progression. Once tumour samples are 
obtained, genomic, transcriptomic and proteomic tools can be used to profile specific compartments 
(Adapted from Samir Hanash 2004). 
 
DNA microarray gene expression profiling can detect lymph node metastases for 
primary head and neck squamous cell carcinomas that arise in the oral cavity and 
oropharynx (Roepman et al., 2005). Regional lymph node metastasis is an important 
prognostic factor in head and neck squamous cell carcinoma (HNSCC) and plays a 
decisive role in the choice of  treatment (Hensen et al., 2008). 
A study showed that pathways differentially expressed between metastasized and 
non-metastasized HNSCC are involved in the processes of  extracellular matrix 
remodelling, hypoxia and angiogenesis (Hensen et al., 2008). 
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Focusing on pathways and functional gene sets instead of individual probes in the 
analysis of microarray data making biological context of the results more 
interpretable. Furthermore, a supervised pathway-based analysis reduces multiple 
testing problems associated with microarray analysis by focusing on a limited 
number of pathways instead of analysing all the probes available on the microarray. 
The comparability of results from distinct microarray studies is greatly improved. A 
supervised, pathway based analysis can reveal biologically relevant similarity 
between results of various gene-expression studies, even if studies have used distinct  
microarray platforms with different probes and probe content, where the insight into 
the biological steps that lead from normal and dysplastic tissue to carcinogenesis in 
OSCC and HNSCC is improved (Hensen et al., 2008). 
Furthermore, removal of the probes that are not relevant to the biological processes 
of interest reduces the statistical noise and multiple testing problems associated with 
microarray analysis. The significant advantage of this strategy is increased 
comparability of data from different microarray studies. Microarray analysis based 
on individual genes is highly dependent on the exact gene content of the employed 
microarray in the study and thus on the chosen microarray platform. In a pathway-
based analysis, gene expression does not have to be measured from every single gene 
involved in a particular pathway, as long as a representative subset of genes is 
assessed. These illustrative subsets of genes involved in a specific pathway may vary 
between studies. A pathway-based analysis thus can reveal biologically relevant 
similarity between results of different microarray studies even though the gene 
contents of the used microarray platforms do not match exactly (Hensen et al., 2008). 
 
1.3 Aetiology and risk factors of oral cancer 
Tobacco consumption in all its forms is the common worldwide aetiological risk 
factor for the development of oral cancer (Blot et al., 1988, Morse et al., 2007, 
Lambert et al., 2011). In developing countries the use of tobacco and/or areca (betel) 
nut produces chronic potentially malignant lesions (leukoplakia, erythroplakia and 
submucous fibrosis) from which most oral cancers arise. The use of tobacco chewing 
products combined with areca nut, betel leaf palm and lime is a strong cultural 
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tradition in south India and Sri Lanka. This combination leads to the production of a 
potent mix of carcinogens as well as mild stimulant substances (Muir and Kirk, 
1960). The mixture is formed into a small pouch or “betel quid” and is held in the 
cheek area of the mouth from where it is slowly absorbed. Conversely, in western 
developed countries, oral cancers are recognized in only a minority of cases and the 
majority of lesions developed from clinically normal mucosa. Furthermore, these 
lesions are more aggressive and followed by a poorer prognosis than those derived 
from an area of tobacco induced leukoplakia (Lopes, 2007). 
In the Western world cigarette smoking is accountable for most tobacco related oral 
cancers. Strength of tobacco usage is directly related to the risk of developing OSCC 
(La Vecchia et al., 2004). Alcohol is another significant risk factor influencing 
development of OSCC and acts synergistically with tobacco. Heavy drinkers and 
heavy smokers have a 24 fold risk of developing OSCC than non-drinkers and non-
smokers (McCoy and Wynder, 1979). Dietary deficiencies or imbalances considered 
as additional risk factor which can contributed to approximately 15% of OSCC 
(LaVecchia et al., 1997), particularly β-Carotene and vitamin E deficiency as well as 
diets with high nitrites and nitrosamines which reported to increase the lifetime risk 
of developing OSCC. 
Many viruses have been aetiologically linked with OSCC including, retroviruses, 
adenoviruses, Epstein-Barr virus (EBV), Herpes Simplex virus and Human 
Papillomavirus (HPV). The role of EBV and HPV in OSCC has convincing evidence 
(Cruz et al., 2000, Ha and Califano, 2004, Syrjanen, 2005). 
A small genetic risk associated with OSCC was also reported with first degree 
relatives of persons with OSCC have a 3.8 fold risk for developing the same disease 
(Foulkes et al., 1996). 
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1.4 Multiplicity of gene expression in human 
According to Darwin's mechanism, cancer is a consequence of continuous, gradual, 
and accidental acquirement of the changes in the population of pre-malignant 
individual cells of genomes. These gradual modifications progressively change the 
phenotype of the normal cells making them more malignant through loss of their 
overall stability of genome.  
Cancers of diverse organ and tissue systems are regularly considered as different 
diseases because of the pragmatic dissimilarities in their cell phenotypes and specific 
prognoses. However, the differences between two types of tumours might be 
explained by the underlying differences in the tissues of their respective origins. 
Each normal human tissue has a discrete gene expression pattern from other tissue 
type, with an exception of constitutively expressing housekeeping genes shared 
between all the tissues (Patti et al., 2003). Further reports revealed that even the 
housekeeping genes are not necessarily expressed at the same level across all tissues; 
rather, each tissue seems to have a specific expression profile of housekeeping genes. 
In fact, housekeeping genes are less compact and developed than tissue-specific 
genes, and they evolve more slowly for both coding and core promoter sequences 
(Zhang and Li, 2004). 
Generally, the unique patterns of gene expression in numerous tissue types are 
elucidated by the dissimilarities in the functions of the resulting proteins in a specific 
tissue. Furthermore, alternative splicing of many human genes resulted in multiple 
expression of mRNA transcripts with different sets of exons joined together (Modrek 
and Lee, 2002). A wide variation in the alternative transcript expression patterns 
across tissues of human body was reported  (Landry and Mager, 2002, Yeo et al., 
2004), though their mechanism remains poorly understood (Matlin et al., 2005, Singh 
and Valcarcel, 2005). 
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1.5 Tumour heterogeneity of the oral cavity 
Oral cancer has a wide heterogeneity in the biological behaviour, however few 
biological indicators are available to help understanding such patterns of behaviour 
(Williams, 2000, Woolgar, 2006). Considering tumour heterogeneity in and between 
patients is required in selecting and interpreting biomarkers to optimize personalized 
cancer therapy for head and neck cancer patients (Williams, 2010). 
OSCC in patients from UK has been described as highly aggressive and 
metastasising, with early recurrence (less than 12 months) and poor survival. 
However, a less invasive, non-metastasising form of OSCC is also seen with a better 
survival. Sri Lankan OSCC is similar to the less aggressive UK phenotype and is 
exophytic (outward growing) in its growth pattern unlike that in UK, which shows 
endophytic (inward growing) and invasive behaviour (Lopes, 2007).  
1.5.1 Oral cancer in the UK and western countries 
The incidence of OSCC in England, Europe, and Scandinavia is reported rising 
(Bonifazi et al., 2011) especially amongst young women; a population not previously 
associated with a high incidence of OSCC. In general, UK OSCC behaves as an 
aggressive, endophytic and deeply invasive tumour that frequently metastasizes to the 
loco-regional lymph nodes in the neck but rarely to distant organs (Lopes, 2007). 
1.5.2 Oral cancer in Sri Lanka and Indo-Asian sub-continent 
Oral cancer behaves very differently in patients from the Indo-Asian sub-continent 
and is typified by that seen in Sri Lanka. Oral cancer is the most common cancer in 
Sri Lanka (Moore et al., 2010, Moore et al., 2000). In Sri Lanka, oral cancer is 
[aetiologically] associated with chewing the Betel leaf quid containing Areca nut 
(Muir and Kirk, 1960, Ranasinghe et al., 1993). Such cancers are phenotypically 
different from those seen in Western countries and clinically display an exophytic 
“cauliflower” appearance. The clinically significant feature of OSCC in Sri Lanka that 
it infrequently metastasizes to the loco-regional lymph nodes of the neck and so most 
patients do not undergo the procedure of neck dissection (Wardbooth et al., 1982) and 
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so it is suggested that OSCC in Sri Lanka is less aggressive than that seen in Western 
countries including the UK (Lopes, 2007). 
1.6 Cancer as a metabolic disease 
Emerging evidences indicate that impaired cellular energy metabolism is the defining 
characteristic of nearly all cancers regardless of cellular or tissue origin. In contrast 
to normal cells, which derive most their usable energy from oxidative 
phosphorylation, most cancer cells become heavily dependent on substrate level 
phosphorylation to meet energy demands. Reviewed evidence supporting a general 
hypothesis that genomic instability and essentially all hallmarks of cancer, including 
aerobic glycolysis (Warburg effect), can be linked to impaired mitochondrial 
function and energy metabolism (Seyfried and Shelton, 2010). 
According to Warburg (Warburg, 1956), modifications of respiratory machinery 
should result in compensatory increase in glycolytic ATP production leading to 
carcinogenesis. In fact, malignant cells meet their energy (ATP) requirements by 
glycolysis rather than through oxidative phosphorylation, possibly an adaptation to 
hypoxia development during growing of tumour (Assaily and Benchimol, 2006). 
Mitochondrial mutations may contribute to the development of a malignant 
phenotype by direct effects from increased reactive oxygen species production as 
well as induction of aerobic glycolysis and growth promotion (Zhou et al., 2007). 
While normal mitochondrial function can reduce tumourigenesis, various studies 
show that tumour mitochondria are structurally and functionally abnormal and 
unable to generate normal levels of energy (Seyfried and Shelton, 2010). 
As retrograde (RTG) response is “off” in healthy cells with normal mitochondrial 
function, It turned “on” following impairment in mitochondrial energy production  
where transcription and signalling commences for multiple energy and anti-apoptotic 
related genes and proteins to include MYC, TOR, p53, RAS, CREB, NFκB, and 
CHOP (Wolfman et al., 2006, Kulawiec et al., 2009, Kulawiec et al., 2008, Singh et 
al., 2005, Miceli and Jazwinski, 2005, Butow and Avadhani, 2004). The RTG 
response also takes a part in the participation of multiple negative and positive 
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regulators, which facilitate the bioenergetics’ transition from respiration to substrate 
level Phosphorylation (Butow and Avadhani, 2004). Most cancer types are similar in 
expressing mitochondrial dysfunction and elevated substrate level Phosphorylation. 
When loss of respiration leads to glycolysis, dedifferentiation, and unbridled 
proliferation (Szentgyorgyi, 1977), it is expected that presence of normal 
mitochondria in tumour cells would restore the cellular redox status, turn off the 
RTG response, and reduce or eliminate the need for glycolysis (Warburg effect) and 
glutaminolysis to maintain viability. Basically, normal mitochondrial function would 
facilitate expression of the differentiated state thereby suppressing the tumorigenic or 
undifferentiated state (Seyfried and Shelton, 2010). 
Moreover, mitochondria and mitochondrial functions are reported to be involved in 
apoptotic cell death (Jacobson et al., 1994, Nguyen et al., 1993, Hockenbery et al., 
1990, Hennet et al., 1993, Newmeyer et al., 1994, Schulzeosthoff et al., 1992). 
Recent studies suggested mitochondrial function may play a substantial role during 
the commitment of cells undergoing apoptosis (Heerdt et al., 1997, Krippner et al., 
1996, Liu et al., 1996, Zhang et al., 1996, Marchetti et al., 1996, Zamzami et al., 
1996, Vayssiere et al., 1994, Hennet et al., 1993, Schulzeosthoff et al., 1992).  
Alternative oxidations of fatty acids, ketone bodies, short-chain carboxylic acids, 
propionate, acetate and butyrate in tumour cells may contribute to ATP supply by 
oxidative phosphorylation (OXPHOS)(Ralph et al., 2010). Tumour cells maintain a 
significant level of OXPHOS capacity to rapidly switch from glycolysis to OXPHOS 
during carcinogenesis. The more realistic theory considers that OXPHOS and 
glycolysis cooperate to enhance energy demands along tumourigenesis (SmolkovÃ¡ 
et al., 2011). 
According to previous studies, glycolysis appeared a feature of several tumours 
associated with faster growth in high glucose environment; however, active 
OXPHOS is also a significant  feature of other tumours occurred at a particular stage 
of carcinogenesis which might be more beneficial than a “glycolysis-only” type of 
metabolism in conditions of intermittent shortage in glucose supply. In addition, the 
metabolism of cancer cells is not constant during carcinogenesis and might depend 
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on both the activated oncogenes and the tumour cell microenvironment (Jose et al., 
2011). Moreover, several studies concluded aerobic glycolysis as a consequence of 
hypoxia rather inherent to cancer (Zu and Guppy, 2004).  
In fact, recent studies considered Mitochondria as therapeutic targets for cancer 
chemotherapy had been suggested combined strategies involving modulation of both 
glycolytic and mitochondrial pathways which might be required for more efficient 
elimination of malignant cells (Rodriguez-Enriquez et al., 2009, Galluzzi et al., 
2006). As tumour cells shift among different patterns of energy metabolism 
(Pedersen, 1978, SmolkovÃ¡ et al., 2011, Nadege et al., 2009, Rodriguez-Enriquez et 
al., 2009), variant pharmacological trials could provide drug specificity through 
variable interference with distinctive steps of cancer energy production pathways.  
Furthermore, any unspecific condition that damages cell’s oxidative phosphorylation, 
but not severe enough to induce apoptosis, can potentially initiate a path to malignant 
tumour. Impaired mitochondrial function can also induce abnormalities in tumour 
suppressor genes and oncogenes. The accumulation of mitochondrial damage over 
time is what ultimately leads to malignant tumour formation.  An increased 
dependency on substrate level Phosphorylation for survival would follow each round 
of metabolic and genetic damage thus initiating uncontrolled cell growth and 
eventual formation of a malignant neoplasm. Basically, the well-documented 
tumour-associated abnormalities in oncogenes, tumour suppressor genes, and 
chromosomal imbalances can arise as a consequence of the progressive impairment 
of mitochondrial function (Seyfried and Shelton, 2010). 
Considering tumour heterogeneity, several reports suggested that distinct OSCC sub-
sites varied on their glycolytic phenotype. Genes related to KEGG Oxidative 
Phosphorylation Pathway, GO (Gene Ontology, www.geneontology.org/) term, 
Organelle ATP Synthesis Coupled Electron Transport, several cytochrome oxidases 
and ATPases showed differences in expression when sub-sites were compared 
(Severino et al., 2008). 
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1.7 Biomarkers as diagnostic tool for HNSCC and 
OSCC 
Biomarkers are defined as biological molecules that; correlate with the presence or 
absence of a disease state; prognostic correlating with a disease course; predictive of 
a tumour’s response to a specific therapy (Williams, 2010). Global approaches for 
tumour assessment via DNA and gene expression microarrays have provided new 
information into altered molecules and pathways for further investigations in 
squamous cell carcinoma; though remain limited in their benefit for individual 
tumour assessment as a biomarker (Williams, 2000). 
In an era in which health economics will dictate the availability of new and 
expensive agents, robust biomarkers for dose, schedule, and patient selection must 
remain as important priority (Banerji et al., 2008). Recent progressions in basic 
research of molecular biology have developed the understanding of the molecular 
process of HNSCC development and resulted in identification and classification of 
numerous biomarkers. Biomarkers of HNSCC are expected to help the early 
detection of primary and relapsed tumours (Lee et al., 2011). 
A distinct pattern of gene expression, with progressive up- or down-regulation of 
expression, is frequently reported during the progression from histologically normal 
tissue to primary carcinoma and to nodal metastasis (Belbin et al., 2005, Roepman 
and Holstege, 2005, Roepman et al., 2006, Roepman et al., 2005, Odani et al., 2006, 
Yan et al., 2008), whilst alternatively expressed genes are potentially useful 
biomarkers for the prediction of malignant transformation (Odani et al., 2006). 
HNSCC comprise a wide spectrum of heterogeneous neoplasms for which 
biomarkers are needed to aid in earlier diagnosis, risk assessment, and therapeutic 
response. The search for biomarkers includes evaluation of tumour tissues and 
surrogate materials by molecular, genomic and phenotypic means. Ideal biomarkers 
should be accurate and easy to perform, highly specific, objective, quantitative, and 
cost effective. Because of the heterogeneity of head and neck tumours, the 
integration of multiple selected markers in association with the histopathological 
features is supported for risk assessment (Williams, 2010). 
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Circulating mRNA biomarkers in serum or plasma have been targets for reverse 
transcription-PCR (RT-PCR)-based detection strategies in patients with cancers 
(Kopreski et al., 2001, Bunn, 2003). Parallel to the increasing number of such 
biomarkers in human body fluids, is the growing availability of technologies with 
more powerful and cost-efficient methods that enable mass screening for genetic 
alterations. Recent discovery by microarray technology revealed a large panel of 
human mRNA exists in saliva (Li et al., 2004b) suggesting a novel clinical approach, 
salivary transcriptome, for diagnostic applications of the disease and normal health 
surveillance. 
Overexpression of EGFR in HNSCC has been associated with poorer overall survival 
and recurrence, while up to 90% of HNSCC patients express EGFR (Kalyankrishna 
and Grandis, 2006, Psyrri et al., 2005, Ang et al., 2002, Grandis et al., 1998). With 
implication of elevated EGFR in poor prognosis, it was one of the first biomarkers 
targeted as a potential therapy for HNSCC. Cetuximab, a monoclonal antibody 
directed against the extracellular receptor domain of EGFR, blocks ligand binding 
and subsequent downstream signalling, in addition to its role in the long-term 
downregulation of the receptor expression (Sunada et al., 1986, Jaramillo et al., 
2006, Prewett et al., 1996, Mendelsohn, 1997, Lilenbaum, 2006). It has been the 
most effective targeted therapy applied to HNSCC to date (Yavrouian and Sinha, 
2012). 
1.8 Metabolomics as tumour biomarkers 
Recent years, tumour metabolome is beginning to be characterized. Using
 
standard 
metabolomic methods, tumours display elevated
 
phospholipids' levels. Characterized 
by an elevation of total
 
choline-containing compounds (tCho) and Phosphocholine), 
increased
 
glycolytic capacity, including increased utilization of glucose
 
carbons to 
drive synthetic processes, high glutaminolytic function,
 
and over-expression of the 
glycolytic isoenzyme, pyruvate kinase
 
type M2 (Glunde and Serkova, 2006, Mazurek 
and Eigenbrodt, 2003, Ackerstaff et al., 2003).  
Interestingly, lipid metabolic
 
profiles have been documented 83% accurate at 
discriminating
 
between cancer patients and controls, using NMR-based 





of blood samples (Bathen et al., 2000). Importantly, in vivo, tCho 
determination
 
via MRSI has detected breast, prostate, and brain tumours and
 
correlates well with diagnosis via dynamic contrast enhanced-MRI (Howe et al., 
2003, Jacobs et al., 2004, Yeung et al., 2001, Bolan et al., 2003, Stanwell et al., 
2005). 
Regarding the use of ¹H NMR metabonomics methods to detect cancer in serum, a  
study by Odunsi group (Odunsi et al., 2005) illustrated that principal component 
analysis of NMR spectra obtained for serum from patients could not only detect 
epithelial ovarian cancer (EOC) but could distinguish EOC patient serum from that 
obtained from  patients with benign ovarian cysts as well (Whitehead and Kieber-
Emmons, 2005).
 
Nuclear magnetic resonance (NMR) spectroscopy is a commonly used analytical 
method to analyse the small- molecule composition of body fluids such as urine and 
blood serum. Variations in metabolite concentrations have been associated with the 
biochemical status of organisms and reflect changes in metabolism arising from 
biologic conditions, including disease and response to chemical treatment. Recent 
studies demonstrate the applicability of NMR-based metabolomics using serum 
samples for the diagnosis and prognosis of disease (Beckwith-Hall et al., 2003, 
Brindle et al., 2003, Carraro et al., 2007, Duarte et al., 2007, Makinen et al., 2006, 
Odunsi et al., 2005, Stubbs et al., 2002, Tsang et al., 2006, Whitehead and Kieber-
Emmons, 2005). 
Both ¹H and ³¹P magnetic resonance spectroscopy have previously been used to 
identify metabolic signatures of squamous cell carcinoma compared with benign 
tumours and normal tissues (Adalsteinsson et al., 1998, Arias-Mendoza et al., 2006, 
Bezabeh et al., 2005, El-Sayed et al., 2002, Maheshwari et al., 2000a, Maheshwari et 
al., 2000b, Mukherji et al., 1997, Star-Lack et al., 2000, Yokota et al., 2007). Both in 
vivo and in vitro clinical studies have shown that the choline-creatine ratio is 
significantly higher in OSCC than in normal tissue (Maheshwari et al., 2000b, 
Mukherji et al., 1997, Star-Lack et al., 2000). Analysis of squamous cell carcinoma 
cell line cultures was suggestive of rapid membrane biosynthesis during increased 
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cell proliferation (Mukherji et al., 1997). Moreover, in vitro studies using two-
dimensional (2D) correlated spectroscopy revealed that a variety of metabolites, such 
as alanine, glutathione, histamine, isoleucine, and leucine, were showed a higher 
concentration in tumour compared to normal tissue (Mukherji et al., 1997). An NMR 
study of ex vivo tumour tissue identified elevated concentrations of taurine, choline, 
glutamic acid, lactic acid, and lipids in squamous cell tissue compared with normal 
tissue (El-Sayed et al., 2002). 
Many solid tumours showed rising in glycolytic metabolism, as in case of OSCC,  
associated with the over-expression of glucose transporters, especially of Glut-1 
(Kunkel et al., 2003). This metabolic change is commonly used to locate primary 
tumours and associated metastases using positron emission tomography by  
monitoring [18F]-2-fluoro-2-deoxy-D-glucose uptake (Kunkel et al., 2003).Additional 
studies examined the role of advanced glycated end products (AGE) and increased 
levels of the AGE receptor (RAGE) in patients with diabetes mellitus type 2 and 
primary gingival carcinoma showing that RAGE expression is closely associated 
with the Invasiveness of OSCC (Bhawal et al., 2005, Ujpal et al., 2007). 
Recent study of cancer patients samples, showed that the levels of valine, ethanol, 
lactate, alanine, acetate, citrate, phenylalanine, tyrosine, methanol, formaldehyde, 
and formic acid were reduced compared with those of healthy controls, whereas 
signals arising from glucose, pyruvate, acetone, acetoacetate, 3-hydroxybutyrate and 
2-hydroxybutyrate, choline, betaine, and to a lesser degree, dimethyl glycine, 
sarcosine, asparagine, and ornithine showed enhanced loadings (Tiziani et al., 2009). 
Further uses of metabolomics are to determine
 
the maximum tolerated dose of new 
drugs or drug combinations
 
while also collecting information on drug tolerability,  
pharmacokinetics,
 
and pharmacodynamics (Spratlin et al., 2009). 
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1.9 Microarray technology 
Microarray technology is based on hybridization of complementary nucleotide 
strands (DNA or RNA). Microarray chips consist of thousands of DNA molecules 
that are immobilized and gridded onto a support such as glass, silicon or nylon 
membrane. Because mRNA is susceptible to degradation it is converted to 
complementary DNA (cDNA) to form the target signal and for each type the probes 
are composed of DNA.  
Each spot on the chip is representative for a certain gene or transcript. Fluorescently 
or radioactively labelled nucleotides (targets) that are complementary to the isolated 
mRNA are prepared and hybridized to the immobilized molecules (probes). Targets 
that did not bind to probes during the hybridization process are washed away. The 
amount of hybridized target molecules is proportional to the amount of isolated 
mRNA. The relative abundance of hybridized molecules on a defined array spot can 
be determined by measuring the fluorescent or radioactive signal. This method 
provides the advantage that it can interrogate the level of transcription of thousands 
of different genes from one sample in one experiment. Several competing 
technologies for microarray probe implementation have emerged, including the use 
of full‐length cDNAs, or pre-synthesized or in situ synthesized oligonucleotides as 
probes. This platform is cDNA based and the probes are double stranded PCR 
products amplified from expressed sequence tags (ESTs) which range from 100-1000 
base pairs in length. This has increased sensitivity but reduced specificity compared 
to oligonucleotide-based systems.  
One of the “gold standard” technologies is the GeneChip distributed by Affymetrix. 
The GeneChips are constructed using a combination of two techniques, 
photolithography and solid‐phase DNA synthesis. In Affymetrix GeneChip 
Microarray the probes are 25 nucleotide bases long and there are multiple 
oligonucleotide probes per gene which leads to a high specificity of the application 
compared to other Microarray platforms. Only a single mRNA population can be 
studied per GeneChip providing an absolute measurement of gene expression level. 
The Affymetrix GeneChip Microarray platform has been widely adopted as a 
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standard within the research community. The endorsed advantage of the Affymetrix 
Microarray platform is the ability to compare any single Microarray with any other 
and in any combination. Other distributors of DNA microarrays include; Applied 
Biosystems, Beckman Coulter, Eppendorf Biochip Systems, Agilent and Illumina. 
1.10 Transcriptomic analysis 
Transcriptomic is the functional analysis at the level of the genome (large-scale DNA 
sequencing that provided insight to the heterogeneity in coding regions of genes that 
lead to polymorphisms of gene expression). The genetic basis of the development of 
oral cancer has been considerably made in recent years. It is known that an 
accumulation of genetic alterations is the basis for the progression from a normal cell  
to a cancer cell (Califano et al., 1996). Progression is enabled by the more aberrant 
function of genes that positively or negatively regulate aspects of proliferation, 
apoptosis, genome stability, angiogenesis, invasion and metastasis (Hanahan and 
Weinberg, 2000). However, several studies suggest that early genetic changes do not 
necessarily correlate with altered morphology. 
Increasing gene dosage through DNA amplification is a common feature of many 
tumours and results in upregulation of tumour- promoting genes (Oh and Mao, 
1997). Although many studies contributed greatly to current understanding, they did 
not explain the complexities of such malignancies (Mendez et al., 2002). 
With the advent of DNA microarrays, genomic-scale differential gene expression 
profiles can be obtained. Microarray analysis was influential in discovering clinically 
relevant knowledge by connecting changes in gene expression patterns with specific 
pathological conditions where mRNA expression profiles are generated for 
thousands of genes once across a collection of samples that belong to either one of 
two classes, for example, pathological specimen versus healthy tissue controls or 
early stage versus late stage of a specific disease. Transcriptional characteristics of 
tumours can be assessed with unprecedented completeness using large-scale 
microarray technologies (Schena et al., 1995) and/ or high-throughput quantitative 
PCR (Bernard and Wittwer, 2002). 
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Because phenotypic changes are heralded by genotypic changes, it also may be 
possible to detect differentially expressed genes that may serve as markers for the 
early detection of pre-malignant lesions, as well as, cancer invasion and metastasis. 
More than just focusing on the expression of a handful of genes, genomic-scale 
expression profiles allow the investigator to look at genetic expression variability in 
proliferation, invasion, carcinogenic metabolism, apoptosis and other genetic themes 
and pathways (Mendez et al., 2002).  
A comparison of tumour profiling studies concluded that the composition of 
microarray gene expression signatures is highly unstable and dependent on the 
selection of patients used for determining the signature (Michiels et al., 2005). 
Furthermore, due to insufficient sample numbers and improper validation, some 
authors concluded that the results of such studies are overoptimistic. This is not 
surprising since many genes are simply interchangeable without affecting predictive 
accuracy because many prognosticative genes have similar, if not identical 
expression patterns across tumour samples (Ein-Dor et al., 2005). HNSCCs including 
OSCCs are complex heterogeneous tumours and microarray technology allows quite 
rapid, large scale screening of genes with the potential to identify candidate genes 
and pathways involved in such complex characteristic disease.  
1.11 Selection of bioinformatics approaches 
Bioinformatics is a specialized scientific discipline which emerged and developed as 
a consequence to the increase of the volume of biotechnological datasets and the 
need for the preservation and analysis of such data. It can be generally described as 
the application of a combination of machine learning and statistical approaches to 
explore biological processes by analysis of the large-scale and multi-dimensional 
data generated from numerous sources. It incorporates organized storage of the data, 
development of tools to analyse the data and the actual analysis of data. 
Bioinformatics uses both informatics and statistical tools implemented to extract and 
analyse information (Wu, 2001). The type and number of employed analytical tools 
in each session of bioinformatics analysis depend on the data type and nature of 
biological question addressed during analysis of a specific dataset. Generally, 
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bioinformatics is a management information system for molecular biology and has 
many practical applications (Umar, 2004), and so it became an inevitable research 
element of the molecular biology. As a consequence of hastened generation of large-
scale datasets by high throughput research platforms, including gene expression 
experiments, cancer biology commonly linked to informatics. Bioinformatics is 
mainly used to identify cancer biomarkers, their function and molecular mechanisms 
underlying cancer progression. A considerable number of novel bioinformatics 
approaches were already recognized with a sophisticated level allowing to perform 
the functional analysis in semi-automated mode, for example, gene set enrichment 
and pathway-based analysis, (Subramanian et al., 2005, Yi et al., 2006).  
Functional analysis of biomarkers identified in large-scale datasets can be performed 
using a wide variety of bioinformatics tools. Gene annotation is the principal 
requirement for the initiation of functional analysis. The annotative information is 
provided by various biotechnological database management organizations like NCBI 
(Gene), EBI (Ensembl), and caArray database, along with independent groups like 
GeneCards (Safran et al., 2002, Curwen et al., 2004, Maglott et al., 2007, Maglott et 
al., 2011). Pathway information systems, for example, Kyoto encyclopaedia of genes 
and genomes (KEGG), and Biocarta provide information concerning the molecular 
interactions of gene products in an organized fashion (Aoki-Kinoshita and Kanehisa, 
2007). Association of genes with their corresponding ontological terms is another 
way of enhancing functional analysis. The gene ontology (GO) database was 
developed to standardize the gene and gene product attributes across the unending 
list of biological databases (Ashburner et al., 2000). Database for annotation, 
visualization, and integrated discovery (DAVID) is a hybrid functional analysis tool 
combining all these systems in a single web interface (Huang et al., 2009b). Such 
integrative tools enhanced the functional analysis of the genes and/or proteins while 
providing a holistic perspective of large-scale datasets (Manyam, 2009). 
Considering metabolomic profile, the human metabolome database (HMDB) 
(http://www.hmdb.ca/), a freely available electronic database containing detailed 
information about small molecule metabolites existed in the human body was 
employed. 




Bioconductor is open source software for bioinformatics 
(www.bioconductor.org/index.html) which provides tools for the analysis and 
comprehension of high-throughput genomic data. Bioconductor uses the R statistical 
programming language, and is open source, has 671 software packages until April 
2013, and continuing development. Bioconductor has advanced facilities for analysis 
of microarray platforms including Affymetrix, Illumina, Nimblegen, Agilent, and 
other one- and two-colour technologies. Bioconductor includes extensive support for 
analysis of expression arrays, and well-developed support for exon, copy number, 
SNP, methylation, and other assays. Major workflows in Bioconductor include pre-
processing, quality assessment, differential expression, clustering and classification, 
gene set enrichment analysis, and genetical genomics. Bioconductor offers extensive 
interfaces to community resources, including GEO, ArrayExpress, Biomart, genome 
browsers, GO, KEGG, and diverse annotation sources. 
1.11.2 Data filtering and normalization 
Normalisation is essential to explicate and minimise systematic and experimental 
variations in the calculation of gene expression data, hence identifying biologically 
relevant data and removing the non-biological effect on the data (Schuchhardt et al., 
2000). The preferred method used in research work of the thesis was the GeneChip 
Robust Multichip Average method (gcRMA) (Wilson and Miller, 2005). 
After normalisation, the data are filtered to reduce variation before machine learning 
or statistical algorithms are used. Genes that have a low overall variance across all 
samples can be removed because they are of little value. Filtration is normally 
incorporated into the first stage of many analysis packages. 
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1.11.3 Corrections of batch effects 
Integration of microarray datasets is advantageous for researchers to increase 
statistical power in detecting biological phenomena from studies where logistical 
considerations restrict sample size (Turnbull et al., 2012). Generally, it is 
inappropriate to combine datasets without adjusting for batch effects (Johnson et al., 
2007a, Lazar et al., 2012). 
Batch effects can be caused by laboratory conditions, reagents, and personnel 
diversity. This becomes a major problem when batch effects correlated with an 
outcome of biological interest and result in incorrect conclusions (Leek et al., 2010). 
In this study, the ComBat batch correction method was utilised to minimise effects 
between studies. ComBat package in R software (Johnson et al., 2007a) implicated 
parametric and non-parametric empirical Bayes frameworks for adjusting data of 
batch effects. According to recent published work (Turnbull et al., 2012), ComBat 
expressed the best performance. 
1.11.4 Differential gene expression analyses 
Samples are relatively compared to examine differential gene expression and to 
extract meaningful biological results from this comparison. Generally, data analysis 
takes two main forms. The first is ‘unsupervised’ analysis where data is sorted and 
gene expression differences are derived based on inherent differences within the 
dataset. Unsupervised clustering is achieved and heatmaps generated using Pearson 
correlation and hierarchical clustering in R. Supervised analysis is carried out using 
the Significance Analysis for Microarrays (SAM) (Tusher et al., 2001) in siggenes 
package available from Bioconductor. SAM  is one of the more potent and effective 
ways of identifying particular gene products involved in differentiating 
transcriptional profiles between two groups (Tusher et al., 2001). SAM gives good 
all-round discriminatory ability based on average signal intensity differences within 
the supervised groups and between the same groups at pre-determined fold-change 
levels and gives an estimate of the false discovery rate for a significantly changed 
gene (Jeffery et al., 2006). Hierarchical clustering heatmaps are generated using 
gplots package (Gentleman et al., 2004). Fold change values for relative 
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“upregulated/over-expressed” and “downregulated/ under-expressed” genes were 
obtained using Wilcoxon Rank Statistics function in siggenes R software. 
Lists of genes are further refined by trimming out low magnitude fold changes and / 
or reducing the false discovery rate (FDR) value of the significant genes by 
adjustment of delta value. The value of delta is chosen that provides the best balance 
between the number of identified genes and the estimated FDR, i.e. that allows to 
simultaneously attain the two competing goals “As many genes as possible" and “As 
low FDR as possible". 
1.11.5 Biological annotations of significant genes and 
metabolites 
Differentially expressed genes and/or metabolites in different comparison analyses 
are subsequently uploaded and examined using tools available from IPA (Ingenuity 
Systems, version 9.0, www.Ingenuity.com) to define the relative cellular functions, 
canonical pathways, upstream regulators, potential biomarkers, and molecular 
processes that are most commonly perturbed in correlation with a set of altered genes 
or metabolites of a specific comparison, as well as, to inspect the most significant 
pre-generated networks associated with the uploaded group of genes or metabolites. 
IPA knowledge base recruits the distinguished genes (and/or metabolites) that 
involved in and regulated a specific disease or disorder to generate and highlight the 
above functions. Canonical pathways analysis identified pathways from IPA library 
of canonical pathways, which are most significant to the input data set. The 
significance of the association between the data set and the canonical pathway was 
determined based on two parameters: (1) A ratio of the number of genes from the 
data set that map to the pathway divided by the total number of genes that map to the 
canonical pathway and (2) a P value calculated using Fischer's exact test determining 
the probability of the association between the genes in the data set and the canonical 
pathway is due to chance alone. 
IPA analysis generates networks connecting the differentially regulated genes (and/or 
metabolites) from published interactions. This approach has the advantage of 
building pathways independently of the traditional canonical pathways database. 
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Therefore, this approach potentially highlights unknown relationships and 
connections between genes and their products including metabolites. The 
relationship between the genes (nodes in the pathway) is indicated by a line, which 
corresponds to at least one reference from the literature. The significance of a 
canonical pathway is controlled by p-value (right-tailed Fisher’s exact test). 
The identification of regulatory networks gives insight into the mechanisms of a 
specific disease, while the use of pathway analysis to further test the validity of 
candidate genes and their likely contribution to a specific disease is certainly a 
valuable tool for gene expression analysis. 
1.12 Metabolomics and metabonomics 
The metabolism reflects an abnormal change in an organism (Griffin and Shockcor, 
2004). Both the theory and the application have been well documented (Nicholson et 
al., 1999, Jurs, 1986, Eriksson et al., 2006). Metabolomics is the systematic 
identification and quantitation of all metabolites in a given organism or biological 
sample. It’s resided at the end of the biological road that commences with DNA. It is 
the place where the variation in genomes, both static and expressed, becomes 
integrated. Its goal is to relate the physiological consequences of disease, i.e. the 
metabolites associated with pathological processes, to those diseases' genomic 
origins.  
The enhanced resolution provided by nuclear magnetic resonance (NMR) 
spectroscopy and mass spectrometry (MS), along with powerful chemo metric 
software, allows the simultaneous determination and comparison of thousands of 
chemical entities, which has led to an expansion of small-molecule biochemistry 
studies in bacteria, plants, and mammals. Continued development of these analytical 
platforms will accelerate the widespread use of metabolomics and allow further 
integration of small molecules into systems biology (Idle and Gonzalez, 2007). 
Metabolomics is an analytic tool used with pattern
 
recognition approaches and 
bioinformatics to detect metabolites
 
and follow their changes in bio fluids or tissue 
(Fiehn, 2002, Griffin and Shockcor, 2004, Kell and Mendes, 2000).
 
Precise number 
of human metabolites is unknown, with estimation
 
ranging from the thousands to 
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tens of thousands. Metabolomics
 
is a term that encompasses several types of 
analyses, including
 
(a) metabolic fingerprinting, which measures a subset of the
 
whole profile with little differentiation or quantitation of
 
metabolites (Ryan and 
Robards, 2006); (b) metabolic profiling, the quantitative study
 
of a group of 
metabolites, known or unfamiliar, within or associated
 
with a particular metabolic 
pathway (Dunn et al., 2005, Roessner et al., 2001); and (c) target isotope-based
 
analysis, which focuses on a precise segment of the metabolome
 
by analysing only a 
few selected metabolites that comprise a
 
specific biochemical pathway (Boros et al., 
2005). 
Metabolomics allows for a global assessment of a cellular state within the context of 
the immediate environment, taking into account genetic regulation, altered kinetic 
activity of enzymes, and changes in metabolic reactions (Griffin and Shockcor, 2004, 
Mendes et al., 1996, Mendes et al., 1992). Thus, compared with genomics or 
proteomics, metabolomics reflects changes in phenotype and therefore, function. The 
“omic” sciences are, however, complementary as "upstream" changes in genes and 
proteins are measured "downstream" as changes in cellular metabolism (Griffin and 
Shockcor, 2004, Boros et al., 2005). Conversely, metabolomics is a terminal view of 
the biological system, not allowing for representation of the increased or decreased 
genes and proteins (Figure 1.2). Other features of metabolomics are similar to those 
of proteomics and transcriptomics, in their ability to assay bio fluids or tumour 
samples and the relatively inexpensive, rapid, and automated techniques once start-
up costs are taken into account (Spratlin et al., 2009).  




Figure 1.2 : A schematic view of metabolomics 
The position of metabolomics is shown in respect to the other omic approaches and the influence of 
the environment. In addition a scheme is shown for producing pattern recognition models capable of 
deducing metabolic profiles. The initial phase usually involves the acquisition of a large dataset in 
terms of both the variables (metabolites) and observations (subjects), commonly using either ¹H NMR 
spectroscopy or mass spectrometry. However, the use of pattern recognition techniques is an integral 
part of the approach if the innate metabolic variation associated with different individuals is to be 
separated from that induced by the insult or physiological stimulus. Following the generation of a 
database from metabolic responses, this can then be used to build a predictive pattern recognition 
model that is capable of predicting class membership (e.g. clustering according to the gene deleted) 
(Adapted from Griffin et al. 2006). 
Metabonomics is defined as ` the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological stimuli 
or genetic modification’. This concept has arisen from work on the application of 
“H-NMR spectroscopy to study the multicomponent metabolic composition of 
biofluids, cells and tissues over the past two decades (Nicholson et al., 1983, Bales et 
al., 1984, Nicholson et al., 1985, Gartland et al., 1989, Foxall et al., 1992, Moka et 
al., 1998). There is also a related concept of the ` Metabolome’ that represents the 
total small molecule complement of a cell. However, metabonomics deals with 
  Chapter 1 
27 
 
detecting, identifying, quantitating and cataloguing the history of time-related 
metabolic changes in an integrated biological system rather than the individual cell. 
Such multidimensional metabolic trajectories are then related to the biological events 
in an ingoing pathophysiological process (Nicholson et al., 1999). 
Metabonomic analysis has been increasingly used to monitor metabolic 
abnormalities in cells and their microenvironment for detection of cancer markers 
(Zhou et al., 2009). Results of Zhou group indicated that ¹H NMR-based 
Metabonomic approach is a feasible and efficient method for differentiating the 
OSCC patient's plasma from the healthy controls. As a potential novel strategy and 
convenient technique, it deserves a further evaluation for an early detection of oral 
cancer (Zhou et al., 2009). 
As a useful tool, ¹H nuclear magnetic resonance (¹H NMR) spectroscopy of blood 
from patients ,were diagnosed with cancers such as breast, ovarian, prostate, and 
brain cancer, has produced better  results lately (Whitehead and Kieber-Emmons, 
2005, Odunsi et al., 2005, Whelehan et al., 2006, Lindon et al., 2003).  
Because only a little biofluid contains a complete metabolic profile, it will be useful 
for assessing overall disease with less stress for the patient. Application of automated 
data reduction algorithms and chemo metric analysis, which called pattern 
recognition analysis, can be competent for the description and recognition of the 
dynamic multivariate metabolism (Zhou et al., 2009).  
The study of proteins at a global level, proteomics, has not yet achieved such 
widespread use (Idle and Gonzalez, 2007), possibly because of the weak points in the 
chain of analysis (such as sample handling, protein separation and digestion) and the 
greatest challenge with regard to protein detection comprised in the fact that there is 
no protein stain currently available that possesses all desired properties; a routine and 
reproducible lowest limit of detection with optimal signal-to-noise ratio; a wide 
dynamic range, with a linear relationship between protein quantity and staining 
intensity; compatibility with downstream microchemical characterization techniques; 
ease of use; and inexpensive, high throughput rates of use (Gauci et al., 2011). 
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 In contrast, metabolomics is emerging as a field with a tremendous promise in 
extending “omics” from the gene to the small molecule (Idle and Gonzalez, 2007). 
Via the fast development of metabolomics technology platforms and incorporating 
metabolomics into research efforts, it is now possible to answer key questions that 
could not be fully addressed by the other omics alone. From bacteria to humans, 
examples of this principle are accruing at a rapid pace that has been made promising 
by remarkable recent developments in analytical chemistry, such as high-field 
nuclear magnetic resonance (NMR) and mass spectrometry (MS) platforms for 
small- molecule separation, detection, and characterization, together with the 
availability of relatively user-friendly multivariate data analysis software packages 
that can de-convolute the huge data matrices generated in a metabolomic experiment. 
Such analysis of the metabolome is applied to an ever-increasing number of 
biological and medical research topics, from bacteria to human (Idle and Gonzalez, 
2007). 
In mammals, the potential of metabolomics is enormous, particularly regarding to 
studying the interface between chemical universe and human biology. Humans are 
probably exposed to some 1–3 million discrete chemicals in the lifetimes, and most 
of these xenobiotics are metabolized in the body to render them less poisonous. 
However, in a significant number of cases, the detoxification apparatus renders a 
xenobiotic more chemically reactive, potentially more toxic, and, in some cases, 
carcinogenic.  
Understanding the role of human genetic differences in xenobiotic metabolism and 
its relationship to inter-individual susceptibility to chemical toxicities and 
carcinogenesis is an area of intense interest (Wogan et al., 2004). A convenient, cost-
effective means to determine metabolic potential would be of great value in 
understanding the molecular epidemiology of cancer (Idle and Gonzalez, 2007). 
This task is quite daunting because of the genetic differences, dietary diversity, and 
other problems inherent in the human population that led to mark inter-individual 
differences in the human serum metabolome, while these difficulties can be 
overcome by studying large populations of cases and controls with powerful 
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statistical multivariate data analysis software that can mine huge data sets. 
Biomarkers that can be used to diagnose pre-diabetes, cancer, and coronary artery 
disease would be of great value in clinical medicine (Idle and Gonzalez, 2007). 
All authors and investigators look forward to a day when metabolomic analysis that 
can capture the whole metabolome is truly accessible and widely available in the way 
that PCR, SNP mapping, and microarray analysis are now (Idle and Gonzalez, 2007, 
Vora et al., 2003). 
1.12.1 NMR metabolomics/metabonomics techniques 
For testing and monitoring procedures, Metabonomic methods are generally non-
invasive, and based upon instrumentation availability they can be conducted either in 
vivo or in vitro. For in vitro applications, samples such as urine, plasma, serum, bile, 
and cerebrospinal fluid can be analysed using the same basic techniques. Whole 
tissue samples may also be analysed if the appropriate instrumentation is available 
(HR-MAS NMR). Depending upon observable metabolites and their patterns, one 
can describe, using the changing concentrations of hydrophilic and lipophilic 
metabolites, a disease in various stages of malignancy as in case of using metabolic 
changes to establish self-organizing maps for breast cancer tissue by Beckonert 
group where breast-cancer tissue was successfully classified as unaffected, of 
intermediate malignancy, or of high malignancy (Beckonert et al., 2003). In addition, 
multiple metabolites were monitored simultaneously and suggested useful for 
classifying tissue type based upon their concentration (Whitehead and Kieber-
Emmons, 2005). 
Generally, techniques are highly quantifiable and reproducible, experimental time 
takes only a matter of minutes, and sample preparation is minimal, usually involving 
the addition of D2O (Heavy Water, 2H2O) directly to the sample and presenting the 
sample to the instrument for analysis. The greatest advantage to the technique is that 
samples are not destroyed during analysis. This allows the investigator to pursue a 
wide range of studies on any one sample, including kinetic analysis, protein–ligand 
binding studies, structural analysis of metabolites, and ‘separation’ methods using 
the magnetic field of the instrument. In addition, by monitoring the same sample over 
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time (kinetically), changes in metabolite concentration or composition can be 
observed (Whitehead and Kieber-Emmons, 2005). 
Recent technological progress in NMR spectroscopy and mass spectrometry (MS), 
the two most accepted methods used in the measurement of metabolites, has 
improved the sensitivity and spectral resolution of analytic assays on metabolomic 
samples in attempts to achieve a comprehensive biochemical assessment. Because 
cancer cells are known to possess a highly unique metabolic phenotype, development 
of specific biomarkers in oncology is possible and might be used in identifying 
fingerprints, profiles, or signatures to detect the presence of cancer, determine 
prognosis, and/or assess the pharmacodynamic effects of therapy (Glunde and 
Serkova, 2006, Griffin and Shockcor, 2004, Serkova et al., 2007, Serkova and 
Niemann, 2006, Denkert et al., 2006, Odunsi et al., 2005, Howe et al., 2003, Bathen 
et al., 2007, Kline et al., 2006, ElDeredy et al., 1997, Morvan and Demidem, 2007). 
MS analysis requires more labour-intensive and destructive tissue preparation than 
NMR, but has greater sensitivity for metabolite detection (Dunn et al., 2005). 
Compared with MS, NMR is less sensitive (on the order of 10
 
µmol/L), and requires 




H-NMR spectra is sensitive to pH, 
ionic content,
 




H-NMR include its nonbiased metabolite detection,
 
quantitative 
nature, and reproducibility. 
1
H-NMR can also be
 
used for liquid or solid samples, 
using magic angle spinning
 
(HR-MAS) techniques, with minimal sample preparation 
(Serkova and Niemann, 2006). Another significant advantage of NMR is that 
metabolic
 
markers discovered and analysed in vitro can be measured in
 
vivo, 
assuming sufficient tissue abundance, using localized
 
magnetic resonance 
spectroscopy imaging (MRSI). MRSI is an additional
 
technology related to magnetic 
resonance imaging (MRI) whereby
 
metabolites instead of anatomy are imaged. 
Essentially , MRSI
 
is a composite of traditional NMR spectroscopy and MRI that
 
allows for non-invasive in vivo visualization and determination
 
of spatial distribution 
of a specific metabolite in patients
 
without exposure to ionizing radiation (Spratlin et 
al., 2009). 
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The major disadvantage of NMR technique involves the complexity of the data 
obtained. The presence of thousands of resonances arising from hundreds of 
metabolites that may be observed in complex biofluids makes spectral interpretation 
difficult, forcing the researcher to rely on statistical algorithms for such analysis. 
Generally, the largest problem in using spectroscopy to analyse such mixtures is the 
presence of water. Water poses a problem for signal-to noise ratios and spectral 
overlap, particularly when using magnetic resonance techniques. Unfortunately, all 
biological fluids and, specifically, the human body, involve ample amounts of water. 
Thus, suppression of the water resonance which requires sophisticated 
instrumentation is a major hurdle that must be overcome. In addition, the human 
body contains other sources of interference (such as lipids), which must be 
suppressed as well (Whitehead and Kieber-Emmons, 2005). However, several 
studies were published to manage this weak point; one of them is a "WAVEWAT 
study" a new processing algorithm to suppress the on resonance water signal in NMR 
spectra. It is based on a Multi-resolution analysis (MRA) of the free induction decay 
(FID) using a dyadic discrete wavelet transforms (DWT). The width of the 
suppressed signal can be adjusted so that signals close to water are recovered without 
distortion of the signal shape and intensity. Computational efficiency is comparable 
to that of convolution filters employing a Fourier transform (Gunther et al., 2002). 
NMR spectroscopic methods focus on the analysis of magnetically susceptible 
atomic nuclei (e.g. 1H, 13C, 15N, 31P) that are present in molecules which are 
introduced to the instrument in small sample volumes, in either the solid or liquid 
state, allowing for the observation of chemical structures and processes at the 
molecular level. In terms of experimental acquisition time, effective spectroscopic 
studies require a relatively short period of time (30–45 min) (Morrison et al., 2007). 
While acquisition times and the presence of interfering biological molecules limit 
clinical MR techniques in terms of spectroscopy, studies can be performed ex vivo 
(intact tissue analysis) and in vitro (soluble tissue extracts and biofluids) using 
classical NMR spectroscopic methods at larger magnetic field strengths and utilizing 
complex pulse sequences which will allow for enhanced suppression of unwanted 
resonances, ultimately leading to greater sensitivity and spectral resolution. In order 
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to perform ex vivo studies, sampling from the body must occur prior to analysis, 
usually involving the clinical excision of tissue from a tumour or the surrounding 
region. Fortunately, only small sample amounts are generally required for such 
studies. In vitro analyses are less invasive, usually focusing on samples such as 
plasma, serum, urine, saliva, and to some extent cerebrospinal fluid which are 
considered ideal for biomarker monitoring. Ex vivo spectroscopy provides detailed 
information that is usually lost or altered during in vitro extraction processes by 
instead focusing on the intact tissue itself (Whitehead and Kieber-Emmons, 2005).  
In vitro analyses can be performed using NMR spectrometers equipped with standard 
probes designed for solution-state samples, with the major limitations for quality 
spectra being that of spectrometer field strength and solvent-suppression capabilities. 
However, extraction techniques that are required for the sample preparation phase 
often alter metabolite concentrations making it difficult to quantitatively determine 
metabolite levels in vivo from in vitro extracts (Whitehead and Kieber-Emmons, 
2005). Despite this fact, a great deal of information has been obtained from in vitro 
extraction studies, with the presence of various metabolites and other small organic 
molecules being correlated to various stages of oral cancer. 
NMR (1H-NMR) advantages include the theoretical possibility to detect and 
structurally elucidate any molecule containing hydrogen and also being very 
quantitative in its nature. However, disadvantages include low sensitivity, typical 
detection limits are in the range milli- to high micromolar (Pendyala et al., 2007), 
and also the fact that one-dimensional spectra gets very dense with spectral 
information resulting in more abundant metabolites masking signal of less abundant 
ones. 





NMR spectra is sensitive to pH, ionic content,
 
and temperature, and may require 




H-NMR include its nonbiased 
metabolite detection,
 
quantitative nature, and reproducibility (Serkova and Niemann, 
2006).  
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In mass spectrometry, mass separation is based on the fact that molecules become 
charged in a process called ionization. Mass spectrometry advantages include high 
sensitivity (milli- to nanomolar) and being easily interfaced with chromatography 
resulting in the capability to temporally resolve the analysis of thousands of 
components. Disadvantages include potential difficulties in quantitation without 
proper internal standards due to variations in ionization efficiency and discrimination 
against metabolites due to their elemental composition. MS analysis requires more 
labour-intensive and destructive tissue preparation than NMR (Dunn et al., 2005). 
Generally, techniques are highly quantifiable and reproducible, experimental time 
takes only a matter of minutes, and sample preparation is minimal, usually involving 
the addition of D2O (Heavy Water, 2H2O) directly to the sample and presenting the 
sample to the instrument for analysis. In both NMR and MS techniques, samples 
must be frozen as quickly as possible after collection, preferably into -20 °C, -80 °C, 
or dry ice. Authors conclude that storage of human urine samples at or below -25 °C 
do not require a preservative. Aliquoting to 3-4 vials before freezing in order to avoid 
freezing-thaw cycles, which can affect the sample. Both techniques can deal with 
tissue and biofluids. However, MS can’t be used in vivo (Morrison et al., 2007). 
1.12.2 Points to be considered using NMR spectroscopy for 
metabolomic analysis 
1-The aspects (nutritional/physiological status, sample type, cohort size and 
heterogeneity, and analytical sensitivity) should be carefully assessed before 
initiation of a metabolomics study aimed at finding clinically relevant biomarkers 
(Nordstrom and Lewensohn, 2010). 
2-Extraction techniques required in the sample preparation phase often alter 
metabolite concentrations making it difficult to quantitatively determine metabolite 
levels in vivo from in vitro extracts. In addition, extract samples frequently contain 
additional resonances not present in vivo. Despite this fact, a great deal of 
information has been obtained from in vitro extraction studies, with the presence of 
various metabolites and other small organic molecules correlated to various stages of 
breast cancer (Whitehead and Kieber-Emmons, 2005). 
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3-A number of potential metabolomics pitfalls lurk in these fluids. Firstly, factors 
like age, sex, nutritional status, and time of sampling might be reflected in the 
metabolite composition of chosen body fluid (Nordstrom and Lewensohn, 2010). 
4-In the metabolomics studies involving urine, plasma, and saliva samples with 
healthy humans; it was demonstrated that standardizing the diet could reduce the 
physiological variation in the urine samples but not in the plasma and saliva samples 
(Walsh et al., 2006). 
5-Another aspect to consider when performing discovery metabolomics in body 
fluids is the dilution of potential markers in the relatively large volumes body fluids 
represent (Lutz et al., 2007). 
6-The heterogeneity of many diseases also poses a problem (Nordstrom and 
Lewensohn, 2010). 
7-High-resolution 1H NMR spectroscopy is a relatively insensitive technique which 
only measures the high-concentration metabolites present in a tissue extract, bio fluid 
or intact tissue. Typically, using a simple one-dimensional pulse sequence 30–100 
metabolites are observable in urine, 20–30 metabolites in blood plasma or serum and 
10–30 metabolites in tissue extracts. Thus, a perturbation at one point in the 
metabolic network can rapidly be transferred to other metabolic pathways through 
these highly connected metabolites. Accordingly, the high-concentration metabolites 
will be greatly variable during a perturbation, and hence 1HNMR spectroscopy is 
sensitive to a wide range of genetic modifications, toxicology insults and 
physiological stimuli (Griffin, 2006). If these metabolites vary across a wide range of 
modifications, it then becomes difficult to use it as unique biomarkers for disease 
processes or for assuming which pathways have been stimulated during a 
modification. This can be further confounded by the detection of non-specific effects, 
which accompany a genetic modification or toxicological insult (Griffin, 2006). 
According to this, sensitivity is accompanied with low specificity, which could reach 
the level of baffling and misleading.  
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1.12.3 Data analysis and interpretation of metabolomics 
The guiding principle of metabolomics
 
is the global assessment of hundreds of 
endogenous metabolites
 
in a biological sample simultaneously. Statistical analyses 
are then applied to provide meaningful information about the metabolic profile of the 
sample. The three major steps in multivariate metabolomic analyses are depicted in 
Figure 1.3. Because 
1
H-NMR or MS spectra from bio fluids or tumour tissue
 
contain 
hundreds of  signals from endogenous metabolites and
 
are highly redundant, spectral 
data sets, reduced to 100 to
 
500 spectral segments, and their respective signal 
intensities
 
are directly entered into statistical programs (Dunn et al., 2005, Dettmer et 
al., 2007, Buchholz et al., 2002).  
 
Figure 1.3: Three major steps of metabolomics analysis 
The example is given for imatinib treatment in chronic myeloid leukemia cells using (1) 1H-NMR 
spectra of cell extracts followed by principal component analysis for pattern recognition (2) 
metabolite identification resulting in a biomarker (3) metabolite quantification and validation 
(Adapted from (Spratlin et al., 2009)). 
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Most of metabolic profiling studies have used
 
computer-aided statistical 
interpretation for the data. This
 
improves refining and distilling of the complex raw 
data. Similar
 
to gene array analysis, multivariate statistics have been designed
 
for 
large data sets, with two major types of pattern recognition
 
processes, unsupervised 
and supervised. Unsupervised data analysis,
 
such as hierarchical cluster analysis and 
principal component
 
analysis, measures the innate variation in data sets, whereas
 
the 
supervised approach, including principal component regression
 
and neural networks, 
uses prior information to generate the
 
clusters of patterns (Lee et al., 2008). Although 
many other statistical approaches exist, including cluster
 
analysis, linear discriminant 
analysis, Bayesian spectral decomposition,
 
and several other chemometric methods 
(Holmes and Antti, 2002). 
1.13 Integrative Analysis of transcriptomics and 
metabolomics 
Transcriptomics provides the tool for deciphering gene expression networks, and 
proteomics links these networks to protein products. The third crucial partner is 
metabolomics, which defines the metabolic network(s) linked to gene expression.  
NMR and mass spectrometry enable the broad screen analysis of the metabolome 
and its transformation pathways, transcending classical targeted metabolic studies. 
Fan et al. combined these tools to investigate the anticancer mechanisms of different 
selenium forms in human lung cancer cells. Using 2D NMR and tandem-MS, they 
mapped perturbations of 13C labelling patterns in numerous metabolites induced by 
selenite and selenomethionine. This information was used to interpret selenite-
induced changes in gene expression networks. Linking metabolic dysfunctions to 
altered gene expression profiles provided new insights into the regulatory network 
underlying the metabolic dysfunctions, enabled the assembly of discrete gene 
expression events into functional pathways, and revealed protein targets for 
proteomic analysis (Fan et al., 2006). 
One advantage of the genotype lies in the realization that it is unaffected by the 
clinical environment. Whereas enzyme activity may vary for one clinical reason or 
another, the genotype provides a point of reference from which to understand 
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differences in enzyme expression of that gene among patients, impossible with the 
more descriptive phenotype assessment. 
Chou group used combined genotype-phenotype relationship of CYP2D6. Allele-
specific PCR and CYP450 GeneChip were used for genotypic analysis. DXT-MR 
was used for metabolic ratio assessment. The study recruits the CYP2D6 genotype to 
provide a point of reference from which to understand differences in CYP2D6 
enzyme expression among patients that are impossible with the more descriptive 
phenotypic assessment (Figure 1.4)(Chou et al., 2003). 
 
Figure 1.4: Plot of CYP2D6 genotype vs. log10 (DXT MR) for 229 individuals 
Seven samples that could not be retested for the _1584G/C promoter polymorphism were excluded 
from the plot. The mean MR for each CYP2D6 genotype group is listed on the right-hand y axis and 
plotted as OE. Genotype groups are divided into four separate categories based on 3, 2, 1, or 0 active 
(fully or partially active) gene copies. The anti-mode separating the PM from the rest of the 
population is shown as a dotted vertical line (Adapted from Chou at al.2003). 
Metabolic profiling can work as a functional genomic tool when the mutation or 
modification produces a severe phenotype such as for many of the inborn errors of 
metabolism. However, mutations of non-rate-determining enzymes, or proteins that 
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do not produce an extreme pathological response, can still influence metabolic 
profiles by perturbing the many small modules that make up the network of 
metabolic pathways. A perturbation at one point will be rapidly transferred to many 
of the key nodes, some of which will be NMR detectable (Ravasz et al., 2002). This 
makes for a powerful analytical tool (Griffin, 2003). 
A considerable number of further studies were carried out using approaches 
integration to correlate transcriptomic and metabolomic data sets. Griffin group 
applied a combined genomic, transcriptomic and metabolomic approach to 
distinguish the fatty liver disease associated with supplementation of orotic acid to 
normal food intake (as the exact mechanism from orotic acid exposure to disrupted 
lipid transport is unknown) (Griffin, 2006).  
To compare the solution and solid-state spectra from the liver with the transcriptional 
profiles measured using DNA microarrays the pattern recognition process (prediction 
to latent structures through partial least squares) was used to cross correlate the 
metabolite changes (X matrix) to the transcriptional dataset (Y matrix) (Figure 1.5).  
This combined analysis identified metabolic changes involving uridine metabolism 
and choline turnover, and transcriptional changes such as the expression of stress 
proteins (Griffin et al., 2004). Coen et al. used combined transcriptional and 
metabolomic approach to investigate acetaminophen induced hepatotoxicity (In this 
study, the transcriptional profile of liver tissue was supplemented by metabolic 
profiles of liver tissue (both extracts and intact tissue); blood plasma and urine 
obtained using 1H NMR spectroscopy. These metabolic profiles identified decreases 
in glucose and glycogen and increases in lipids in liver tissue, alongside glucose, 
pyruvate, alanine and lactate increases in blood plasma. These metabolic changes 
were indicative of an increased glycolytic flux, and this was also confirmed at the 
transcriptional level demonstrating that the two approaches provided complementary 
information about the drug safety assessment process (Coen et al., 2003).  




Figure 1.5: Two methods for cross correlating data from different ‘omic’ approaches 
(a) shows a heat map plot of correlation coefficients from a partial least squares model of 20 
transcripts (along the x-axis) and 200 metabolites (along the y-axis). Regions with an intense red 
colour are positively correlated. (b) Histograms of bootstraps for correlation coefficients between key 
metabolite regions and transcripts. The x-axis represents the correlation coefficients while the y-axis 
represents the number of times this correlation was returned during 10 000 iterations. Key: SCD, 
stearoylCoA desaturase 1; ApoC, apolipoprotein C III; MVLC, mitochondrial very long-chain acyl 
CoA thioesterase; GPAT, glycerol 3 phosphate acyltransferase; FAC, fatty acid CoA ligase 4; CHaCH 
unsaturated lipid resonance, CH2CH2CH2 saturated lipid resonance (Adapted from Griffin et al. 
2004b). 
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Clish group investigated the alterations in the liver at transcriptomic, proteomic and 
metabolomic levels. They identified a range of transcripts, proteins and metabolites 
changed in the ApoE knock-out mouse. Finally, these changes were used to produce 
a correlation network, highlighting which metabolic pathways were most perturbed 
(Clish et al., 2004). 
Martin et al. studied insulin resistance, obesity, dyslipidaemia, and high blood 
pressure metabolic syndrome. The factors extracted using the phenotypic, genetic, 
and genome wide LOD score correlation matrices followed different patterns, which 
may suggest a distinct effect. The results implied that different methods of 
multivariate data reduction provide unique clues on the clustering of this complex 
syndrome (Martin et al., 2003). 
The U.S. Department of Health and Human Services (DHHS)/USDA Dietary 
Guidelines for Americans used similar approach to analyse the nutritional genotype- 
phenotype relationship which can lead to future individualized dietary 
recommendations to diminish cancer risk. One of the strategies used, is the systems 
biology approach: genes, proteins, and metabolite nutrients or nutritionary regimens 
is catalogued and integrated into a functional metabolism assessment tool to develop 
biomarkers of early metabolic dysregulation and susceptibility influenced by diet. 
Through ‘omic’ technologies, all the DNA sequences, mRNAs, all the proteins, a 
large multiple feedback loop from metabolites to proteins or transcripts involved in a 
particular cellular process are measured (Go et al., 2005). 
This massive database is then integrated and analysed by advanced computer 
modules and bioinformatics techniques that potentially will lead to the genotypic-
phenotypic characterization of different cellular network systems responding to a 
specific diet (Romero et al., 2005). However, functional analysis is incomplete unless 
quantification of metabolic fluxes is determined by tracer-based metabolomics 
(Nielsen, 2003, Lee and Go, 2005). Numerous databases have been created and 
employed in the development of various biological networks to understand the 
relationship of diet and cancer during exploration of genotype-phenotype relationship 
(Chou et al., 2003, Martin et al., 2003, Eerligh et al., 2004). 
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These approaches will lead to a systems biology understanding as the interplay 
between genotype, environment, and nutrition in health (Desiere, 2004). Eventually, 
the future target is to be able to examine personal variations responding to specific 
diet and provide knowledge of how diet influences metabolic regulation in health and 
prevention of chronic diseases at the personal level to achieve the goal of personal 
dietary guideline recommendations throughout an individual’s life cycle (Go et al., 
2005).  
In the context of systems biology, few sparse approaches have been proposed so far 
to integrate several data sets. It is, however, an important and fundamental issue that 
will be widely encountered in post genomic studies, when simultaneously analysing 
transcriptomics, proteomics, and metabolomics data using different platforms, to 
understand the mutual interactions between the distinct data sets (Le Cao et al., 
2009). 
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Chapter 2: Common gene expression profiling 
reveals biological alterations involved in early 
tumourigenesis of Oral Squamous Cell 
carcinomas 
2.1 Introduction 
Early stage (I and II) oral cancer may be curable by surgery or radiation therapy 
alone but advanced cancers (stage III and IV) are generally treated by surgery 
followed by radiation therapy (Harrison et al., 1999, Idle and Gonzalez, 2007). In 
fact, survival of advanced –stage patients rarely exceeds 30 months, even for those 
that initially achieve complete clinical remission (Hill and Price, 1994).  
A critical factor in the lack of prognostic improvement is that a significant proportion 
of cancers initially are asymptomatic lesions and are not diagnosed or treated until 
they reach an advanced stage. Early detection of cancer is the most effective means 
to reduce death from this disease (Li et al., 2004a). Moreover, most patients are 
recommended to have radiotherapy and chemotherapy after surgery to reduce the 
possibility of recurrence. Tumour molecular profiles including transcriptomic and or 
metabolomic abnormalities are likely to find increasing application in predicting 
which individuals will benefit from additional treatment and which individuals do 
not need it. 
Cancer may be accompanied by the production and release of a substantial number of 
proteins, metabolites and/or hormones into the blood, saliva, and other body fluids 
that could serve as useful markers for assessing prognosis, metastasis, monitoring 
treatment, and detecting malignant disease at an early stage. 
In the perspective of OSCC and HNSCC, possible themes can be addressed with the 
help of microarray data include distinguishing the disease from normal at the  
molecular  level; determining whether specific biomarkers or profiles are predictive 
for cancer; and  identifying  biologic pathways necessarily altered in the 
tumourigenesis, potentially illuminating novel therapeutic targets (Choi and Chen, 
2005). 
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2.2 Aim of the study 
In this study, an attempt was carried out to find common genes that can be used as 
biomarkers and would allow the development of a screening test having the potential 
to increase the early discovery and treatment of OSCC, as well as to explore the 
underlying biological pathways, functions, and molecular processes. 
2.3 Materials and methods 
Published reports of gene expression profiles of OSCC and HNSCC were identified 
using Medline database search. A review of the reports was performed to 
identify genes repeatedly exhibiting substantially altered expression in 
OSCC and HNSCC compared to normal oral mucosa. 
2.3.1 Selection of study samples 
2.3.1.1 Sample’s site of studies 
The selected studies consist of pure samples of oral cavity while studies with other 
origins of tissue samples (e.g., nasopharyngeal, maxillary sinus, oropharynx, and 
larynx (Belbin et al., 2002, Sok et al., 2003, Ginos et al., 2004, Reis et al., 2005, 
Kuriakose et al., 2004)) were excluded from the review as these samples already 
originated from hetero-origins and can reflect different molecular gene expression 
profiles regardless of the disease status, whilst some of them are associated with 
HPV infection. 
2.3.1.2 Technology used in the analyses 
Current work comprised only studies using DNA microarray or cDNA library 
technology in measuring gene expression of OSCCs. Studies using other analytical 
methods (such as; PCR, immunohistochemical, ELISA, RNA sequencing, flow 
cytometry, optical sensors, proteomic, and metabolomic signature (Leethanakul et 
al., 2000b, Kuo et al., 2002, Vora et al., 2003, Kuo et al., 2003, Kitajima et al., 2004, 
Kobayashi et al., 2004, Schneider-Stock et al., 2004, St John et al., 2004, Kim et al., 
2006, Madan et al., 2006, Sartini et al., 2007, Shpitzer et al., 2007, Sasahira et al., 
2007, Katakura et al., 2007, Bergmann et al., 2008, Zhao et al., 2008, Bagchi and 
Mills, 2008, Choi et al., 2008, Tan et al., 2008b, Shigeishi et al., 2009, Yuan et al., 
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2006, Vairaktaris et al., 2008)) were removed from the initial selection of the studies. 
Other studies used in vitro cell-lines culture methodology (Moriya et al., 2003, 
Zhang et al., 2002, Huang et al., 2002, Banerjee et al., 2003, Vigneswaran et al., 
2005, Diamond et al., 2008, Sinpitaksakul et al., 2008, Pettus et al., 2009, Al 
Moustafa et al., 2002, Jeon et al., 2004, Shibata et al., 2005) and those targeting gene 
expression signature of distant and lymph nodes metastasis of OSCC were also 
excluded.  
2.3.1.3 Status of the collected OSCCs 
Studies targeting staging evaluation of oral cancer disease and its metastasis (Zhong 
et al., 2008, Odani et al., 2006, Nagata et al., 2003, Irie et al., 2004, Marcus et al., 
2004, Schmalbach et al., 2004, Warner et al., 2004, Carinci et al., 2005, Chin et al., 
2005, Roepman et al., 2006, Belbin et al., 2005, Kato et al., 2006, Tomioka et al., 
2006, Sartini et al., 2007, Hensen et al., 2008, Gu et al., 2008, Chiang et al., 2008) 
were exempted from the current review. However, some studies harvested 2 
signatures (Signatures for both early detection and metastasis) were included in this 
review by implementing their specific signature only related to early detection.  
2.3.2 Construction of the list of common genes 
Searching for duplicate genes across the 28 studies had difficulty in matching the 
gene symbols. Since most of genes have more than one synonym (aliases) and not all 
studies used the same gene synonym in their final list of genes, there was a demand 
to construct a gene library that contains all reported synonyms of all genes identified 
in the 28 studies of the review. NCBI's repository for gene-specific information, 
Entrez Gene, (http://jura.wi.mit.edu/entrez_gene/) was used to collect the 
information essential for constructing the library. The library can be searched 
without having access to the internet service (Supplementary file 1b). However, to 
provide quick and precise list of common genes, all provided genes from the 28 
studies were unified to ENSEMBL gene ID using David conversion tool (Huang et 
al., 2009a, Huang et al., 2009b). 
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2.3.3 Exploration of the common genes expression in the raw 
data 
“Merge” function in R statistical programming language was used to assess the 
availability of the common gene expression among the genes in the raw data. 
2.3.4 Biological Annotations of significant common genes 
Differentially expressed genes in tumours were subsequently examined using tools 
available from IPA (Ingenuity Systems, version 9.0, www.Ingenuity.com) to define 
the relative canonical pathways, upstream regulators, and molecular processes that 
are most commonly perturbed in the early tumorigenic transformation of OSCC and 
HNSCC, as well as, to inspect the most significant pre-generated networks associated 
with the uploaded group of genes including those related to OSCC development. IPA 
knowledge base recruits the distinguished genes that regulated OSCC and HNSCC to 
generate and highlight the above functions. Canonical pathways analysis identified 
pathways from IPA library of canonical pathways, which are most significant to the 
input data set. The significance of the association between the data set and the 
canonical pathway was determined based on two parameters: (1) A ratio of the 
number of genes from the data set that map to the pathway divided by the total 
number of genes that map to the canonical pathway and (2) a P value calculated 
using Fischer's exact test determining the probability of the association between the 
genes in the data set and the canonical pathway is due to chance alone. 
IPA cannot map pseudogenes, hypothetical genes, ESTs and ambiguous (mapping to 
multiple) genes as well as duplicates of multiple IDs mapped in one molecule or 
multiple molecules snapped in one ID. However, the unmapped genes were 
converted using David conversion tool (Huang et al., 2009a, Huang et al., 2009b) to 
include them in the subsequent analysis, some were substantial key players in the 
master networks of the analysis and contributing to the tumorigenic process. 
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2.4 Results  
From 2000 to 2009, more than 60 studies recruiting DNA microarray analyses were 
reviewed to examine genome wide genetic expression changes associated with the 
development of OSCC and HNSCC were reviewed. 28 studies were coincided with 
the criteria previously specified in the methods section and selected as samples for 
the current study (Table 2.1) (Ziober et al., 2006, Villaret et al., 2000, Leethanakul et 
al., 2000a, Alevizos et al., 2001, El-Naggar et al., 2002, Mendez et al., 2002, Nagata 
et al., 2003, Hwang et al., 2003, Tsai et al., 2004, Leethanakul et al., 2003, Gonzalez 
et al., 2003, Ha et al., 2003, Toruner et al., 2004, Irie et al., 2004, Li et al., 2004a, 
Whipple et al., 2004, Carinci et al., 2005, Shimada et al., 2005, Chin et al., 2005, 
Belbin et al., 2005, Dysvik et al., 2006, Tomioka et al., 2006, Lopes, 2007, Li et al., 
2006, Suhr et al., 2007, Ye et al., 2008, Chen et al., 2008a, Estilo et al., 2009). 
Although the selected studies are similar in many features (criteria of study’s 
selection, material and methods), there is a considerable  heterogeneity among these 
studies in study design, number of samples, proportion of tumour-to-stromal  cells 
analysed, variety of microarray platform, and  validation methods of the results. 
Some studies employed split-up of tumour cells from stromal cells by LCM, while 
others estimated the percentage of tumour cells within tumour specimens before 
RNA extraction and subsequent analyses.
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Table 2.1: Selected studies using DNA Microarray technology for transcriptional analysis of OSCC and HNSCC. 
     Studies*          Year published                         Sample types                                                    Array platform                                                LCM                          Validation 
Villaret et al. 2000 16 HNSCC from multiple sites, 22 unmatched controls 
from multiple different organs 
(e.g., tonsil, soft palate, esophagus, skin, lung, small 
intestine, stomach, heart, brain, kidney) 
Synteni cDNA (~985) N NONE 
Leethanakul et al. 2000 5 HNSCC, 5 matched normal tissue controls Clontech cDNA array (~588) Y NONE 
Alevizos et al. 2001 5 OSCC, 5 matched normal tissue controls  Affymetrix HuGeneFL (~7000) Y qRT-PCR 
El-Naggar et al. 2002 12 OSCC, 12 matched normal tissue controls Research Genetics cDNA arrays GF200    ( 
~ 5184) or GF211 ( ~4048) 
N (90%) IHC, qRT-
PCR 
Mendez et al. 2002 26 OSCC, 18 matched and unmatched normal tissue 
controls 
Affymetrix Test-1 and HuGeneFL (~7000 
genes) 
N (60%) qRT-PCR 
Nagata et al. 2003 15 OSCC, Normal control: pooled mRNA from oral 
cavity of 58 patients without 
cancer 
Takara IntelliGene Human Cancer CHIP 
2.1 cDNA array (~557) 
N IHC, qRT-
PCR 
Hwang et al. 2003 5 OSCC, 5 matched normal tissue controls Affymetrix HuGeneFL (~7000) Y qRT-PCR 
Leethanakul et al. 2003 5 OSCC, 3 cDNA libraries from normal tissue controls Custom oral cancer-specific cDNA 
microarray (~384) 
Y NONE 
Gonzalez et al. 2003  1) Differential display RT-PCR N IHC, qRT-
PCR  2) Incyte Genomics UniGEM V cDNA array 
(~9350) 
3 OSCC, 3 matched normal tissue controls 3) Research Genetics cDNA array GF204 
(~5184) 
Ha et al. 2003 7 primary OSCC, 6 unmatched normal tissue controls Affymetrix HG-U95A.v2 (~12,650) N (85%) qRT-PCR 
Tsai et al. 2004 22 OSCC, 22 pair-wise matched normal tissue 
controls 
MillenniaChip II (~1177) N Northern 
blotting, 
qRT-PCR  
Toruner et al. 2004 16 OSCC, 4 matched normal tissue controls Affymetrix Hu133A (over 39,000 
transcripts)  
Y qRT-PCR 
Irie et al.  2004 11  OSCC, 11 normal tissue controls Human Cancer 1.2 Atlas cDNA array 
(Clontech)  
Y NONE 
Li et al. 2004 32 salivary sample from OSCC patients, 32 salivary Affymetrix HG U133A (over 39,000 N qRT-PCR 
Continue 
  Chapter 2 
48 
 
     Studies*          Year published                         Sample types                                                    Array platform                                                LCM                          Validation 
samples from individuals without OSCC transcripts)  
Whipple et al. 2004 29 OSCC, 19 unmatched normal tissue controls Affymetrix TM oligonucleotide (~7070) N NONE 
Carinci et al. 2005 8 OSCC, 11 unmatched normal tissue controls custom array-Ontario Cancer Institute 
(~19,200) 
N NONE 
Shimada et al. 2005 58 OSCC, 58 matched normal tissue controls in-house cDNA microarray (~2304) N (80%) qRT-PCR 
Chin et al. 2005 7 OSCC, 7 matched normal tissue controls custom array-Ontario Cancer Institute 
(~19,200) 
N IHC 
Belbin et al. 2005 9 OSCC, 9 matched normal tissue controls Custom cDNA clones (~17840) N (70%) IHC 
Dysvik et al. 2006 11OSCC, pool of 8 matched normal tissue controls human cDNA DNR (~15,000) N (70%) IHC, qRT-
PCR 
Tomioka et al. 2006 14 OSCC, 14 Pair-wised control tissue samples 16 617 human cDNA fragments N qRT-PCR 
Ziober et al. 2006 13 OSCC, 13 Pair-wised control tissue samples Affymetrix HG U133A (over 39,000 
transcripts)  
N (80%) IHC, qRT-
PCR 
Li et al. 2006 32 serum sample from OSCC patients, 32 serum 
samples from individuals without OSCC 
Affymetrix HG U133A (over 39,000 
transcripts)  
N qRT-PCR 
Suhr et al. 2007 15 OSCC, 15 Pair-wised control tissue samples Operon human oligonucleotide 
microarrays (~34,580) 
N (70%) qRT-PCR 
Lopes et al. 2007 48 primary OSCC, 8 unmatched normal tissue 
controls 
Affymetrix Human Genome U133 Plus 2.0 
(over 47,000transcript+ FOCUS Array 
(over 8,500 )  
N (65%) qRT-PCR 
Ye et al. 2008 26 Tongue OSCC, 12 matched tissue controls Affymetrix Human Genome U133 Plus 2.0 
(over 47,000 transcripts ) 
N (80%) IHC, qRT-
PCR 
Chen et al. 2008 167 OSCC, 45 unmatched normal tissue controls Affymetrix Human Genome U133 Plus 2.0 
(over 47,000 transcripts ) 
N qRT-PCR 
Estilo et al. 2009 16 Tongue OSCC, 22 matched tissue controls Affymetrix HG_U95Av2 (~12,625) N qRT-PCR 
LCM: laser capture microdissection; Y: yes; N: no; qRT-PCR: quantitative real-time polymerase chain reaction; IHC: immunohistochemistry; * Summary of head and 
neck carcinoma genetic profiling literature. Studies were identified by Medline database search, and are listed according to the year published. Microarray platforms 
used, array data validation methodologies, and whether laser capture microdissection was employed are listed for each study. Minimum percentage of tumour cell 
content of samples in non-LCM studies is shown in parentheses. 
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2.4.1 Gene expression profile of OSCC versus normal oral 
mucosa  
Reviewing the reports identified genes that constantly differentially expressed among 
the studies with significantly altered expression in OSCC and HNSCC relative to 
normal oral mucosa (Table 2.2 and Table 2.3). A total of 368 genes were common 
among at least three studies of the total 28 review studies, while 63.3% (233) 
downregulated, only 36.6% (135) were upregulated genes in tumours. Among the 
genes identified commonly altered in these studies, overexpression of several genes 
encoding for matrix metalloproteinases (MMP1, MMP3, MMP7, MMP9, MMP10, 
MMP12, and MMP13), collagens (COL1A2, COL3A1, COL4A1, COL5A2, 
COL4A2, COL5A1, COL6A3, COL7A1, and COL11A1), C-X-C chemokines 
(CXCL1, CXCL2, CXCL6, CXCL9, CXCL10, and CXCL11), interferons (IFI6, 
IFI27, IFI44, and IFI44L), transforming growth factors (TGFB1, TGFBR3, and 
TGFBI), tumour necrosis factors (TNFAIP1, TNFAIP6, and TNFSF10), laminins,  
fibronectins, tenascin C, along with perturbation of interleukins, integrins, serpin 
peptidase inhibitors. These accompanied with repression of DNA binding inhibitors, 
protein phosphatase 1 regulatory (inhibitor) subunits, several genes encoding for 
keratins, especially those frequently involved in OSCC and HNSCC including 
aerodigestive tract cancers (KRT4, 13, 15, and 19). 
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Table 2.2: Common genes significantly higher in OSCC tumours compared to normal 
oral tissue samples**. 
GENE 
SYMBOLE 
NO.*  GENE 
SYMBOLE 
NO.*  GENE 
SYMBOLE 
NO.*  GENE 
SYMBOLE 
NO.* 
MMP1 11  COL5A1 4  CXCL11 3  SERPINH1 3 
COL1A2 9  COL6A3 4  CXCL6 3  SFN 3 
KRT17 9  COX4I1 4  CXCL9 3  SLC39A14 3 
PLAU 9  CTNNA1 4  DFNA5 3  SLC7A11 3 
SOD2 9  CXCL1 4  EBNA1BP2 3  TEAD4 3 
POSTN 8  CXCL2 4  FAP 3  THBS1 3 
SPARC 8  EXT1 4  FLNA 3  TNFAIP1 3 
CDH3 7  FAT1 4  FSCN1 3  TNFAIP6 3 
COL1A1 7  HIF1A 4  FTH1 3  TNFSF10 3 
COL4A1 7  IFI44 4  FTL 3    
FN1 7  IL1B 4  GBP1 3    
IFI6 7  ITM2A 4  GJA1 3    
LAMC2 7  KRT14 4  GSK3B 3    
MMP12 7  LAMA3 4  GSTO1 3    
MMP3 7  LAMB1 4  H3F3A//H3F3B 3    
STAT1 7  LGALS1 4  HMGA2 3    
COL3A1 6  LOXL2 4  HOMER3 3    
IL8 6  MMP7 4  IFI27 3    
ISG15 6  PDPN 4  IFI44L 3    
LUM 6  PRNP 4  INHBA 3    
MMP10 6  PTHLH 4  IGFBP7 3    
MYO1B 6  RHOA 4  LAMB3 3    
SERPINE1 6  SLC16A1 4  LY6E 3    
SPP1 6  SOX4 4  MICAL2 3    
TGFBI 6  TGFB1 4  MMP13 3    
TPBG 6  THBS2 4  MMP9 3    
ADH1A/B/C 5  THY1 4  MSN 3    
BST2 5  TMSB10 4  MYO10 3    
COL5A2 5  TPM1 4  NRG1 3    
CTSL1 5  VEGFA 4  OASL 3    
CXCL10 5  APOL2 3  PKM2 3    
ITGA6 5  BIRC3 3  PLA2G7 3    
KRT16 5  C5ORF13 3  PLAUR 3    
KRT5 5  CALD1 3  PPIAL3 3    
RAB31 5  CASP1 3  PSMB2 3    
TNC 5  CD44 3  PXDN 3    
ACTN1 4  CD47 3  RAN 3    
AIM2 4  CFL1 3  RBP1 3    
APOL1 4  CHST2 3  REL 3    
CAV1 4  COL11A1 3  RHOC 3    
CAV2 4  COL7A1 3  S100A2 3    
COL4A2 4  CTSC 3  SCRN1 3    
* Number of studies where the gene exists. ** Full names and genes IDs presented in Supplementary 
file 2. 
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Table 2.3: Common genes significantly lower in OSCC tumours compared to normal oral tissue samples.** 
GENE 
SYMBOL 
NO.*  GENE 
SYMBOL 
NO.*  GENE 
SYMBOL 
NO.*  GENE 
SYMBOL 
NO.*  GENE 
SYMBOL 
NO.* GENE SYMBOL NO.* 
KRT4 11  CCNG2 4  ANXA1 3  DUSP1 3  MALL 3  SREBF2 3 
KRT13 10  CD24 4  ANXA11 3  DUSP6 3  MAOA 3  SRPX 3 
MAL 10  CEACAM5 4  AP2S1 3  EHD3 3  MAPK9 3  STK39 3 
TGM3 8  CEACAM7 4  AP3D1 3  EHF 3  MC1R//TUBB3 3  THBD 3 
EMP1 7  CKMT1A// 
CKMT1B 
4  APP 3  EIF3B 3  MFGE8 3  TJP1 3 
KRT15 7  CLU 4  APPBP2 3  ENO3 3  MICA 3  TM7SF2 3 
RPL10 //4 7  CRCT1 4  ASAH1 3  ERBB2 3  MXD1 3  TPM2 3 
ALDH3A2 6  CRIP1 4  ATP1A2 3  ERBB3 3  MYH11 3  TPM4 3 
ALDH9A1 6  CRNN 4  ATP5A1 3  ERCC5 3  NCOA1 3  TRIM13 3 
CES2 6  CSTB 4  BACH1 3  ERO1L 3  NET1 3  TRIO 3 
CLEC3B 6  EVPL 4  BID 3  ESPL1 3  NFE2L2 3  TRPS1 3 
CRISP3 6  GNAI1 4  BPGM 3  FAM107A 3  P4HB 3  TSPAN3 3 
ECM1 6  HSPB8 4  C10ORF116 3  FOXN3 3  PCOLCE 3  TSPAN6 3 
GPX3 6  IGFBP5 4  C2ORF54 3  GLTSCR2 3  PEBP1 3  TUBA1A 3 
HPGD 6  IK 4  CAPG 3  GPD1L 3  PGD 3  TYRP1 3 
KRT1 6  KRT10 4  CAPN3 3  HBA1//HBA2 3  PKP4 3  UBE2C 3 
MAOB 6  KRT76 4  CAST 3  HBB 3  PLAGL1 3  UBE2L3 3 
ADH7 5  MEIS1 4  CCDC6 3  HRAS 3  PMM1 3  UCK2 3 
CRYAB 5  NDRG2 4  CDKN1A 3  HS3ST1 3  PPP1R7 3  UGP2 3 
DNASE1L3 5  NT5C2 4  CEACAM1 3  ID2 3  PSCA 3  VAV3 3 
HLF 5  NUCB2 4  CEACAM6 3  ID3 3  PTP4A1 3  VCAN 3 
ID4 5  PDCD4 4  CEBPD 3  IDH3G 3  QARS 3  WNK1 3 
IL1RN 5  PHLDA2 4  CETN3 3  IL18 3  RCAN2 3  XBP1 3 
KRT19 5  PPL 4  CLCA4 3  IL1F6 3  RHCG 3    
LEPR 5  PPP1R1A 4  CLIC3 3  IRS1 3  RNASE4 3    
MGLL 5  PRSS3 4  COL18A1 3  ITGA2 3  RORA 3    
MGST2 5  RPL10A 4  COX5B 3  ITGB1 3  RRAGD 3  Continue  
NEBL 5  SCNN1A 4  COX7A1 3  IVL 3  S100A11 3    





NO.*  GENE 
SYMBOL 
NO.*  GENE 
SYMBOL 
NO.*  GENE 
SYMBOL 
NO.*  GENE 
SYMBOL 
NO.* GENE SYMBOL NO.* 
NMU 5  SP100 4  CSNK1G2 3  JUP 3  S100A14 3    
PPP1R3C 5  TGFBR3 4  CUL3 3  KAT2B 3  SCNN1B 3    
PTK6 5  TGM1 4  CYB5A 3  KLK11 3  SCP2 3    
SCEL 5  TSPAN8 4  CYP2C18 3  KLK13 3  SERPINB13 3    
SERPINB1 5  TYRO3 4  CYP3A5 3  KRT7 3  SERPINB2 3    
SPINK5 5  UBL3 4  CYP51A1 3  LCN2 3  SFRS5 3    
TNXA//TNXB 5  UGT1A7 4  DBI 3  LGALS3 3  SKP1 3    
ZNF185 5  ABCD3 3  DEFB1 3  LGALS7 3  SLC26A2 3    
ABCA8 4  ACAA2 3  DEGS1 3  LIMK2 3  SLC9A3R1 3    
ACPP 4  ACYP1 3  DHCR24 3  LMO4 3  SLURP1 3    
ALOX12 4  AIM1 3  DMD 3  LOX 3  SMAD4 3    
BLNK 4  ALDH3A1 3  DPT 3  LPIN1 3  SPARCL1 3    
BTF3P11 4  ALOX12B 3  DR1 3  LTA4H 3  SPINT1 3    
CCL14//CCL15 4  ALOX5 3  DSG1 3  LYN 3  SPRR2C 3    
* Number of studies where the gene expressed. ** Full names and genes IDs presented in Supplementary file2. 
  Chapter 2 
53 
 
2.4.2 Exploring the set of common genes in a raw data 
Because of the lack of consistency of the expressed common genes across the 28 
studies, an attempt was carried out to search for the common genes expression in raw 
data. The raw data selected was belong tumour versus normal from UK population 
which will be analysed separately in chapter 4. A significant overlapping of the 
common genes over the genes from the raw data was observed while the expression 
(whether up- or down-regulated) of all overlapped genes were constant between both 
groups of common and raw data genes (Figure 2.1). 




Figure 2.1: Hierarchical clustering displaying common genes overlapped over raw data 
of UK tumour versus normal samples.  
Red and blue bars represent cancerous and normal samples, respectively. Heatmap represents absolute 
expression of genes in rows and samples in columns. Expression (red= high, green= low, black= not 
changed) is represented on absolute expression scale.  
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2.4.3 Biological interpretation of the common expressed 
genes 
To obtain more biological understanding of why expressed genes in OSCCs are 
different to normal oral tissue samples, the Ingenuity pathway analysis was used to 
examine gene molecular function, biological process, canonical pathways, and 
upstream/transcriptional regulators analysis. IPA system depends on the knowledge 
database of selected functional and regulatory interactions extracted from the 
literature and provides integrated graphical representation of the biological 
relationships between genes and gene products considering both up- and down-
regulated genes from the comparison analysis. 
2.4.3.1 Functional analysis   
Cellular Movement, Growth, Proliferation, Development, Death and Survival, and 
Immune cell trafficking functions displayed at the top of the perturbed molecular 
cellular functions in relation to cancer (Figure 2.2).   
 
Figure 2.2: Molecular cellular functions of common genes related to OSCC using IPA 
functional annotation analysis. 
Higher bars denote greater significance and the numbers of genes above the yellow line, which 
signifies a p value of 0.05, represent those that are significantly differentially expressed than by 
chance alone 
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2.4.3.2 Associated network analysis 
Investigation of the biological relationships between genes and gene products was 
carried out by performing a network analysis of the common genes. A master 
network was constructed by connecting the selected genes involved in cancer using 
Fisher’s exact test. The highly connected nodes are likely to reflect their ability to 
regulate a large number of genes in the master network and potentially to control the 
gene expression pattern identified tumour signature of the comparison. Over-
expression of VEGFA, HIF1A, TGFB1, IL8, IL1B, FN1, SPP1, STAT1, SERPINE1, 
MMP1, MMP3, MMP7, MMP9, MMP13, TNC, RHOA, PLAU, CXCL10, CXCL2, 
THBS1, COL1A1, COL1A2, COL3A1, and PTHLH along with under-expression of 
CDKN1A, ERBB2, ERBB3, IGFBP5, ITGB1, LGALS3, SMAD4, HRAS, NFE2L2, 
MAPK9, and DUSP1 gene nodes were identified at the centre of the network (Figure 
2.3).  
Additional, more specific master network was constructed by highlighting the only 
selected genes involved in OSCC and HNSCC using Fisher’s exact test (Figure 2.4). 




Figure 2.3: Central area of the comprehensive molecular network of the common genes related to cancer. 
Master network built by connecting significant genes involved in cancer disease, identified by IPA tool (version 9.0) from up- and downregulated genes using overlap 
function of core analysis. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationship between the nodes). The tumours 
relative to normal overexpressed genes are shaded in red and under-expressed genes in green. The nodes are represented using various shapes that represent the 
functional class of the gene products. Highly interconnected nodes (‘hub genes’) are highlighted with black edges as potential key regulators of the master network. 
The network represents significant genes common among the review studies in at least 3 studies. For full view of the network, see supplementary file 3.




Figure 2.4: Master molecular network of the common genes related to OSCC and head and neck cancer. 
Master network built by identifying significant genes involved in OSCC and HNSCC by IPA tool (version 9.0) from up- and downregulated genes using overlap 
function of core analysis. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationship events between the nodes and the 
tumour types). The tumours relative to normal overexpressed genes are shaded in red and under-expressed genes in green. The numbers displayed under the nodes 
represent the number of studies where the gene exists. The nodes are represented using various shapes that represent the functional class of the gene products.
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2.4.3.3 Upstream regulators  
It’s well known that regulation of human genes depends on sets of transcription 
factors rather one individual factor. For this reason “Upstream and Transcriptional 
Regulator Analysis” tool available from IPA system was used to identify several key 
players in the biological context. These include activation of CTNNB1, JUN, 
NFKBIA, and STAT3, along with inhibition of TP53 and MYC transcriptional 
regulators. In addition, activation of TGFB1, EGF, and EGFR growth factors and 
growth factor’s receptor was accompanied with activation of TNF and IFNG 
cytokines along with repression of ERBB2 cytokine.  
2.4.3.4 Canonical pathway analysis 
By utilizing canonical pathway analysis tool (IPA), Role of Tissue Factor in Cancer, 
Leukocyte Extravasation Signalling, Inhibition of matrix metalloproteases, HIF1a 
Signalling, ILK Signalling, and Xenobiotic Metabolism signalling displayed as the 
most common perturbed pathways involved in tumour transformation. Previous 
works extensively described the role of these pathways during tumour 
transformation. The determination of the significant dysregulated pathways is 
accomplished by overlapping the input common genes over the pre-generated 
pathways. Figure 2.5 displays the top pathway dysregulated in this study (Role of 
Tissue Factor in Cancer).  
2.4.3.5 Biomarker analysis 
In an attempt to find potential biomarkers that reported an involvement in OSCC and 
HNSCC among the common genes set, running biomarker filter analysis (IPA) 
identified 27 specific biomarkers related to OSCC and HNSCC (Figure 2.6). The 
figure describes clearly the particular function of each biomarker related to specific 
tumour type. 




Figure 3.4.: Highly involved biological pathway in OSCC, The Role of Tissue Factor in Cancer Pathway; A- TF in angiogenesis and tumour 
growth. 
Red denotes upregulation and green denotes downregulation of the gene. Ingenuity Systems, (version 9.0). Full comprehensive view of the pathway is available in 
supplementary file 4. 




Figure 2.5: Highly involved biological pathway in OSCC, The Role of Tissue Factor in Cancer Pathway; B- Intracellular TF in metastasis. 
Red denotes upregulation and green denotes downregulation of the gene. Ingenuity Systems, (version 9.0). Full comprehensive view of the pathway is available in 
supplementary file 4. 




Figure 2.6: Common genes biomarkers related to OSCC and HNSCC. 
Biomarker network built by connecting significant genes involved in OSCC and HNSCC, identified by biomarker filter tool (IPA, version 9.0) from up- and down-
regulated common genes using overlap function of the biomarker analysis. The network is displayed graphically as nodes (genes/gene products) and edges (the 
biological relationship events between the nodes and the tumour types). The tumours relative to normal overexpressed genes are shaded in red and under-expressed 
genes in green. The nodes are represented using various shapes that represent the functional class of the gene products. The numbers displayed under the nodes 
represent the number of studies where the gene exists.  
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2.5 Discussion  
The review study specified several genes and pathways exhibiting 
substantially altered expression in cancerous versus noncancerous states 
across studies. Among the genes identified commonly altered in these studies, 
included overexpression of several genes encoding for matrix metalloproteinases, 
collagens, C-X-C chemokines, interferons, transforming growth factors, tumour 
necrosis factors, laminins,  fibronectins, tenascin C, along with perturbation of 
interleukins, integrins, serpin peptidase inhibitors. These accompanied with 
repression of DNA binding inhibitors, protein phosphatase 1 regulatory (inhibitor) 
subunits, several genes encoding for keratins, especially those frequently associated 
with OSCC and HNSCC including aerodigestive tract cancers (KRT4, 13, 15, and 
19). Furthermore, both activation and inhibition of the upstream and transcriptional 
regulators detected in the result section have been reported to have a major 
contribution in the tumorigenic process. In fact, according to the knowledge base of 
IPA, Figure 2.4 displayed 76 (over 20% of the total common genes) genes associated 
with OSCC and HNSCC where 27 of them are verified biomarkers (Figure 2.6).  
Over-expression of chemokines in tumours has been ascribed frequently to 
constitutive stimulus of NFκB, the signalling pathway which plays a key role in anti-
apoptosis and is widely proposed now as potential molecular tumorigenic marker in 
various types of tumours including colorectal, bladder, pancreatic, breast, ovarian, as 
well as oral cancer (He et al., 2009). Elevated level of several members of CXC 
family in tumours was another finding which enhances angiogenesis 
(Vandercappellen et al., 2008, Vinader and Afarinkia, 2012, Zhu et al., 2012). These 
include CXCL8 (IL8), CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL7. 
Besides their functions in the immune system, they also play a critical role in tumour 
initiation, promotion and progression (Vandercappellen et al., 2008). C-X-C 
chemokines 2, 3, 9, and genes encoding for extracellular matrix proteins and 
collagens have previously been involved in the motility and invasion of tumour 
(Chen et al., 2008a). 
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Notably, some of these changes, although identified in multiple reports, may also 
present in other sample studies which are not identified, basically due to the absence 
of probes for these genes in the platforms used for these studies. Arrays used by 
different research groups contained probes for as few as 384 genes to as many as 
over 47,000 transcripts (Table 2.1). These results were encouraging considering the 
heterogeneity of the studies where the samples are collected. Although, the criteria of 
studies’ selection in this review reduced the impact of anatomic specific genetic 
expression differences might have on comparison of OSCCs by selecting only 
tumours from oral cavity, considerable heterogeneity among these studies in study 
design, number of samples, ratio of tumour-to-stromal cells analysed, and choice of 
microarray platform were still existed. Some studies employed separation of tumour 
cells from stromal cells by LCM, whereas others estimated the percentage of tumour 
cells within tumour samples before RNA extraction and subsequent analyses. The 
impact of interaction between tumour cells and their surrounding stromal and non-
tumour constituents (e.g. immune response cells) is well recognized in tumours of 
human epithelium and other tissue of the body (Moinfar et al., 2000, Matrisian et al., 
2001, Mueller and Fusenig, 2002, Chung et al., 2005). Comprehensive genetic 
profiling of OSCC and HNSCC, therefore, must not calculate only cancer cell-
specific gene expression, but the surrounding stromal cell expression as well, to 
provide complete understanding of altered gene expression. Furthermore, the most 
significant source of heterogeneity among microarray tumour profiling studies was 
derived from the various methods of data generation and analysis (Choi and Chen, 
2005). Although these findings may  serve  focusing  in  selecting markers for  
further analysis to improve understanding and  management of OSCC and HNSCC, 
limitations to the  function  of the  list of genes and  pathways were noticed in the  
current study. Considering the top differentially expressed gene, only 11 out of 28 
studies found common, suggesting doubts about the reasons making that gene absent 
in the other remaining studies. Other genes from the list of common genes were 
much poorer in their common existence (Table 2.2 and Table 2.3). Perhaps the 
largest downside of microarray based examination of HNSCC is the lack of well 
defined standards for their use, interpretation, and validation. Variability in tissue 
procurement, tumour cell isolation, RNA extraction, choice of array platform, and   
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data normalization and   analysis preventing rigorous comparison of results from one 
laboratory with those from others. Furthermore, estimation of tumour-to-stromal cell 
ratios in tumour samples by histological evaluation of adjacent tissue sections is 
imprecise. This  is mainly due  to  the  nature of HNSCCs, which are not  simple, 
homogeneous masses with  discrete edges, but   rather complex, three-dimensional 
entities with  varying  degrees of  specular projections and  interlaced stromal 
components, not  to  mention the  potential clonal heterogeneity among tumour cells 
themselves. Estimation of percentage tumour cell content within one or a few 
histologic sections of a tissue sample does not ensure the same percentage tumour 
cell content within the entire sample. Nevertheless, estimated tumour-to-stromal cell 
ratios can be useful in establishing the simple presence or absence of cancer cells, 
and repeating the pathologic diagnoses of experimental samples (Choi and Chen, 
2005). The current review pointed out to a popular significant inaccuracy among the 
studies using microarray technologies in underestimating the tumour origin of 
HNSCC during sample collection. A study used microarray design demonstrated that 
HNSCCs originating from different anatomical locations can exhibit varying 
behaviours and concluded that HNSCC tumours originating from different anatomic 
sites share consistent changes in gene expression when comparing primary tumours 
to normal adjacent mucosa, where these common changes most likely reflect 
alterations required for tumour development. In contrast, once a tumour has 
developed, tumour-host interactions at different anatomic sites are likely responsible 
for the site-specific signatures associated with aggressive versus non-aggressive 
disease. Hence, predictions of outcome based on gene expression profiling are 
therefore heavily influenced by the anatomical site of the primary tumour (Belbin et 
al., 2008). 
The top differentially expressed gene in 11 out of 28 studies is considered a poor 
outcome in finding unique identifier/s for OSCC. The weakness of tumour profiling 
of the list of common genes originates primarily from limited sample sizes and 
heterogeneity in the experimental design and execution, as well as the differences in 
the size of the final set of genes published by the individual studies. One study 
provided only 9 genes from the whole set of microarray genes without revealing the 
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other significant genes harvested before the final filter of their statistical analysis 
(Gonzalez et al., 2003). Published data from such studies should not viewed as 
endpoints of research accomplishments, but rather as screening tools of identifying 
potential genes for validation and further investigation. Nevertheless, the capability 
to measure the expression of thousands of genes simultaneously gives researchers a 
powerful method to analyse global genetic events responsible for HNSCC 
progression (Choi and Chen, 2005). 
The attempt of searching common genes among raw data of UK tumour versus 
normal samples displayed clearly the satisfactory overlapping between the two gene 
sets (common genes vs. genes of raw data). This finding confirms the impact of 
using different post-lab analytical approaches in modifying and shaping of the 
procurement final list of genes. 
This review did not access raw data expression of most of the studies, and therefore 
did not consider how different fold changes in gene expression might impact 
different clinical outcomes or biological pathways. Ideally, all published studies 
containing DNA microarray analyses should deposit their raw expression data in 
publically accessible repositories (e.g., NCBI GEO, Array express, others), to permit 
accomplishment of systematic and comprehensive meta-analysis. For this reason, 
additional attempt was carried out (chapter 3) to perform meta-analysis profiling 
OSCCs relative to normal mucosa by recruiting similar bioinformatics approach on 
multiple raw data sets. 
Conclusion of the current review suggests not only relying on the final set of genes 
published by the individual studies, but to access the raw data of each study and start 
subsequent analysis from that stage using unified bioinformatics approaches to 
acquire useful and complete understanding of the systems biology and identifying the 
subsequent dysregulated biological pathways, molecular functions, and processes. 
  Chapter 3 
67 
 
Chapter 3: Detection of a robust gene signature 
for oral squamous cell carcinoma by 
integrating multiple microarray datasets 
3.1 Introduction 
The pathogenic pathways that contribute to OSCC remain poorly characterised (Liu 
et al., 2012); hence, a clinically applicable gene expression signature is in high 
demand and improved characterization of the OSCC gene expression profiles would 
constitute substantial progress. Analysing the publicly available gene expression 
datasets has already proven new promising insights on biological processes.  
The review study (chapter two) demonstrated that whilst there is a number of 
promising microarray studies on HNSCC and OSCC in the literature, many of these 
lack the acceptable characteristics to be clinically useful in practice. 
There are many limiting factors to perform meta-analysis of the various profiles, 
these include; differences in numbers of laboratory samples and processing, 
microarray platform (e.g., Affymetrix, Illumina, Agilent chips), gene chip model 
(e.g., Affymetrix HU-U133A, HU-U133 Plus2, HU-U95A) and diverse 
bioinformatics approaches used for data analysis (Sims et al., 2008, Kitchen et al., 
2010). The limited sample size of the individual studies along with different 
bioinformatics approaches used for post-laboratory analysis are considered the most 
influencing of the above mentioned factors resulting in only a small overlap between 
the various gene signatures of OSCC. Large studies and frequently repetitive 
experimentation for an individual research study is undesirable due to the high costs. 
The problems of low accuracy and efficiency in a single analysis can be, to some 
extent, overcome by merging different single datasets to generate a larger sample 
size study accompanied by applying the same subsequent bioinformatics analysis 
approaches (Ein-Dor et al., 2006, Tseng et al., 2012).  
  Chapter 3 
68 
 
With the availability of considerable publicly accessible microarray datasets, it is of 
substantial concern to understand how to merge microarray data across various 
individual studies of OSCC to enlarge sample size, which may improve the 
establishment of more reliable and solid gene signature of OSCC. 
Integration of microarray datasets is advantageous for researchers to increase 
statistical power in detecting biological phenomena from studies where logistical 
considerations restrict sample size (Turnbull et al., 2012). Generally, it is 
inappropriate to combine datasets without adjusting for batch effects (Johnson et al., 
2007a, Lazar et al., 2012).  
Batch effects can be caused by laboratory conditions, reagents, and personnel 
diversity. This becomes a major problem when batch effects correlated with an 
outcome of biological interest and result in incorrect conclusions (Leek et al., 2010). 
In this study, the ComBat batch correction method was utilised to minimise batch 
effects across studies. 
3.2 Aims and objectives of the study 
1-Using multiple bioinformatics approaches to integrate and process large and 
widely variable samples in an attempt to increase statistical power in detecting and 
identifying specific biomarkers and prediction models for OSCC. 
2-To investigate the harvested transcriptomic profile using multiple biological 
annotation tools in an attempt to identify potential mechanisms underlying the 
biological changes during tumorigenic transformation of OSCC. Furthermore, to 
detect biological pathways necessarily altered in tumourigenesis which can 
potentially illuminate novel therapeutic targets. 
3.3 Materials and Methods 
Four public microarray datasets of OSCC were integrated to determine the common 
set of genes, biomarkers, and the relative regulatory pathways possibly accountable 
for tumour transformation and growth in OSCC. 
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Raw Affymetrix .CEL files from published datasets were downloaded from public 
datasets repositories (explained below in details), summarised with Ensembl 
alternative CDF (Dai et al., 2005) and normalised with RMA (Irizarry et al., 2003), 
before integrating using ComBat (Johnson et al., 2007b) to remove dataset-specific 
bias as previously described (Sims et al., 2008).  
The pre-processing steps were performed as a submitted job on the Edinburgh 
Compute and Data Facility high performance compute cluster 'Eddie', due to 
lack a of memory on a standalone PC. 
3.3.1 Selection of datasets  
A search for OSCC and HNSCC microarray datasets among NCBI Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo/), ArrayExpress Archive 
(http://www.ebi.ac.uk/arrayexpress/), and caARRAY array data management system 
(https://array.nci.nih.gov/caarray/home.action) was carried out. Only microarray 
gene expression datasets from published studies of oral and head and neck cancer 
performed on frozen material extracted before chemotherapy, radiotherapy or 
adjuvant treatment were selected. Studies using Laser Capture microdissection 
technologies were excluded as it reflects non-comprehensive gene expression profile 
of just tumour cells, neglecting the tumour-stromal interaction (the signature of each 
tumour sample is a reflection of the combined tumour, stromal and inflammatory 
components of the original heterogeneous tumour sample (Ross et al., 2000)). 
The study comprises pure samples of oral cavity in which other origins of tissue 
samples (e.g., nasopharyngeal, maxillary sinus, posterior wall of oropharynx, and 
larynx) were excluded from the analysis as these samples already originated from 
different origins which can reflect different molecular gene expression profiles 
regardless of the disease status, whereas some of them associated with HPV infection 
(oropharyngeal tumour). HPV positive samples were also excluded. Four datasets 
(Table 3.1) were selected that used the same platform (Affymetrix U133 Plus2, 
www.affymetrix.com) for the gene expression analysis of tumour versus normal 
tissue samples (Ye et al., 2008, Chen et al., 2008a, Pyeon et al., 2007, Reis et al., 
2011). Harvested samples consist of 270 tumour and 95 normal samples comprising 
a total of 365 samples.  
  Chapter 3 
70 
 
Table 3.1: Characteristics of the selected datasets samples*. 












Array series No. 
Ye et al, 2008 US, Los Angeles, Chicago 26 12 76.3 I-IV HG- U133 Plus2.0 GSE9844 
Chen et al, 2008 US, Washington 167 45 70 I-IV HG- U133 Plus2.0 GSE26549, GSE30784, 
GSE31056 
Pyeon et al, 2007 US, Iowa 22 14 52.7 I-IV HG- U133 Plus2.0 GSE6791 
Reis et al, 2011 Canada, Toronto 55 24 77.2 I-IV HG- U133 Plus2.0 E-GEOD31056 
* All samples are harvested from whole tumour specimens.
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3.3.2 Data processing and analysis 
Data analysis was performed using Bioconductor packages (Gentleman et al., 2004), 
http://www.bioconductor.org/) and the statistical programming language, R. The 
simpleaffy package was used to assess average background, Scale factors, Number of 
genes called present (% Present), 3’ to 5’ ratios. Normalization was performed using 
RMA algorithm to extract gene expression values (Irizarry et al., 2003). 
Subsequently, Nonspecific Filtering was performed using the function rowSds (Row 
variance and standard deviation of a numeric array)/ genefilter in R statistical 
software package available on Bioconductor.  
3.3.2.1 Number of genes called present (% Present)  
Present/Marginal/Absent calls are generated by looking at the difference between 
Perfect Match (PM) and Mismatch (MM) values for each probe pair in a probeset. As 
the Mismatch (MM) probe intensity increases and becomes equal to or greater than 
the Perfect Match (PM) intensity, the Discrimination score decreases. More 
specifically, as the intensity of the Mismatch (MM) increases, the ability to 
discriminate between the PM and MM decreases. 
Probesets are flagged “Marginal” or “Absent” when the PM values for that probeset 
are not considered to be significantly above the MM probes. The ‘% Present’ call 
simply represents the percentage of probesets called Present on an array. 
3.3.3 Integration of datasets and batch correction 
Integration of all normalized single datasets was carried out using ComBat package 
in R software (Johnson et al., 2007a), while parametric and non-parametric empirical 
Bayes frameworks were implicated for adjusting data of batch effects. 
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3.3.4 Differential gene expression analyses 
Tumour samples were compared to normal samples to examine differential gene 
expression and to extract meaningful biological results from this comparison. In this 
comparison, data analysis takes two main forms. The first is ‘unsupervised’ analysis 
where data is sorted and gene expression differences are derived based on inherent 
differences within the dataset. Unsupervised clustering was achieved and heatmaps 
generated using Pearson correlation and hierarchical clustering in R. Supervised 
analysis was carried out using the Significance Analysis for Microarrays (SAM) 
(Tusher et al., 2001) in siggenes package available from Bioconductor. SAM  is one 
of the more potent and effective ways of identifying particular gene products 
involved in differentiating transcriptional profiles between two groups (Tusher et al., 
2001). SAM gives good all-round discriminatory ability based on average signal 
intensity differences within the supervised groups and between the same groups at 
pre-determined fold-change levels and gives an estimate of the false discovery rate 
for a significantly changed gene (Jeffery et al., 2006). Hierarchical clustering 
heatmaps were generated using gplots package (Gentleman et al., 2004). Fold change 
values for relative “upregulated/overexpressed” and “downregulated / under-
expressed” genes were obtained using Wilcoxon Rank Statistics function in siggenes 
R software. 
Lists of genes were further refined by trimming out low magnitude fold changes and 
/ or reducing the false discovery rate (FDR) value of the significant genes by 
adjustment of delta value. The value of delta is chosen that provides the best balance 
between the number of identified genes and the estimated FDR, i.e. that allows to 
simultaneously attain the two competing goals “As many genes as possible" and “As 
low FDR as possible". 
  Chapter 3 
73 
 
3.3.5 Biological annotations of significant genes 
Ingenuity Pathway Analysis 9.0, IPA, was used to highlight the most dysregulated 
molecular and cellular bio-functions, canonical pathways, diseases and disorders, 
transcriptional regulators, and most significant pre-generated networks associated 
with the uploaded group of genes (8995 meta-genes at FDR ≤ 0.05 with no fold 
change cut -off) including those related to OSCC development. IPA knowledge base 
recruits the distinguished genes that regulated OSCC and HNSCC to generate and 
highlight the above functions.  
As mentioned in the previous chapter, IPA cannot map pseudogenes, hypothetical 
genes, ESTs and ambiguous (mapping to multiple) genes as well as duplicates of 
multiple IDs mapped in one molecule or multiple molecules snapped in one ID. 
However, the unmapped genes were converted using David conversion tool (Huang 
et al., 2009a, Huang et al., 2009b) to include them in the subsequent analysis, some 
were substantial key players in the master networks of the analysis and contributing 
to the tumorigenic process. 
3.4 Results  
3.4.1 Filtering and processing of the datasets 
After normalization, the huge number of probesets was reduced by Nonspecific 
Filtering using the function rowSds/ genefilter in R statistical software package 
available on Bioconductor 
(www.bioconductor.org/packages/release/bioc/vignettes/genefilter/inst/doc/howtoge
nefilter.pdf). By applying this filtering method (Figure 3.1, Figure 3.2, and Figure 
3.3), not only a reduction in the non-useful and non-diagnostic probe sets found, but 
also an improvement in the sample discrimination ability of the subsequent analysis. 
Whilst all probe sets whose standard deviation below 0.242 were discarded as they 
have very low variability and can safely assumed that it will not be able to infer 
differential expression for their target genes. 




Figure 3.1: Filtration of probe sets of both tumour and normal samples 
The filtration carried out using non-specific filtering method from genefilter in R statistical software 
package available on Bioconductor.  The blue dotted vertical lines represent the cut-off value of 
rowSds =0.242. 
   




Figure 3.2: Density and Q-Q plot of normalized genes before filtration method. 
The density plots (density vs. log2 intensity (1/2(log2(cy5*cy3)))) (produced using the R statistical 
language with the LIMMA package), illustrating the distribution of single-channel intensities.  The 
plots allow visually comparing different normalization methods. The Q-Q (Quantile-Quantile) plots 
(produced using the R statistical language with the Bioconductor package) displaying the magnitude 
of differentially gene expression within the sample tested based on the Students t-test relative to a 
theoretical t-statistic.  The Q-Q plot indicate the degree a sample diverges from a normal distribution 
where points which deviate markedly from a linear relationship to a theoretical t-statistic could be 
considered suspect genes exhibiting differentially expression. 




Figure 3.3: Density and Q-Q plot of normalized genes after filtration method. 
The density plots (density vs. log2 intensity (1/2(log2(cy5*cy3)))) (produced using the R statistical 
language with the LIMMA package), illustrating the distribution of single-channel intensities.  The 
plots allow visually comparing different normalization methods. The Q-Q (Quantile-Quantile) plots 
(produced using the R statistical language with the Bioconductor package) displaying the magnitude 
of differentially gene expression within the sample tested based on the Students t-test relative to a 
theoretical t-statistic.  The Q-Q plot indicate the degree a sample diverges from a normal distribution 
where points which deviate markedly from a linear relationship to a theoretical t-statistic could be 
considered suspect genes exhibiting differentially expression. 
3.4.2 Integration of datasets and correction of batch effect 
The four datasets were merged using ComBat data integration method in R software 
(Figure 3.2 and Figure 3.3). Ensembl IDs were used to form the comparison of the 
common genes.  
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3.4.3 Verification of data integration 
To assess the removal of microarray bias effect across datasets, Pearson correlation 
and hierarchical clustering were applied to the datasets after the application of data 
integration method (ComBat). The results of these tests are shown in Figure 3.4 and 
Figure 3.5. As can be seen from those figures, ComBat was successful in removing 
dataset-specific biases (Figure 3.5) where samples clustered independent to the 
dataset after correction compared to those merged randomly before the use of 
ComBat (Figure 3.4). 
3.4.4 Gene expression profile of OSCC versus normal oral 
mucosa  
Following data normalization, probeset filtering, and batch correction for dataset 
integration, unsupervised analysis of tumour and normal samples was performed 
using Pearson correlation comparison in which normal samples clustered together 
away from tumour samples (Figure 3.5). The samples did not cluster by the datasets 
from which they were derived, suggesting that intra- and inter-platform batch effects 
have been minimised, whilst samples from the same individual dataset still cluster 
independently, signifying that the true biological differences (disease status) are 
maintained. This indicates ComBat correction significantly reduced the bias between 
samples from different datasets.




Figure 3.4: Unsupervised Pearson correlation hierarchical clustering of merged 18394 normalized genes before ComBat integration, 
discriminating normal oral mucosal samples (N=95) from OSCC samples (N=270). 
Heatmap represents sample distribution according to the Pearson correlations (red= 1, yellow= lower than 1, white= lowest value than 1). Red and blue bars below the 
heatmap represent cancerous and normal samples, respectively. The green, brown, yellow, and purple bars on the bottom represent the samples of Reis et al., Chen et 
al., Ye et al., and Pyeon et al. datasets respectively.




Figure 3.5: Unsupervised Pearson correlation hierarchical clustering of 12092 normalized genes after ComBat integration, discriminating 
normal oral mucosal samples (N=95) from OSCC samples (N=270). 
Heatmap represents sample distribution according to the Pearson correlations (R-values 0.55-1; red= 1, yellow= lower than 1, white= lowest value than 1). Red and 
blue bars below the heatmap represent cancerous and normal samples, respectively. The green, brown, yellow, and purple bars on the bottom represent the samples of 
Reis et al., Chen et al., Ye et al., and Pyeon et al. datasets respectively.
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Initial supervised analysis of all tumour and normal samples was carried out using 
SAM method with a false discovery rate (FDR) = 0 and fold change above or below 
1.5 (Figure 3.6). A group of Thirty four samples belonging to one study (Reis et al.), 
which comprises a part of one of the four datasets, was collected from the normal 
margins during removal of the tumour lesions, but as described in the original study, 
they had a different molecular profile from other pure normal tissue predicting 
tumour recurrence of individuals after surgical removal of original primary tumour. 
These samples were included in the study as tumour samples to see if they behave 
independently among the normal and tumour samples from the four datasets. 
However, all of them cluster with the normal rather than tumour samples, indicating 
that their molecular profiles are more similar to normal tissue, despite having some 
predicting sign of tumour recurrence according to their original study (Figure 3.6). 
These samples were removed from the subsequent analysis to end up with 329 
samples instead of 365 totals (236 tumour and 93 normal samples).  
The 329 samples were subjected to the SAM method in two groups according to 
sample type; OSCC and normal mucosa identifying 334 differentially expressed 
genes with a fold change cut-off equal to ±1.5 and FDR level = 0, where 121 genes 
were higher and 213 genes lower in OSCC compared to normal mucosal samples 
(Table 3.2, Table 3.3, and Supplementary file 5).  




Figure 3.6: Hierarchical clustering of differentially expressed genes separating OSCC tumour (n=236) and both pure oral normal (N=95) and 
marginal normal oral samples (n=34) using SAM supervised analysis at FDR=0. 
Heatmap represents mean-centred expression of 334 differentially expressed genes in rows and samples in columns. Expression (red= high, green= low, black= not 
changed) is represented on a log2 mean- centred scale. Gene expression values were either above or below fold change magnitudes equal ± 1.5. Red, pink, and blue 
bars below the heatmap represent cancerous, marginal, and normal samples, respectively. The green, brown, yellow, and purple bars on the bottom represent the 
samples of Reis et al., Chen et al., Ye et al., and Pyeon et al. datasets respectively.
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Table 3.2: Upregulated differentially expressed meta-genes in OSCC compared to 







MMP1 6.16  CDH3 2.08  KRT75 1.67 
MMP13 4.42  TREM2 2.07  IFI44 1.67 
MMP10 4.31  CDSN 2.03  ABCA12 1.67 
MMP3 4.24  RSAD2 2.02  IFI44L 1.65 
MMP12 3.95  APOL1 2.02  COL4A6 1.65 
COL11A1 3.43  COL5A2 2.01  LAMA1 1.64 
SERPINE1 3.10  PLAU 2.01  CYP27C1 1.64 
PTHLH 3.09  CXCL3 2.00  SH2D5 1.63 
CXCL13 3.07  ADAM12 2.00  TGFBI 1.63 
APOC1 2.92  PRR9 1.94  C7ORF10 1.63 
ISG15 2.80  TDO2 1.94  EN1 1.61 
IL8 2.79  CXCL9 1.94  APOBEC3A 1.59 
ZIC2 2.74  ODZ2 1.93  IFIT1 1.59 
CCL20 2.72  CSPG4 1.91  LEPREL1 1.58 
MUCL1 2.63  CXCL6 1.89  HOXC10 1.58 
CTHRC1 2.60  COL4A1 1.88  IFI27 1.57 
GPR39 2.58  PMEPA1 1.87  CA2 1.57 
LAMC2 2.56  SPP1 1.87  HOXB7 1.57 
IFI6 2.55  AIM2 1.85  HSD17B6 1.57 
POSTN 2.52  COL5A1 1.84  SLC16A1 1.56 
FAP 2.49  TNC 1.83  PPP4R4 1.55 
CXCL10 2.46  PPAPDC1A 1.83  WISP3 1.54 
COL10A1 2.44  SERPINH1 1.83  LPCAT1 1.54 
KRT17P1 2.43  HOXA10 1.82  MFAP2 1.54 
CXCL11 2.39  CST1 1.79  GBP1 1.53 
SCG5 2.38  ESM1 1.79  CCL11 1.52 
TNFRSF12A 2.36  IDO1 1.79  COL4A2 1.52 
KRT16 2.35  GBP5 1.77  IBSP 1.52 
BST2 2.33  MYO1B 1.77  KANK4 1.52 
GALNT6 2.31  CMPK2 1.77  CNTNAP2 1.51 
CXCL1 2.27  KHDC1 1.76  C6ORF150 1.51 
MAGEA4 2.27  IL1F9 1.76  ARSJ 1.51 
GPR158 2.26  HOXD10 1.76  BCL2A1 1.50 
SLCO1B3 2.22  SOST 1.72  TNFAIP6 1.50 
SPRR2C 2.22  TREM1 1.71  TMEM45A 1.50 
CXCL5 2.17  HAS3 1.71    
HOXD11 2.17  DFNA5 1.71    
MMP9 2.14  BNC1 1.70    
LOC100129940 2.11  C20ORF103 1.70    
COL1A1 2.10  PDPN 1.70    
LIPG 2.08  EPSTI1 1.68    
WDR66 2.08  CYP27B1 1.67    
GREM1 2.08  COL1A2 1.67    
* FDR value = 0. The complete lists of upregulated gene names and ENSEMBL IDs were presented 
in Supplementary file 5. ** Log2 folds change values. 
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Table 3.3: Downregulated differentially expressed meta-genes in OSCC compared to 







CRISP3 -5.69 ADH7 -2.56 UPK1A -2.14 
CRNN -4.95 SFTA2 -2.55 ASPA -2.14 
TMPRSS11B -4.95 TNNC1 -2.54 HPGD -2.14 
MAL -4.28 GBP6 -2.53 LMOD2 -2.13 
KRT4 -4.01 MAMDC2 -2.52 FUT6 -2.12 
TGM3 -3.86 CHRDL1 -2.49 MUC15 -2.12 
KRT78 -3.77 ANGPTL1 -2.47 DAPL1 -2.11 
PRSS27 -3.68 ATP6V0A4 -2.47 CILP -2.11 
ENDOU -3.62 SLITRK5 -2.46 PYGM -2.11 
CLCA4 -3.51 SLC6A4 -2.42 LOC643008 -2.10 
FAM3B -3.46 STATH -2.41 ATP13A4 -2.09 
SLURP1 -3.38 HLF -2.38 ATP1A2 -2.08 
SPINK7 -3.31 CLEC3B -2.36 ECM1 -2.07 
FAM3D -3.25 SPRR3 -2.35 CA3 -2.06 
KRT13 -3.23 TF -2.34 PTN -2.06 
ADH1A -3.20 C9ORF169 -2.34 MYOZ1 -2.06 
CAPN14 -3.14 ENO3 -2.32 MYOT -2.05 
RHCG -3.11 C2ORF40 -2.32 TOX3 -2.05 
ACTA1 -3.05 RBM20 -2.32 PLP1 -2.04 
SLC27A6 -3.01 SCIN -2.30 CGNL1 -2.03 
ABCA8 -3.01 CYP3A5 -2.29 CLIC3 -2.03 
SCEL -3.00 EPHX2 -2.26 UGT1A7 -2.01 
CKM -2.94 SH3BGRL2 -2.24 TCEAL2 -2.00 
MYH2 -2.87 BBS5 -2.24 SLN -2.00 
PPP1R3C -2.86 CYP4B1 -2.23 LAMB4 -1.99 
PLAC9 -2.79 MFAP4 -2.22 GPD1L -1.98 
SNX31 -2.78 A2ML1 -2.21 MAOB -1.98 
MYL1 -2.76 MYRIP -2.21 EMP1 -1.98 
ALDH3A1 -2.75 CASQ1 -2.20 CNFN -1.97 
MYBPC1 -2.71 MB -2.20 CFD -1.96 
TNNI2 -2.70 ABI3BP -2.19 NCCRP1 -1.95 
SERPINB11 -2.70 FCER1A -2.19 PLA2G2A -1.95 
GYS2 -2.70 PADI1 -2.17 ST6GALNAC1 -1.95 
TMPRSS11E -2.69 GREM2 -2.17 TMEM100 -1.93 
SPINK5 -2.68 ALOX12 -2.16 C2ORF54 -1.93 
FLG -2.64 HOPX -2.16 OSR1 -1.92 
AADAC -2.62 C7 -2.16 CXCL17 -1.92 
SCARA5 -2.58 TYRP1 -2.15 ADIPOQ -1.92 
TNNC2 -2.58 IGSF10 -2.15 IL1F6 -1.92 
TSPAN8 -2.57 CEACAM5 -2.14 TMPRSS2 -1.91 
GSTA1 -1.90 FOXA1 -1.67 SUSD4 -1.53 
NMU -1.90 TNNT3 -1.67 KLHDC8A -1.52 
MEOX2 -1.88 RAET1E -1.66 DPT -1.52 
TGM1 -1.87 C10ORF116 -1.66 ETNK2 -1.51 
COX7A1 -1.87 C1QTNF7 -1.65 CRISP2 -1.51 
FXYD1 -1.87 SAMD5 -1.65 EXPH5 -1.51 
MYOC -1.86 PAX9 -1.65 ZBTB7C -1.50 
Continue 









TPRG1 -1.85 RBP7 -1.64 KLB -1.50 
CYP4F12 -1.85 ALDH1A1 -1.64 GPR133 -1.50 
CRYM -1.84 PPL -1.64 EYA2 -1.50 
COBL -1.83 KLK13 -1.64 IL33 -1.50 
GALNT12 -1.82 PRSS3 -1.64 CWH43 -1.50 
ANXA9 -1.82 CTTNBP2 -1.64 C4ORF31 -1.50 
NR3C2 -1.82 EVPL -1.64   
CYP2C18 -1.82 TM7SF2 -1.63   
CHST9 -1.81 C9ORF152 -1.63   
SPNS2 -1.81 GDPD3 -1.62   
DARC -1.81 FMO2 -1.62   
MMRN1 -1.81 KLK12 -1.62   
ATP2A1 -1.81 FHL1 -1.62   
CLDN8 -1.80 GCNT3 -1.61   
NPY1R -1.80 IL1RN -1.61   
PITX1 -1.78 KRT15 -1.61   
IL12A -1.77 GCHFR -1.59   
NRAP -1.77 TCP11L2 -1.59   
CEACAM7 -1.76 TGFBR3 -1.59   
DLK1 -1.76 OGN -1.59   
CLDN17 -1.75 SASH1 -1.59   
SCNN1B -1.75 DEPDC6 -1.57   
CKMT2 -1.72 TTC9 -1.57   
GGTA1 -1.72 BLNK -1.57   
APOD -1.71 VIT -1.56   
GABRP -1.71 PLN -1.56   
C15ORF62 -1.70 C7ORF46 -1.56   
KLK11 -1.69 MGLL -1.55   
SGCG -1.69 MYL3 -1.55   
FAM149A -1.68 BNIPL -1.55   
LYVE1 -1.68 PAX1 -1.54   
HS3ST6 -1.68 BTC -1.54   
CLDN10 -1.67 PPARGC1A -1.53   
* FDR value = 0. The complete lists of downregulated gene names, ENSEMBL IDs were presented in 
Supplementary file 5. ** Log2 folds change values. 




Figure 3.7: Hierarchical clustering of differentially expressed genes after removal of marginal samples separating tumour (n=238) and normal 
samples (n=91) using SAM supervised analysis at FDR=0. 
Red and blue bars represent cancerous and normal samples, respectively. Heatmap represents mean-centred expression of 334 differentially expressed genes in rows 
and samples in columns. Expression (red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. Gene expression values were either 
above or below fold change magnitudes equal ± 1.5. The green, brown, yellow, and purple bars on the bottom represent the samples of Reis et al., Chen et al., Ye et al., 
and Pyeon et al. datasets respectively.
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Figure 3.7 displays better discrimination between tumour and normal samples than 
before removal of the marginal normal samples. 
At FDR level ≤ 0.05, a set of 8995 differentially expressed genes (74% of the total 
normalized genes) was obtained, which subsequently uploaded to IPA system for 
comprehensive biological interpretation of the resultant set of meta-genes 
differentiating tumour from normal samples of the four datasets.  
3.4.5 Prediction models 
Additional supervised analyses were performed in an attempt to improve the 
discrimination power separating tumour from normal samples with less number of 
genes. Delta value of SAM was further adjusted to accept only top 100, 50, 38, 8, 
and 3 differentially expressed genes. Despite the small number of genes, the 
prediction models still have the capability of discriminating OSCCs from normal oral 
mucosa. Figure 3.8, Figure 3.9, and Figure 3.10 display the model of top 38, 8, and 3 
genes respectively. The top 8 significantly differentially expressed genes had better 
discriminating power between OSCC tumours and normal oral tissue than the 334 
genes (Figure 3.9) with fewer normal samples clustered in the tumour area of the 
hierarchy positioned very close to the area of normal samples. From the set of 8 and 
3 genes, LAMC2 and MMP1 reported as biomarkers overexpressed in the diagnosis 
of oral, head and neck cancer respectively Figure 3.16, while repression of  MAL 
employed as diagnostic biomarker of gastric cancer. The other 5 genes (PTHLH, 
GPD1L, TPBG, SLC27A6, and TMPRSS11B) are suggested as candidates for 
diagnostic, prognostic, and disease prognosis biomarkers of OSCC. Uploading the 8 
genes of the model to IPA, revealed Cell-To-Cell Signalling and Interaction, Cellular 
Assembly and Organization, Cellular Compromise, Cell Death and Survival, and 
Cellular Development functions where most of the genes involved in. Oncostatin M 
Signalling, Inhibition of Matrix Metalloproteases, HIF1α Signalling, Role of Tissue 
Factor in Cancer, and Glucocorticoid Receptor Signalling exhibited as the top, cancer 
related, canonical pathways where the 8 genes participated. KEGG pathway analysis 
(Kanehisa and Goto, 2000) of the 8 genes was performed with DAVID, online 
pathway annotation software based on scoring and visualization of the dysregulated 
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pathways collected in KEGG database (http://david.abcc.ncifcrf.gov/home.jsp). 
KEGG analysis highlighted additional two activated pathways; the extracellular 
matrix- receptor interaction (ECM Receptor Interaction) and Peroxisome 
proliferator-activated receptors (PPAR) signalling pathways corresponding to the 
model of 8 genes.   
3.4.5.1 The discrimination power of the variant prediction models 
The distribution of misclassified tumour and normal samples clustered in the 
hierarchy was used to examine the discrimination power of each prediction model. 
The model with 38 genes (Figure 3.8) showed 12% (11 normals) and 7.5% (18 
tumours) misclassified compared to 6.6% (6 normals) and 17.6% (42 tumours) in the 
model of 334 genes at FDR=0 (Figure 3.7). This is considered an improvement in the 
discrimination power; especially as it is accompanied with a reduction in the number 
of discriminators (from 334 to 38 genes). Further improvement was observed with 
the model of 8 genes (Figure 3.9) showing only 7.6% (7 normals) and 10.9% (26 
tumours) misclassified in the hierarchical cluster. However, the model consisting of 3 
genes presented less improvement in the discrimination power relative to the one of 8 
genes with 43.9% (40 normals) and 6.3% (15 tumours) misclassified in the hierarchy. 
Table 3.4: The percentages of misclassified tumour and normal samples among the 
prediction models.* 
Prediction Models 334 genes 38 
genes 
8 genes 3 genes 
Misclassified tumour samples (%) 17.6 7.5 10.9 6.3 
Misclassified normal samples (%) 6.6 12 7.6 43.9 
Total misclassified tumour and normal Samples (%) 24.2 19.5 17.6 50.2 
* The number of misclassified tumour and normal samples can be distinguished roughly from the red 
and blue bars presented in the hierarchical clusters of the models.   




Figure 3.8: Hierarchical clustering of top 38 differentially expressed genes after removal of marginal samples separating tumour (n=238) and 
normal samples (n=91) using SAM supervised analysis. 
Red and blue bars represent cancerous and normal samples, respectively. Heatmap represents mean-centred expression of genes in rows and samples in columns. 
Expression (red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. The green, brown, yellow, and purple bars on the bottom 
represent the samples of Reis et al., Chen et al., Ye et al., and Pyeon et al. datasets respectively.




Figure 3.9: Hierarchical clustering of top 8 differentially expressed genes after removal of marginal samples separating tumour (n=238) and 
normal samples (n=91) using SAM supervised analysis. 
Red and blue bars represent cancerous and normal samples, respectively. Heatmap represents mean-centred expression of genes in rows and samples in columns. 
Expression (red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. The green, brown, yellow, and purple bars on the bottom 
represent the samples of Reis et al., Chen et al., Ye et al., and Pyeon et al. datasets respectively. 




Figure 3.10: Hierarchical clustering of top 3 differentially expressed genes after removal of marginal samples separating tumour (n=238) and 
normal samples (n=91) using SAM supervised analysis. 
Red and blue bars represent cancerous and normal samples, respectively. Heatmap represents mean-centred expression of genes in rows and samples in columns. 
Expression (red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. The green, brown, yellow, and purple bars on the bottom 
represent the samples of Reis et al., Chen et al., Ye et al., and Pyeon et al. datasets respectively.
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3.4.5.2 Validation of the prediction models 
The prediction models of top 8 and 3 genes were selected for validation with an 
external validation dataset from GEO (http://www.ncbi.nlm.nih.gov/geo/, GSE6631 
containing 22 paired samples of HNSCC and normal tissue from the same donors 
using Affymetrix U95A platform) (Kuriakose et al., 2004). The prediction models 
were applied to find their altered expression in the normalised datasets. 6 out of 8 
genes (MMP1, LAMC2, PTHLH, TPBG, GPD1L, and MAL) were correspondingly 
expressed in the dataset (Figure 3.11) while the probes of the remaining 2 genes 
(TMPRSS11B and SLC27A6) were absent in U95A platform. Student t-test was 
applied to identify the significant expression of the 6 genes discriminated tumour 
from normal samples of the independent dataset and whether the expression direction 
(up- or downregulation) of each gene in the models expressed similarly to the 
expression direction of the corresponding genes in the independent dataset. Boxplots 
showed the significant over-expression of MMP1, LAMC2, PTHLH, and TPBG6 
genes along with under-expression of MAL and GPD1L genes in tumours relative to 
normal samples of the external independent dataset with all genes show significant 
differences between tumour and normal samples at  p-value ≤ 0.0001 (LAMC2, 
TPBG, MAL, and GPD1L) and p-value ≤ 0.001 (MMP1 and PTHLH). 
Both LAMC2 and PTHLH genes showed 2 probes in the external dataset where both 
probes confirmed the overexpression of genes in tumours relative to normal samples 
as seen in the boxplots. Further validation was carried out using two additional 
processed data sets of both UK and Sri Lanka discriminating tumour from normal 
samples of the oral cavity (samples of chapter 4) using HG Focus microarray 
platform. MMP1, PTHLH, LAMC2, TPBG, MAL, and SLC27A6 were 
correspondingly expressed in both UK and Sri Lankan gene sets differentiated 
tumour from normal samples while the probes of TMPRSS11B and GPD1L found 
absent in HG Focus platform. 
Further information related to the 8 genes’ model were gathered and summarized 
from different biological annotation tools including; Source 
(http://puma.princeton.edu/cgi-bin/source/sourceResult), Entrez Gene 
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(http://www.ncbi.nlm.nih.gov/gene/), and GeneCards tools 
(http://www.genecards.org/) in addition to IPA (Table 3.5).   




Figure 3.11: Box Plots displaying expression of 6 genes (MMP1, LAMC2, PTHLH, TPBG, GPD1L, and MAL) chosen for validation with an 
external dataset from GEO (GSE6631).  
** P-value ≤ 0.01, *** P-value ≤ 0.001, **** P-value ≤ 0.0001 compared tumour to normal samples determined by using unpaired student 
t-test. 
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Table 3.5: Summary and biological annotations of the 8 genes' model. 





Collagen catabolism Zinc ion binding 
Calcium ion binding 
Interstitial 
collagenase activity 
11q22.3 Proteins of the matrix metalloproteinase (MMP) family 
are involved in the breakdown of extracellular matrix in 
normal physiological processes, as well as in disease 
processes. This gene encodes a secreted enzyme which 
breaks down the interstitial collagens, types I, II, and III. 





1q25-q31 Laminins, a family of extracellular matrix glycoproteins, 
are the major noncollagenous constituent of basement 
membranes. 
      Heparin binding    




Positive regulation of cell 
proliferation 





This hormone regulates endochondral bone 
development and epithelial-mesenchymal interactions 
during the formation of the mammary glands and 
teeth. The receptor of this hormone, PTHR1, is 
responsible for most cases of humoral hypercalcemia of 
malignancy. 
                     TPBG Trophoblast 
glycoprotein 
Cell motility cell communication, 
playing a role in 
placentation or 
metastasis 
6q14-q15 This gene encodes a leucine-rich transmembrane 
glycoprotein that may be involved in cell adhesion. In 
adults this protein is highly expressed in many tumor 
cells and is associated with poor clinical outcome in 
numerous cancers. 
  Cell adhesion 
Signal transduction 
Cell differentiation 
Induction of apoptosis 
        MAL Mal, T-cell 
differentiation 
protein 





2cen-q13 The protein has been localized to the endoplasmic 
reticulum of T-cells and is a candidate linker protein in 
T-cell signal transduction. The protein plays a role in 
the formation, stabilization and maintenance of 
glycosphingolipid-enriched membrane microdomains. 
Continue 
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Gene ID Gene name Biological processes Molecular function     Chromosome/Cytoband                    Entrez Gene Summary 
                                               Continue  












(NAD+) activity, NAD 
binding 
 
3p22.3 The protein encoded by this gene catalyzes the 
conversion of sn-glycerol 3-phosphate to glycerone 
phosphate. The encoded protein is found in the 
cytoplasm, associated with the plasma membrane, 
where it binds the sodium channel, voltage-gated, 
type V, alpha subunit (SCN5A). Defects in this 
gene are a cause of Brugada syndrome type 2 
(BRS2) as well as sudden infant death syndrome 
(SIDS). 





       SLC27A Solute carrier 





Very-long-chain fatty acid 
metabolism 
5q23.3 This gene encodes a member of the fatty acid 
transport protein family (FATP). FATPs are 
involved in the uptake of long-chain fatty acids and 
have unique expression patterns. 
       










4q13.2 TMPRSS11B is active in the following subcellular-
locations: extracellular region, integral to plasma 
membrane. It's molecular function is through catalysis 
of the hydrolysis of internal, alpha-peptide bonds in a 
polypeptide chain by a catalytic mechanism that 
involves a catalytic triad consisting of a serine 
nucleophile that is activated by a proton relay involving 
an acidic residue (e.g. aspartate or glutamate) and a 
basic residue (usually histidine). 
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3.4.6 Biological interpretation of the differentially expressed 
meta-genes 
To obtain more biological understanding of why expressed genes in OSCCs are 
different to the normal oral tissue samples, the Ingenuity pathway analysis (IPA, 
http://www.ingenuity.com/) system was recruited to examine gene molecular 
function, biological process, canonical pathways, and transcriptional regulators 
analysis. IPA system depends on the knowledge database of selected functional and 
regulatory interactions extracted from the literature and provides integrated graphical 
representation of the biological relationships between genes and gene products 
considering both up- and downregulated genes from comparison analysis. 
3.4.6.1 Functional analysis  
The most relevant activated and inhibited functions at FDR<0.05 are reported in 
Figure 2.2. Cellular Movement, Growth, Proliferation, Development, and Cell-To-
Cell Signalling and Interaction functions displayed at the top of the perturbed 
molecular cellular functions in relation to cancer.   





Figure 3.12: Molecular cellular functions of meta-genes related to cancer with the 
greatest numbers of differentially expressed genes using IPA functional annotation 
analysis. 
Higher bars denote greater significance and the numbers of genes above the yellow line, which 
signifies a p value of 0.05, represent those that are significantly differentially expressed than by 
chance alone 
3.4.6.2 Associated network analysis 
Investigation of the biological relationships between genes and gene products was 
carried out by performing a network analysis of the meta-genes. The master network 
was constructed by connecting the selected genes involved in cancer using Fisher’s 
exact test. The highly connected nodes are likely to reflect their ability to regulate 
large number of genes in the master network and potentially to control the gene 
expression pattern that identified tumour signature of the comparison. Upregulation 
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of IL8, IL6, IL1B, FN1, PTGS2 (COX2), SPP1, CXCL3, STAT1, SERPINE1, 
MMP3, MMP9, ISG15, OSM, CXCL1, CXCL2, CXCL10, PLAU, MMP1, MMP13, 
AHR, HOXA10, COL1A1, CDKN2A, and CCL20 along with downregulation of 
ADIPOQ, PLA2G2A, MAPK3, IL1RN, CXCL12, PPARGC1A, NR3C2, RORC, 
and MUC1 nodes were identified at the centre of the network (Figure 2.3). As 
molecular relationships represented on the network include not only activation or 
inhibition of expression, but also protein-protein interactions, DNA-protein 
interactions and activation, localization, inhibition of the corresponding proteins 
(Debily et al., 2009), it is not surprising that microarrays may fail to identify some of 
the hub genes as significantly differentially expressed among the tumour versus 
normal samples. These genes might play a major role through protein activation for 
instance. Alternatively, their modulations may be very subtle and below the threshold 
for reliable detection of differences of the microarray platform despite its high 
sensitivity. 
Additionally, a more specific master network was constructed by connecting the 
selected genes involved in only OSCC and HNSCC using Fisher’s exact. 
Upregulation of SERPINE1, MMP3, MMP9, MMP1, IL8, IL6, IL1B, PLAU, 
IGFBP3, FN1, PTGS2 (COX2), SPP1, STAT1, CDKN2A, and COL1A1 along with 
downregulation of CXCL12, CLU, PPARGC1A, and MUC1 nodes test (Figure 3.14) 
forming the main structure of the network. Interestingly, these nodes forming the 
majority of the hub genes positioned at the centre of the previous network relating to 
cancer disease in general. 
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Figure 3.13: Central area of the comprehensive molecular network of meta-genes related to cancer. 
Master network built by connecting significant genes involved in cancer disease, identified by IPA tool (version 9.0) from up- and downregulated genes using overlap 
function of core analysis. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationship between the nodes). The tumours 
relative to normal overexpressed genes are shaded in red and under-expressed genes in green. The intensity of colours reflects the magnitude of the fold change of the 
expressed molecule. The nodes are represented using various shapes that represent the functional class of the gene products. Highly interconnected nodes (‘hub genes’) 
are highlighted with black edges as potential key regulators of the master network. The network represents significant genes at FDR level ≤ 0.05 with no fold change 
cut-off. For full view of the network, see supplementary file 6.





Figure 3.14: Master molecular network of meta-genes related to OSCC and head and neck cancer. 
Master network built by connecting significant genes involved in OSCC, HNSCC, and oesophageal cancer, identified by IPA tool (version 9.0) from up- and down-
regulated genes using overlap function of core analysis. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationship 
between the nodes). The tumours relative to normal overexpressed genes are shaded in red and under-expressed genes in green. The intensity of colours reflects the 
magnitude of the fold change of the expressed molecule. The nodes are represented using various shapes that represent the functional class of the gene products. Highly 
interconnected nodes (‘hub genes’) are highlighted with black edges as potential key regulators of the master network. The network represents significant genes at FDR 
level ≤ 0.05 with no fold change cut-off. 
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3.4.6.3 Upstream regulators  
It’s well known that regulation of human genes depends on sets of transcription 
factors rather one individual factor. For this reason, “Transcriptional Regulator 
Analysis” tool available from IPA system was recruited, identifying the activation of 
STAT3, CTNNB1, and JUN, along with the inhibition of MEF2C and SMARCA4 
potential regulators which have a major contribution in the tumorigenic process.  
3.4.6.4 Canonical pathway analysis 
By utilizing canonical pathway analysis tool, Role of Tissue Factor in Cancer, 
Inhibition of matrix metalloproteases, Calcium Signalling, Dendritic cell maturation, 
IL-17 Signalling, LXR/RXR activation, IL6 signalling, Oncostatin M signalling, 
Leukocyte extravasation signalling, Interferon signalling, xenobiotic metabolism 
signalling pathways, as well as FAK, P53, Wnt/β catenin transcriptional signalling 
pathways, were found the most common perturbed pathways involved in the process 
of tumour transformation. Overlying these pathways over those dysregulated from 
the review study in chapter 2, show considerable overlapping as well. Role of Tissue 
Factor in Cancer, Inhibition of matrix metalloproteases, Leukocyte extravasation 
signalling, and xenobiotic metabolism signalling pathways were among those top 
dysregulated pathways common between the two set of genes indicating the 
significant similarity despite the differences in the number of genes forming the two 
sets (only 368 common genes forming the set of genes in the review study comparing 
to 8995 genes of the meta-analysis signature). 
3.4.6.5 Biomarker analysis 
In an attempt to find reportedly potential biomarkers among the differentially 
expressed set of meta-genes, running biomarker filter analysis (IPA) identified 35 
specific biomarkers related to OSCC, HNSCC, and oesophageal cancer (Table 3.6 
and Figure 3.15). Only 14 biomarkers were differentially expressed in tumour 
samples at fold change cut-off log value ± 1.5 (Figure 3.16). These include 
ADAM12, COL1A1, COL4A1, IL8, LAMC2, MMP1, MMP3, MMP9, MMP12, 
PDPN, POSTN, PTGS2, SERPINE1, and STAT1 over-expression, associated with 
under-expression of SPINK5 and TGM3 biomarkers. Figure 3.16 displays the role of 
each biomarker in diagnosis, progression, prognosis, and efficacy of oral, head and 
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neck, and oesophageal cancer using “Path Designer” advanced tool in IPA. The vast 
reduction in the number of biomarkers (from 35 to 14) using fold change cut-off 
criterion highlights the necessity not to limit biomarker tools based on the fold 
change magnitude. A specific biomarker showing consistent existence in a specific 
type of disease, not necessarily highly expressed to be considered a reliable 
biomarker, as long as sufficient sensitive monitoring tool is provided. 
Uploading these biomarkers to canonical pathway tool (IPA), displayed the top 
perturbed pathways in the following rank; Glucocorticoid receptor signalling, 
Inhibition of Matrix Metalloproteases, HIF1α Signalling, IL17 Signalling, Dendritic 
Cell Maturation, IL6, and IL8 signalling pathways. Although the number of 
biomarkers is not appropriate for build-up and identification of pathways, it remains 
displaying essential pathways reported in the tumorigenic process.  
Table 3.6: Oral, oropharyngeal, and head and neck cancer biomarkers of differentially 
expressed meta-genes. 
Symbol Location Family     Fold Change*                 Biomarker Application(s) 
MMP1 Extracellular Space Peptidase 6.1 diagnosis, response to therapy: head and 
neck, oesophageal cancer 
MMP3 Extracellular Space Peptidase 4.2 diagnosis: head and neck, oesophageal cancer 
MMP12 Extracellular Space Peptidase 3.9 diagnosis: oesophageal cancer 
SERPINE1 Extracellular Space Other 3.1 diagnosis, disease progression, prognosis, 
response to therapy: oral, head and neck 
cancer 
IL8 Extracellular Space Cytokine 2.7 diagnosis, disease progression, prognosis, 
response to therapy: head and neck, oral 
cancer 
LAMC2 Extracellular Space Other 2.5 diagnosis: oral cancer 
POSTN Extracellular Space Other 2.5 unspecified application: head and neck cancer 
COL1A1 Extracellular Space Other 2.1 diagnosis; oral cancer 
MMP9 Extracellular Space Peptidase 2.1 diagnosis, disease progression, prognosis: 
head and neck, oral cancer 
ADAM12 Plasma Membrane Peptidase 1.9 diagnosis; head and neck cancer 
COL4A1 Extracellular Space Other 1.8 diagnosis; oral cancer 
PDPN Plasma Membrane Transporter 1.6 Diagnosis ,disease progression, prognosis: 
head and neck, oral cancer 
Continue 
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Symbol Location Family     Fold Change*                 Biomarker Application(s) 
IFI27 Cytoplasm Other 1.5 disease progression; head and neck cancer 
TMEM45A Plasma Membrane Other 1.4 disease progression: head and neck cancer 
RBP1 Extracellular Space Transporter 1.3 diagnosis: oesophageal cancer 
SLC2A1 Plasma Membrane Transporter 1.3 efficacy: head and neck cancer 
CDKN2A Nucleus transcription 
regulator 
1.2 diagnosis, disease progression, efficacy, 
prognosis; oral, head and neck cancer 
STAT1 Nucleus transcription 
regulator 
1.2 diagnosis, prognosis: head and neck cancer 
DKK1 Extracellular Space growth factor 1.1 diagnosis, prognosis; oesophageal cancer 
IL1B Extracellular Space Cytokine 1.1 diagnosis, prognosis: oral cancer 
MCM2 Nucleus Enzyme 1.1 diagnosis, disease progression, prognosis: 
head and neck cancer,  oropharyngeal cancer 
ECT2 Nucleus Other 1 disease progression; head and neck cancer 
IL6 Extracellular Space Cytokine 1 diagnosis, disease progression, prognosis, 
response to therapy: head and neck, 
oesophageal cancer 
PTGS2 Cytoplasm Enzyme 1 diagnosis, disease progression, prognosis: oral, 
head and neck, oesophageal cancer 
SPARCL1 Extracellular Space Other -1 disease progression: head and neck cancer 
EHF Nucleus transcription 
regulator 
-1.1 unspecified application: head and neck cancer 
TIMP4 Extracellular Space Other -1.1 diagnosis, prognosis: head and neck cancer 
CCL21 Extracellular Space Cytokine -1.2 diagnosis, disease progression; oral cancer 
CXCL12 Extracellular Space Cytokine -1.2 diagnosis, disease progression, prognosis; 
head and neck cancer 
CRYAB Nucleus Other -1.3 diagnosis, disease progression, prognosis;  oral 
cancer, head and neck cancer 
KRT19 Cytoplasm Other -1.4 diagnosis, disease progression, prognosis: 
head and neck cancer 
SERPINB13 Cytoplasm Other -1.4 unspecified application: head and neck cancer 
ZNF185 Nucleus Other -1.4 unspecified application: head and neck cancer 
SPINK5 Extracellular Space Other -2.6 unspecified application: head and neck cancer 
TGM3 Cytoplasm Enzyme -3.8 unspecified application: head and neck cancer 
* Log2 folds change values.  




Figure 3.15: Biomarker network of meta-genes involved in OSCC and head and neck cancer 
Biomarker network built by connecting significant genes involved in OSCC, HNSCC, and oesophageal cancer, identified by biomarker filter tool (IPA, version 9.0) 
from up- and down-regulated genes using overlap function of the biomarker analysis. The network is displayed graphically as nodes (genes/gene products) and edges 
(the biological relationship between the nodes). Each edge supported by at least one study in the literature and peer reviewed by Ingenuity team. The tumours relative 
to normal overexpressed genes are shaded in red and under-expressed genes in green. The nodes are represented using various shapes that represent the functional class 
of the gene products. The network represents significant genes at FDR level ≤ 0.05 with no fold change cut-off. 




Figure 3.16: Highly expressed meta-genes biomarkers related to OSCC, HNSCC, and Oesophageal cancer. 
Biomarker network built by connecting significant genes involved in OSCC, HNSCC, and oesophageal cancer, identified by biomarker filter tool (IPA, version 9.0) 
from up- and down-regulated genes using advanced function (Path Designer) of the biomarker analysis. The network is displayed graphically as nodes (genes/gene 
products) and edges (the biological relationship between the nodes). Each edge supported by at least one study in the literature and peer reviewed by Ingenuity team. 
The tumours relative to normal overexpressed genes are shaded in red and under-expressed genes in green. The nodes are represented using various shapes that 
represent the functional class of the gene products. The network represents significant genes at FDR level ≤ 0.05 with 1.5 fold change cut-off. 
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3.4.7 Comparison between meta-genes and common genes of 
the review study 
Comparing meta-genes set (334genes at FDR level=0 and fold change cut-off ±1.5) 
and the common genes procured from the review study in chapter 2 (368 genes), 
highlighted over a quarter (96) of common genes as differentially expressed in both 
datasets. Reducing FDR stringency of the differentially expressed meta-analysis to ≤ 
0.05 with no fold change cut-off criteria increased the overlap to 326 genes, 89% of 
the total. This variation in the number of the final set of common genes highlights the 
impact of using different bioinformatics criteria and analysis approaches on the 
formulation of the final list of genes. 
Among the differentially expressed genes, several potential diagnostic biomarkers 
were identified which have previously been reported in OSCC and HNSCC (Table 
3.6). Notably, elevation of seven members of collagens (COL1A2, COL1A1, 
COL4A1, COL5A2, COL4A2, COL5A1, and COL11A1), six members of MMPS 
(MMP1, MMP3, MMP9, MMP10, MMP12, and MMP13), and five members of C-
X-C motif chemokines (CXCL1, CXCL6, CXCL9, CXCL10, and CXCL11) were 
observed which accompanied with repression of three keratins (KRT4, KRT13, and 
KRT15). 
Additional potential key players of tumour, including elevation of SPP1, LAMC2, 
IL8, IFI6, ISG15, MYO1B, SERPINE1, BS2, AIM2, and PTHLH along with 
repression of CRNN, MAL, TGM3, EMP1, CRISP3, PPP1R3C, ECM1, IL1RN, 
SCEL, SPINK5, TGFBR3, CEACAM5, CEACAM7, TGM1, and TYRP1 genes 
were observed in tumour relative to normal cohorts (Table 3.7). 
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Table 3.7: Significant genes commonly expressed between meta-genes set and common 
genes from the review study (chapter 2).* 




ENSEMBL Gene ID Gene Symbol Fold 
Change 
Over-expressed genes in tumour 
samples 
  Under-expressed genes in tumour 
samples 
 
ENSG00000196611 MMP1 6.16  ENSG00000096006 CRISP3 -5.69 
ENSG00000137745 MMP13 4.42  ENSG00000143536 CRNN -4.95 
ENSG00000166670 MMP10 4.31  ENSG00000172005 MAL -4.28 
ENSG00000149968 MMP3 4.24  ENSG00000170477 KRT4 -4.01 
ENSG00000110347 MMP12 3.95  ENSG00000125780 TGM3 -3.86 
ENSG00000108821 COL1A1 3.43  ENSG00000016602 CLCA4 -3.51 
ENSG00000060718 COL11A1 3.43  ENSG00000126233 SLURP1 -3.38 
ENSG00000106366 SERPINE1 3.10  ENSG00000171401 KRT13 -3.23 
ENSG00000087494 PTHLH 3.09  ENSG00000140519 RHCG -3.11 
ENSG00000187608 ISG15 2.80  ENSG00000141338 ABCA8 -3.01 
ENSG00000169429 IL8 2.79  ENSG00000136155 SCEL -3.00 
ENSG00000058085 LAMC2 2.56  ENSG00000119938 PPP1R3C -2.86 
ENSG00000126709 IFI6 2.55  ENSG00000108602 ALDH3A1 -2.75 
ENSG00000133110 POSTN 2.52  ENSG00000133710 SPINK5 -2.68 
ENSG00000078098 FAP 2.49  ENSG00000127324 TSPAN8 -2.57 
ENSG00000169245 CXCL10 2.46  ENSG00000196344 ADH7 -2.56 
ENSG00000169248 CXCL11 2.39  ENSG00000108924 HLF -2.38 
ENSG00000186832 KRT16 2.35  ENSG00000163815 CLEC3B -2.36 
ENSG00000130303 BST2 2.33  ENSG00000108515 ENO3 -2.32 
ENSG00000163739 CXCL1 2.27  ENSG00000106258 CYP3A5 -2.29 
ENSG00000100985 MMP9 2.14  ENSG00000108839 ALOX12 -2.16 
ENSG00000062038 CDH3 2.08  ENSG00000107165 TYRP1 -2.15 
ENSG00000100342 APOL1 2.02  ENSG00000105388 CEACAM5 -2.14 
ENSG00000204262 COL5A2 2.01  ENSG00000164120 HPGD -2.14 
ENSG00000122861 PLAU 2.01  ENSG00000018625 ATP1A2 -2.08 
ENSG00000138755 CXCL9 1.94  ENSG00000143369 ECM1 -2.07 
ENSG00000124875 CXCL6 1.89  ENSG00000169583 CLIC3 -2.03 
ENSG00000187498 COL4A1 1.88  ENSG00000167165 UGT1A7 -2.01 
ENSG00000118785 SPP1 1.87  ENSG00000152642 GPD1L -1. 98 
Continue 
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ENSEMBL Gene ID Gene Symbol Fold 
Change 
ENSG00000163568 AIM2 1.85  ENSG00000069535 MAOB -1.98 
ENSG00000130635 COL5A1 1.84  ENSG00000134531 EMP1 -1.98 
ENSG00000041982 TNC 1.83  ENSG00000172478 C2ORF54 -1.93 
ENSG00000149257 SERPINH1 1.83  ENSG00000136694 IL1F6 -1.92 
ENSG00000128641 MYO1B 1.77  ENSG00000109255 NMU -1.90 
ENSG00000105928 DFNA5 1.71  ENSG00000092295 TGM1 -1.87 
ENSG00000162493 PDPN 1.70  ENSG00000161281 COX7A1 -1.87 
ENSG00000164692 COL1A2 1.67  ENSG00000108242 CYP2C18 -1.82 
ENSG00000137965 IFI44 1.67  ENSG00000007306 CEACAM7 -1.76 
ENSG00000137959 IFI44L 1.65  ENSG00000168447 SCNN1B -1.75 
ENSG00000120708 TGFBI 1.63  ENSG00000167757 KLK11 -1.69 
ENSG00000165949 IFI27 1.57  ENSG00000148671 C10ORF116 -1.66 
ENSG00000155380 SLC16A1 1.56  ENSG00000118898 PPL -1.64 
ENSG00000117228 GBP1 1.53  ENSG00000167759 KLK13 -1.64 
ENSG00000134871 COL4A2 1.52  ENSG00000010438 PRSS3 -1.64 
ENSG00000123610 TNFAIP6 1.50  ENSG00000167880 EVPL -1.64 
    ENSG00000149809 TM7SF2 -1.63 
    ENSG00000136689 IL1RN -1.61 
    ENSG00000171346 KRT15 -1.61 
    ENSG00000069702 TGFBR3 -1.59 
    ENSG00000095585 BLNK -1.57 
    ENSG00000074416 MGLL -1.55 
    ENSG00000143196 DPT -1.52 
* FDR value = 0. Fold change represents the log2 magnitude of expression in OSCC relative to 
normal oral samples. 
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3.5 Discussion  
Both supervised and unsupervised analyses largely discriminated gene expression 
profiles between OSCC and normal mucosa samples, with the majority of tumour 
and normal samples clustering together. Although absolute specificity was not 
achieved, increasing the criteria stringency of the comparison between normal and 
tumour cohorts (to accept only the top 100, 50, 38, 8, and 3 genes), showed an 
improved discrimination power by a small set of genes as predictive discriminators. 
These results proved that SAM tool (siggenes package) is capable to elect the top 
discriminatory genes beyond the level of FDR = 0. As the sets of 334, 100, 50, 38, 8, 
and 3 genes are all significant at FDR level= 0, further adjustments of delta value 
(explained in materials and methods, 1.11.4) with FDR = 0, continue nominating 
smaller number of significant genes with better, or at least similar appropriate 
discrimination power of tumour from normal samples rather than selecting genes 
randomly. One of the four merged datasets in the meta-analysis study was used by its 
individual study to extract prediction models for OSCC (Chen et al., 2008a), 
however, their models failed in discriminating tumour from normal samples of the 
independent datasets (GSE6631, UK, and Sri Lankan sets comparing tumour vs. 
normal samples) that used for validation of the models harvested by current study 
(the models of 8 and 3 genes). This highlights the advantage of meta-analysis 
(employed large and wide range samples from different research centres) in creating 
more robust and comprehensive predictive signature. The model that consists of 8 
genes showed the best discriminating power among the prediction models. Whilst 3 
of the 8 genes are already recruited as biomarkers for OSCC, HNSCC, and gastric 
cancer (elevation of LAMC2 and MMP1 along with repression of MAL 
respectively), the other 5 genes (elevated PTHLH and TPBG along with repressed 
GPD1L, SLC27A6, and TMPRSS11B) might be novel biomarkers for OSCC. Cross-
correlating the 8 genes of the model over the genes harvested from the review study 
was carried out in chapter 2, which displayed complete match in 7 out of 8 genes of 
the model whilst only one gene (TMPRSS11B) shown absent in the review study 
(chapter 2). MMP1, LAMC2, PTHLH, and TPBG genes were found regularly over-
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expressed whereas, MAL, GPD1L, and SLC27A6 constantly under-expressed in 
tumour relative to normal samples of the review study (Table 3.8).  
Table 3.8: Distribution and expression of the 8 genes model among external datasets. 









MMP1↑ ↑ HNSCC Elevated Elevated Elevated Elevated 
LAMC2↑ ↑ OSCC Elevated Elevated Elevated Elevated 
PTHLH↑  Elevated Elevated Elevated Elevated 
TPBG↑  Elevated Elevated Elevated Elevated 
MAL↓ ↓ Gastric 
cancer 
Repressed Repressed Repressed Repressed 
GPD1L↓  Repressed Absent Absent Repressed 
SLC27A6↓  Absent Repressed Repressed Repressed 
TMPRSS11B↓  Absent Absent Absent Absent 
* Dataset refers to tumour vs. normal samples comparison. ↑ and ↓ arrows denoted to the elevated and 
repressed expression levels. Absent refers to the absence of the gene probe in the platform 
manufacturer used in the analysis of the corresponding dataset.  
In fact, PTHLH exhibited as one of the potential key players over-expressed in the 
comprehensive molecular network of the common genes related to cancer in the 
review study (Chapter 2). Previous findings from both in vivo and in vitro analyses 
showed essential associations regarding the role of PTHLH in breast cancer, 
suggesting the proliferative effects of PTHLH in breast cancer cells are mediated 
through regulation of cell cycle and apoptosis, and that controlling PTHLH 
production in breast cancer may be therapeutically useful (Falzon and Du, 2000, 
Tabuenca et al., 1995, Sepulveda et al., 2002). Additional reports specified the 
possible significance of autocrine/paracrine effects of PTHLH in the progression of 
early-stage lung adenocarcinoma, as well as, growth and dedifferentiation of 
malignant cells in cervical cancer (Monego et al., 2010, Dunne et al., 1994). Some 
reports identified PTHLH to serve as a tumour marker in animal models of 
pancreatic cancer and may be a useful tumour marker for clinical pancreatic 
adenocarcinoma (Bouvet et al., 2002), while additional findings suggested PTHLH 
as a common target molecule in specific immunotherapy for patients with a wide 
variety of tumour types, particularly bone metastases (Arima et al., 2005). Further 
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results pointed to the role of PTHLH as a cancer modifier gene in skin 
tumourigenesis (Kaiser et al., 1994, Manenti et al., 2000). Lastly, overexpression of 
PTHLH reported being strongly related to tumour progression of gastric cancer (Ito 
et al., 1997). 
TPBG gene (trophoblast glycoprotein gene) encodes 5T4 oncofetal antigen. The 
human oncofetal antigen 5T4 (h5T4), a transmembrane glycoprotein, is 
overexpressed by a wide spectrum of cancers including colorectal, ovarian, and 
gastric, but with a limited normal tissue expression. Such properties make 5T4 an 
effective putative target for cancer immunotherapy (Mulryan et al., 2002). Moreover, 
elevated level of TPBG reported a relation to Leiomyoma uterine cancer (Luo et al., 
2005). 
The reduced expression of SLC27A6 was defined in oral submucous fibrosis (OSF), 
a high-risk precancerous condition of the oral cavity (Li et al., 2008). Recent work 
identified the enzyme glycerol-3-phosphate dehydrogenase 1-like (GPD1L) as a 
novel regulator of HIF1-alpha stability. Whilst the ectopic expression of GPD1L 
attenuates the hypoxic response, preventing complete HIF1-alpha induction, 
decreased GPD1L protein causes increased stability of HIF-1alpha (Kelly et al., 
2011). The last gene in the model, TMPRSS11B, showed, according to a recent 
study, differentially downregulation between both normal and dysplastic tissues, as 
well as, between dysplastic and tumour tissues of oral cavity and it showed 
consistent downregulation throughout the entire process of oral carcinogenesis 
(Sumino et al., 2013).  
Further validations of the model of 8 genes with additional external datasets are 
required to confirm it’s specificity in discriminating OSCC from other tumour types 
of the body as well as other molecularly similar inflammatory processes (e.g., 
atherosclerosis and periodontitis).  
Both potential biological and technical reasons are accountable for incomplete 
separation between normal and tumour samples. Tumours may genuinely have 
molecular profiles resembling normal tissue and normal samples may have gene 
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expression profiles similar to tumours, which could be evidence of occult disease 
(not identifiable by histology). In addition, non-biological explanations could result 
from incomplete batch correction due to various stages of microarray pre-processing 
including; distinct laboratory conditions, reagents, and personnel. Previous studies 
have demonstrated that batch effects can occur even when the same samples are 
processed on the same chips, in the same lab on different days (Kitchen et al., 2010). 
In fact, many gene expression datasets were underpowered (Ein-Dor et al., 2006) 
whilst other study described issues of multiple-testing as a consequence of datasets 
with many more features than samples (Clarke et al., 2008), though ComBat method 
has been shown to reduce batch effects to an absolute minimum in a number of 
studies (Johnson et al., 2007), (Walker et al., 2008, Chen et al., 2011a). A number of 
previous studies have integrated microarray datasets from cancer studies, using 
different integrating tools, in order to generate consensus findings independent of the 
cohort or platform used. According to recent published work (Turnbull et al., 2012), 
ComBat expressed the best performance. Furthermore, the study demonstrated that 
integrating comparable gene expression datasets processed on Affymetrix and 
Illumina platforms increases the statistical power. 
Searching for genes that are both differentially expressed in the meta-analysis study 
and commonly identified as communal genes across published studies in chapter 
two, highlights the importance of the criteria used in differential gene expression 
analysis (fold change cut-off and FDR criteria). Altering the stringency of criteria of 
the differentially expressed meta-genes from FDR level =0 and fold change cut-off 
±1.5 to FDR level ≤ 0.05 with no fold change cut-off criteria, increased the number 
from 97 to 326 cross-correlated genes forming 89% of the total common harvested 
genes (368) from the review study (illustrated in chapter 2), with only 22% of these 
expressed genes having less than 0.5 log fold change. This variation in the number of 
the final set of cross-correlated genes highlighted the impact of the differences in 
bioinformatics approaches and the criteria selected in formulating the final set of 
genes. The result of current study suggests dealing with fold change as cut-off 
criteria with caution, especially in determining the final set of genes and identifying 
the subsequent biological dysregulated pathways, molecular functions, and 
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processes, since molecular relationships in the system biology comprise not only 
activation or inhibition of expression, but also protein-protein interactions, DNA-
protein interactions and activation, localization, and inhibition of the corresponding 
proteins (Debily et al., 2009), and it is not surprising that microarrays results 
(especially those with a high fold change cut-off) may fail to identify some of the 
hub genes as significantly differentially expressed among the tumour versus normal 
samples. These genes might play a major role through protein activation, for 
instance. Instead, their modulations may be very subtle and below the threshold for 
reliable detection of differences of the microarray platform despite its high sensitivity 
(Debily et al., 2009). Alternatively, study suggestion is to consider comprehensive 
inclusion of the whole expressed genes, accompanied with using a Biological 
Annotation tool (like; IPA, KEGG, STRING, etc.) in an attempt to obtain a true and 
complete understanding of the biological concept of the system biology from which 
the sample extracted at the time of collection, considering the fact that genes are 
highly interchangeable. However, setting a low threshold for a significant correlation 
between genes will result in the inclusion of many spurious links, whereas a high 
threshold will control the false-positive rate at the expense of omitting many genuine 
edges. For this reason, the suggestion of this study is the production of two separate 
sets; the one with less stringent criteria including large amount of genes is recruited 
for subsequent biological annotation purposes (like for identifying the dysregulated 
pathways and the affected transcriptional regulators), after which selection of a 
specific disease and its relative pathways will be focused on. The other set of small 
number of genes can be obtained by applying stringent criteria to fulfil the 
requirements of monitoring tool with a high specificity and can used as a biomarker 
identification tool (where a small number of gene set is suitable for clinical screening 
test). However, a set of genes with a reasonable size was obtained from the meta-
analysis study as well as those cross-correlating between the review study (chapter 2) 
and the meta-analysis signature of this chapter with most of genes related to OSCC 
and HNSCC. Of these genes, potential biomarkers involved in OSCC and HNSCC 
were observed which confirmed the efficiency of bioinformatics approaches used in 
merging datasets from different studies. Importantly, these common differentially 
expressed genes are obtained from different collection centres, population groups, 
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different stages of microarray pre-processing including; distinct laboratory 
conditions, reagents, and personnel. Two datasets from the met-analysis study (Ye et 
al. and Chen et al. studies) were among the microarray datasets in the review study of 
chapter 2, have already been illustrated to have very low overlapping signature 
(22.8% of the total common genes). 
Similar to the results of the review study in chapter 2, significant over-expression of 
chemokines in tumours was observed which has been ascribed frequently to 
constitutive stimulus of NFκB, the signalling pathway which plays a key role in anti-
apoptosis and is widely proposed now as potential molecular tumorigenic marker in 
various types of tumours including colorectal, bladder, pancreatic, breast, ovarian, as 
well as oral cancer (He et al., 2009). Elevated level of several members of CXC 
family in tumours was another finding which behaves as angiogenic factors 
(Vandercappellen et al., 2008, Vinader and Afarinkia, 2012, Zhu et al., 2012). These 
include CXCL8 (IL8), CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL7. 
Besides their functions in the immune system, they also play a critical role in tumour 
initiation, promotion and progression (Vandercappellen et al., 2008). CXC 
chemokines 2, 3, 9, and genes encoding for extracellular matrix proteins and 
collagens have previously been involved in the motility and invasion of tumour 
(Chen et al., 2008a). 
In an attempt to explore more specific signature of OSCC and understand the 
tumorigenic process reflected by the simultaneous perturbed genetic and metabolic 
system, additional analysis was conducted in chapter 5 to integrate transcriptomic 
signature harvested from the meta-analysis study in this chapter and the metabolomic 
signature obtained from the review study of metabolomic profiling (explained in 
chapter 5) by employing various IPA biological tools.  
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Chapter 4: Gene expression profiling reveals 
biological pathways responsible for phenotypic 
heterogeneity between UK and Sri Lankan oral 
squamous cell carcinomas 
4.1 Introduction 
Oral squamous cell carcinoma is responsible for a significant mortality and morbidity 
with poor overall survival. The pace of invasiveness, metastasis, and recurrence of 
OSCCs is a multifactorial event. The tumour site, type of the environmental 
carcinogens, immune response and resistance of the body against the disease all play 
important role. To date, little is known about the biological mechanisms underlying 
such phenotypic variation in different populations. 
4.2 Aims and objectives of the study 
1-To define gene expression profiles of UK and Sri Lankan OSCCs compared to 
their normal comparators using supervised and unsupervised strategies and to 
identify associated pathways. 
2-To determine the impact of differences in gene expression between UK and Sri 
Lankan normal oral mucosa upon the above two profiles. 
3-To define gene expression differences between UK and Sri Lankan OSCC and to 
further assess the contribution of expression differences between groups of normal 
tissues has on those seen between the two groups of OSCC 
4-To examine the most related genetic factors, carcinogenic related pathways, and 
molecular processes that might be responsible for the phenotypic heterogeneity of 
OSCC between UK and Sri Lankan population groups which impact the vast 
differences in clinical behaviour of the two tumour groups. 
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4.3 Materials and Methods 
4.3.1 Sample characteristics and biopsy specimens 
All biopsy specimens of OSCC and normal oral mucosa were harvested with 
appropriate ethical approval and informed consent of patients. Identical protocols for 
tissue collection and processing were used in both countries. 
Tissue samples of OSCC from UK population were obtained from sequential 
incident cases treated surgically by a single consultant at University Hospital 
Birmingham NHS Foundation Trust, Birmingham, UK Tissues specimens were 
harvested during the period 2001 to 2004 and stored. A total of 24 samples yielded 
RNA that was of suitable quality for Microarray analysis (Table 4.2). Patient’s 
population included 13 (54%) males and 11 (46%) females. The average age of 
patients was 61.2 years with a range of 37 to 79 years. The detailed staging of OSCC 
in to group’s I-IV and high / low stage is shown in Table 4.1. 
Table 4.1: Factors contributing to the clinical staging of OSCC. 
 Stage  T N M 
Low stage I T1 N0 M0 
 II T2 N0 M0 
  T1 N1 M0 
 III T2 N1 M0 
  T3 N0 M0 
  T3 N1 M0 
High stage IV A T4 N0, N1 M0 
 IV A Any T N2, N3 M0 
 IV A Any T Any N M1 
 IV B Any T N3 M0 
 IV C Any T Any N M1 
     T1  Tumour less than 2cm  
T2  Tumour 2-4 cm   
T3  Tumour greater than 4 cm  
T4  Tumour invading surrounding structures 
N0  No nodal spread   
N1  Single node less than 3cm  
N2  Multiple/single nodes 3-6cm  
N3  Nodes greater than 6cm  
M0  No distant metastasis  
M1  Distant metastasis   
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OCS 001 C M 59 NK T2N1Mx surgery T4N2bMx High No smoker no yes  
OCS 003 C F 72 K T4N2bMx surgery T4N2bMx High No none no no Takes oral snuff 
OCS 004 C F 67 K T4N0Mx surgery T4N0Mx High Yes none no yes Chews betel quid 
OCS 006 C F 53 T T1N0Mx surgery T1N0Mx Low No none no no  
OCS 007 C F 67 K T2N0Mx surgery T4N0Mx High No smoker no no  
OCS 008 C F 65 K T4N0Mx radiotherapy no surgery High No none no yes  
OCS 011 C F 49 T T1N0Mx surgery T1N0Mx Low No smoker no no  
OCS 012 C F 72 T T4N2aMx radiotherapy no surgery High No smoker yes yes  
OCS 013 C M 43 NK T1N0Mx surgery T1N0Mx Low No smoker no no  
OCS 014 C M 46 T T2N1Mx surgery T2N2bMx High Yes smoker yes no  
OCS 015 C M 51 T T4N0Mx surgery T4N0Mx High Yes none no yes  
OCS 016 C M 66 T T2N1Mx surgery T2N2bMx High Yes smoker yes yes  
OCS 019 C F 73 K T4N0Mx surgery T2N0Mx Low No none no no Takes oral snuff 
OCS 020 C M 64 NK T4N0Mx surgery T4N0Mx High No smoker no no  
OCS 021 C M 58 NK T2N0Mx surgery T2N0Mx Low No smoker yes no  
OCS 022 C F 65 T T2N0Mx surgery T2N0Mx Low No smoker yes no  
OCS 023 C M 70 K T2N0Mx surgery T2N2bMx High No smoker no no  
OCS 024 C F 68 K T4N2bMx surgery T2N1Mx Low Yes smoker no yes  
OCS 025 C F 79 NK T2N0Mx surgery T2N0Mx Low No none no no  
OCS 026 C M 37 NK T2N0Mx surgery T1N0Mx Low No smoker yes no  
OCS 027 C M 66 NK T2N0Mx surgery T2N0Mx Low No smoker no no  
OCS 029 C M 52 NK T4N2Mx surgery T4N0Mx High No smoker yes no  
OCS 031 C M 67 NK T4N0Mx radiotherapy no surgery High No smoker yes yes  
OCS 032 C M 60 NK T2N0Mx surgery T2N0Mx Low Yes smoker no no  
Site of tumour was classified as tongue (T), non-keratinising mucosa (NK) or keratinising (K.).
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Tissue samples of OSCC from Sri Lankan population were obtained from sequential 
incident cases treated by a single consultant at Kandy General Hospital, Kandy, Sri 
Lanka. All patient details were verified by a local translator. Biopsy specimens of 
tissues were harvested during the period January to May 2004. A total of 27 samples 
yielded RNA that was of suitable quality for Microarray analysis (Table 4.3). The 
study population included 6 (22%) females and 21 (78%) males with a range of 38 - 
82 years and average age of 61.9 years. 










































KC01 M 72 K T2N0Mx surgery T2NxMx  low No yes No BALT no 
KC02 M 50 NK T2N0Mx surgery T2NxMx low No yes No BALT yes 
KC04 M 66 NK T1N0Mx surgery T1NxMx low No no No BALT no 
KC07 M 50 K T2N0Mx surgery T2NxMx low No no No BALT no 
KC09 F 54 T T1N1Mx surgery T1NxMx low No no No BALT no 
KC13 M 73 NK T2N1Mx surgery T2NxMx low No no No BALT no 
KC15 F 40 T T2N0Mx surgery T2NxMx low No no No No no 
KC16 F 71 NK T2N0Mx surgery T2NxMx  low No yes No BALT no 
KC17 M 48 K T2N0Mx surgery T2NxMx low No yes No BALT no 
KC19 M 76 NK T2N1Mx surgery T2NxMx low No yes yes BALT no 
KC20 M 76 NK T1N0Mx surgery T1NxMx low No yes yes BALT no 
KC21 F 56 NK T2N1Mx surgery T2NxMx low No no No BALT no 
KC24 F 55 NK T1N1Mx surgery T1NxMx low No no No BALT no 
KC25 M 74 NK T2N1Mx surgery T2NxMx  low No yes No BALT no 
KC26 F 85 K T2N0Mx surgery T2NxMx low No no No BALT no 
KC29 M 55 NK T2N0Mx surgery T2NxMx low No yes yes BALT no 
KC31 M 95 NK T2N0Mx surgery T2NxMx low No no No BALT no 
KC32 M 52 NK T2N0Mx surgery T2NxMx low No yes yes BALT no 
KC38 M 51 K T2N0Mx surgery T2NxMx low No yes yes BALT no 
KC39 M 64 K T3N0Mx surgery T3NxMx high No yes yes BALT no 
KC41 M 82 T T3N1Mx surgery T3NxMx high No yes No No no 
KC44 M 42 K T3N0Mx surgery T3NxMx high No no No BALT no 
KC45 M 58 T T2N0Mx surgery T2NxMx low No yes yes BALT no 
KC46 M 38 T T2N1Mx surgery T2NxMx low No yes yes BALT no 
KC47 M 50 NK T2N0Mx surgery T2NxMx low No no No BALT no 
KC51 M 78 NK T2N0Mx surgery T2NxMx  low No no No BALT no 
KC53 M 60 NK T3N0Mx surgery T3NxMx low No yes No BALT no 
Site of tumour was classified as tongue (T), non-keratinising mucosa (NK) or keratinising (K.) Betel 
quid chewing contents was classified as: Betel nut (B); areca nut (A); lime (L); and Tobacco (T.) 
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Normal samples consist of 11 normal oral mucosa specimens (seven samples from 
UK & four samples from Sri Lankan population). All normal samples were harvested 
from patients under the age of 30 years (undergoing either a minor surgery in the 
mouth for a non-neoplastic condition or a dental extraction) All were non-smokers; 
did not chew betel quid and did not consume exceeding the national recommended 
weekly gender allowance of alcohol. Normal samples had no personal history of 
cancer and had no first degree relatives with a history of cancer. A total of 8 samples 
from the two countries yielded RNA that was of suitable quality for Microarray 
analysis (Table 4.4). 
Table 4.4: Site of origin of normal oral mucosa samples from both population groups 
 
After surgical extraction, samples were immediately wrapped in foil and dipped in 
liquid nitrogen for 20 seconds to freeze thoroughly. Then samples were transferred to 
labelled cryo-vials and returned to liquid nitrogen.  
Using H&E-stained sections from snap-frozen tissue, all tumours were 
histopathologically confirmed as squamous cell carcinoma and staged according to 
the AJCC/UICC TNM Classification system. Tumours were pathologically 
designated as high/ low stage, while the patients who experienced no early 
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recurrence for at least 12 months post-operatively were scored as "non-recurrence 
cases”.  
To standardize stromal cell contribution, each selected tumour was confirmed 
histopathologically to contain ≥60% tumour tissues and <10% necrotic debris by 
analysis of corresponding H&E sections. 
4.3.2 RNA extraction / cDNA synthesis, processing, labeling, 
and hybridization to microarray chip 
RNA was extracted using TRIZOL RNA extraction method. The yielded RNA from 
the samples was quantified using Nano-spectrophotometer and stored at -80C. The 
labelled cDNA was then hybridised to the Affymetrix Focus and U133 plus 2.0 
Gene Chips (Affymetrix Santa Clara, US). For full details of procedures for this 
section, see supplementary file 1b.  
4.3.3 Data quality control, pre-processing and analysis 
Data analysis was performed using Bioconductor packages (Gentleman et al., 2004), 
http://www.bioconductor.org/). The simpleaffy package was used to assess average 
background, Scale factors, Number of genes called present (% Present), 3’ to 5’ 
ratios 
(http://www.affymetrix.com/support/downloads/manuals/data_analysis_fundamental
s_manual.pdf ), 6 chips (3tumour samples and 3 normal samples) were observed of 
poor quality and are filtered out.       
Normalization was performed using gcRMA algorithm from Bioconductor to extract 
gene expression values (two independent normalization procedures were conducted 
per study cohort; normal and tumour group).  
Tumour samples from both UK and Sri Lanka were analysed using the Affymetrix 
Human Genome Focus array. The normal samples from both countries were analysed 
using the Affymetrix Human Genome U133 Plus2.0 Array. The probesets that 
identically represented on both U133 Plus2.0 array and Focus GeneChip were used 
for comparative analysis. 
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A number of pre-processing steps including background adjustment, probe filtering, 
normalization and quality control checks were performed using the R package, 
Simpleaffy (www.bioconductor.org). 
It is important to mention here that the author who composed the current thesis 
started the work analysis of this chapter from this section, while the previous steps of 
methods were carried out by another author (Lopes, 2007). 
4.3.4 Quality checks of microarray GeneChip results (QC) 
To obtain accurate results from the subsequent analysis, Quality Checks were 
performed to evaluate whether to include results from each Gene chips using the 
simpleaffy package (http://bioinformatics.picr.man.ac.uk/simpleaffy/), a part of the 
Bioconductor project (http://www.bioconductor.org/). 
The Microarray data quality reporting shown here is generated using the quality 
control function of the SimplyAffy software package from Affymetrix® using R 
programming software. OSCC from both the UK and Sri Lanka were analysed using 
the Affymetrix® Human Genome Focus Array that represents over 8500 verified 
human sequences from the NCBI RefSeq database. The normal oral mucosa 
specimens were analysed using the Affymetrix® Human Genome U133 Plus2.0 
Array that can examine over 47,000 transcripts.  
The simpleaffy function, QC, generates the most commonly used metrics which all 
their values are parameters computed for/from the MAS 5.0 algorithm. The standard 
recommendations from Affymetrix are as following: 
4.3.4.1 Average background  
This should be similar across all chips, if chips have significantly different average 
backgrounds this could be for a number of reasons. It might simply that the overall 
signal from the array is greater, perhaps because different amounts of cRNA were 
present in the hybridisation cocktails, or because the hybridisation was more efficient 
in one of the reactions, incorporating more label, and producing brighter chip. The 
accepted upper limit for background signal equal 100. 
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4.3.4.2 Scale factors  
The default normalisation used by MAS 5.0 (and many other algorithms) makes 
assumption that gene expression does not change significantly for most of transcripts 
in an experiment. The amount of scaling applied is represented by the ‘scale factor’, 
which, therefore, provides measurement of the overall expression level for an array, 
and (assuming all else remains constant), a reflection of how much labelled RNA is 
hybridised to the chip. Large variations in scale factors signal cases where the 
normalisation assumptions are likely to fail due to issues with sample quality or 
amount of starting material. Alternatively, they might occur if there have been 
significant issues with RNA extraction, labelling, scanning or array manufacture. In 
order to successfully compare data produced using different chips, Affymetrix 
recommend that their scale factors should be within 3-fold of one another. 
4.3.4.3 Number of genes called present (% Present)  
Present/Marginal/Absent calls are generated by looking at the difference between 
PM and MM values for each probe pair in a probeset. Probesets are flagged 
“Marginal” or “Absent” when the PM values for that probeset are not considered 
significantly above the MM probes. As with scale factors, large differences between 
the numbers of genes called present on different arrays can occur when varying 
amounts of labelled RNA have been successfully hybridized to the chips. This can 
occur for similar reasons (differences in array processing pipelines, variations in the 
amount of starting material, etc.). The ‘percent present call simply represents the 
percentage of probesets called Present on an array and should be between 35-55%. 
As with “Scale Factors”, significant variations in % Present call across the arrays in 
a study should be treated with caution.  
4.3.4.4 3’ to 5’ ratios  
Most cell types ubiquitously express β-actin and GAPDH. These are relatively long 
genes, and most Affymetrix chips contain separate probesets targeting the 5’, mid 
and 3’ regions of their transcripts. By comparing signal number from the 3’ probeset 
to either the mid or 5’ probesets, it is possible to obtain a quality measure of the 
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RNA hybridised to the chip. If the ratios are high, this indicates the presence of 
truncated transcripts. This may occur if the in vitro transcription step has not 
performed well or if there is general degradation of the RNA. Hence, the ratio of the 
3’ and 5’ signal gives a measure of RNA quality. GAPDH is the smaller of the two 
genes and the 3’:5’ ratio should always be at or around 1.  
The β-Actin gene is a housekeeping gene which commonly used to determine array 
quality by measuring the 3’/5’ ratio of hybridized labelled target RNA to control 
probes on the GeneChip array. This ratio for β-Actin is assumed representative of the 
ratio for other probesets on the array and a lower value ratio is generally considered 
desirable but no absolute limits have been determined. Affymetrix suggest that a β-
actin 3’:5’ ratio of less than 3 is acceptable.  
4.3.5 Differential gene expression analyses 
Analysing gene expression of the study samples was carried out  into seven specific 
categories of comparisons: Tumour vs. normal of the common genes exist in both 
UK and Sri Lankan samples; Tumour vs. normal of UK samples; Tumour vs. normal 
of Sri Lankan samples; Normal UK vs. normal Sri Lankan samples; UK tumour 
samples vs. Sri Lankan tumour samples; low vs. high/late stage tumours for both UK 
and Sri Lankan samples; Tongue Site vs. other Sites tumours for both UK and Sri 
Lankan samples; Invasive (refers to cancer spreading to the space surrounding the 
nerve) vs. non-invasive tumours of UK samples. 
To examine differential gene expression and to extract meaningful informative 
results from the seven comparisons, data analysis takes two main forms. The first is 
‘unsupervised’ algorithms where data is sorted and gene expression differences are 
derived based on inherent differences within the dataset. Unsupervised clustering 
was achieved and heatmaps generated using Pearson correlation hierarchical 
clustering in R. Supervised analysis was carried out using SAM (Tusher et al., 2001) 
in siggenes package available from Bioconductor. Heatmaps were generated using 
gplots package (Gentleman et al., 2004). Fold change value for “upregulated 
/overexpressed” and “downregulated/under expressed” genes were obtained Using 
Wilcoxon Rank Statistics function in siggenes R software. 
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The supervised methodology has the advantage of skill to define differences between 
known groups more easily than the unsupervised but it is possible to overlook 
biologically important gene changes because they do not fall in to the final 
significantly changed gene group. 
This is a problem of statistical significance versus biological significance and 
attempts to define both will support all Microarray analysis.  
List of genes were further narrowed by trimming out the low magnitude of the fold 
changes and / or reduce the FDR value of the significant genes. 
4.3.6 Biological interpretation of the expressed genes 
Functional annotation analysis of the differentially expressed genes was performed 
using Ingenuity Pathway Analysis (Ingenuity Systems, www.Ingenuity.com) tool 
which relies on a knowledge database of selected functional and regulatory 
interactions extracted from the literature and provides integrated graphical 
representation of the biological relationships between genes and gene products 
considering both up- and down-regulated genes from each comparison analysis. 
IPA was used to highlight the most affected Molecular and Cellular functions, 
canonical pathways, Diseases and Disorders, Transcriptional Regulators, and most 
significant pre-generated networks associated with the uploaded group of genes 
including those related to OSCC development. 
The master network was constructed by connecting the selected genes involved in 
OSCC, HNSCC, and SCC using fisher exact test. The high connectivity nodes are 
likely to reflect their ability to regulate an important number of genes in the master 
network and potentially to control the gene expression pattern / modulations 
identified tumour signature of that specific comparison. 
It’s well known that regulation of human genes depends on sets of transcription 
factors rather one individual factor. For this reason, available tool from IPA system 
was used to identify potential transcriptional regulators. Transcriptional Regulator 
Analysis tool from IPA system highlighted the activation and inhibition of certain 
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genes acting as transcriptional regulators and have a major contribution in the 
tumorigenic process. 
As explained in previous chapter, IPA cannot map pseudo genes, hypothetical genes, 
ESTs and ambiguous (mapping to multiple) genes as well as duplicates of multiple 
IDs snapped in one molecule or multiple molecules snapped in one ID, re-
arrangement of unmapped genes was carried out by converting them using David 
conversion tool (Huang et al., 2009a, Huang et al., 2009b) to obtain more unmapped 
genes to the subsequent analysis where in  some of them are substantial key players 
contributing to the tumorigenic process and in the master networks of the analysis. 
4.3.7 Quantitative real-time PCR analysis (validation of gene 
expression level) 
Three genes downregulated in both UK and Sri Lankan tumours relative to their 
normal samples including Clusterin (CLU) T-cell differentiation protein (MAL), and 
Protein tyrosine phosphatase, non-receptor-type, 13 (PTP313/FAP1) were selected 
for further investigation and qPCR validation Using a combined thermal cycler and 
fluorescence detector (Perkin-El mer Applied Biosystems 7700 sequence detector). 
Samples used in the qPCR include all Sri Lankan and UK normal oral mucosa 
samples. These were compared to 12 of each UK and Sri Lankan samples.  
The QPCR data presented here were repeated and confirmed over four separate 
rounds of experimental determination consistently confirming the expression array 
findings that, these three genes are downregulated in OSCC compared to normal in 
both UK and Sri Lankan samples. 
4.4 Results  
4.4.1 Study populations 
The OSCC cases in both UK and Sri Lankan populations were older than their 
controls. Compared to controls, OSCC cases were more reliable to alcoholic 
consumption, and current smokers. Normal control were all under the age of 30 
years, non-smokers, did not consume exceeding the national recommended weekly 
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gender allowance of alcohol, and had no personal history of cancer and had no first 
degree relatives with a history of cancer. 
Tumour population included 34 males (13 UK and 21 Sri Lanka) and 17 females (11 
UK and 6 Sri Lanka). The UK average age was 61.2 years with a range of 37 to 79 
years and Sri Lankan average age of 61.9 years with a range of 38 to 82 years. A 
significant male predominance of disease in both countries was observed; Table 4.2 
and Table 4.3. These two groups is representative of the general population of 
patients with OSCCs in each country. All tumour samples of both populations were 
from oral cavity; including 7 (29%) UK patients presented with cancers of 
keratinized mucosa, 10 (42%) with cancers of non-keratinized mucosa and 7 (29%) 
with cancer of specialised mucosa of the tongue. Eleven patients (46%) presented 
with low stage disease and 13 (54%) with high stage. Eight (33%) patients had loco-
regional lymph node metastasis at presentation and six (25%) samples displayed 
perineural invasion at histopathology. Eight (33%) patients developed early 
recurrence (defined as recurrence of OSCC at the same anatomical site or in the neck 
nodes within 12 months of completion of definitive therapy). Sri Lankan tumour 
samples consist of 7 (26%) patients presented with cancer of the Keratinising 
mucosa, 15 (55%) with cancers of the non-keratinising mucosa and 5 (19%) with 
cancer of the specialised mucosa of the tongue. Three patients (11%) presented with 
early invasive disease (perineural invasion at histopathology), 21 (78%) with low 
stage disease and 3 (11%) with high stage. Importantly, although eight (30%) 
patients had loco-regional lymph node enlargement at presentation, none of these 
patients had a neck dissection as the nodal enlargement is regarded as insignificant 
and frequently resolves after excision of the primary tumour. None of Sri Lankan 
samples displayed perineural invasion at histopathology and only one (4%) patient 
developed early recurrence (defined as recurrence of OSCC at the same anatomical 
site or in the neck nodes within 12 months of completion of definitive therapy). 
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4.4.2 Report of microarray quality control 
To obtain accurate results for the subsequent analysis, Quality Checks were 
conducted to evaluate whether to include results from each gene chips using the 
simpleaffy® package (http://bioinformatics.picr.man.ac.uk/simpleaffy/) which is part 
of the Bio conductor Affymetrix that already mentioned in materials and methods 
section.  
(http://www.affymetrix.com/support/downloads/manuals/data_analysis_fundamental
s_manual.pdf ). In order to assess the quality of data generated in this experiment, 
four out of the five metrics mentioned will be considered as following: 
4.4.2.1 Average background  
The average background for each chip shows a considerable amount of variation. 
This is represented in Figure 4.1and Figure 4.2 by colouring the average background 
values for all chips red. Specifically the average background for OCS21, OCS19, 
KC46, and KC31 tumour samples along with V6_1, V2A_1, and KN1 normal 
samples which significantly exceed the accepted upper limit for background signal 
equal 100. Although this may indicate a problem with these samples all other QC 
measures correlate well with those of its peers (as seen below). 
4.4.2.2 Scale factor  
To achieve overall experimental consistency the scaling factor for an array should 
not exceed three. The scale factors for OCS23 and OCS21 UK tumours are greater 
than 3-fold away from the average scale factor for all samples (Figure 4.1). This 
suggests that the overall intensity of these samples was lower, resulting in higher 
scale factors. This may result from less RNA present in these samples.  
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4.4.2.3 Number of genes called present  
The number of genes called present (% present calls) shows a broad spread in values 
across the whole experiment (25.6-57%) for tumours and (17-42) for normal samples 
(Figure 4.1and Figure 4.2). After removal of the six bad quality chips, a good general 
agreement between samples was achieved in each group and between each 
experimental condition with new % present calls 36-60% for tumour and 30-42% for 
normal samples, very close to the ideal range between 35-55% and so judged within 
acceptable limit (Figure 4.1and Figure 4.2). The qc plot has coloured these numbers 
red to indicate a spread of more than 10% across the whole experiment. Considering 
“percent” present and scale factor together, OCS19, OCS21, and OCS23 samples 
that have lower % present calls also have higher scale factors. These factors certainly 
warrant further attention. Higher scale factors with lower “percent” present calls may 
indicate that less RNA has been hybridised to these chips. Accordingly, the above 
three samples were excluded from analysis as mentioned previously. 
4.4.2.4 3’ to 5’ ratios for β-actin and GAPDH  
At first glance the results for the 3’:5’ ratios for the tumour samples (Figure 4.1) 
appear less than satisfactory, with many of the GAPDH and β-actin ratios  flagged. 
This may indicate that these samples contain degraded RNA. However, considering 
other criteria all together will give the final judgment specifically after removing the 
bad quality chips (Figure 4.1). All normal samples show both probes ratios within 
satisfactory limit before and after trimming of the bad quality chips (Figure 4.2). 
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Figure 4.1:Simpleaffy plots displaying the QC of 51 and 48 tumour samples from UK 
and Sri Lankan population groups before (Left) and after (Right) removal of bad 
quality microarray chips respectively. 
Each row shows the %present, average background, scale factors and GAPDH / β-actin ratios for an 
individual chip. GAPDH 3’:5’ values are plotted as circles. According to Affymetrix they should be 
about 1. GAPDH values that are considered potential outliers (ratio > 1.25) are coloured red, 
otherwise they are blue. β -actin, 3’:5’ ratios are plotted as triangles. 3’:5’ ratios recommended to be 
below 3; values below 3 are coloured blue, those above, red. The blue stripe in the image represents 
the range where scale factors are within 3-fold of the mean for all chips. Scale factors are plotted as a 
line from the centre line of the image. A line to the left corresponds to a down-scaling, to the right, to 
an up-scaling. If any scale factors fall outside this ‘3-fold region’, they are all coloured red, otherwise 
they are blue. %present and average background, are listed to left of the figure.  
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4.4.2.5 QC conclusions  
For normal and tumour group samples, 6 chips (OCS19, OCS21, OCS23, V6_1, 
V2A_1, and KN1; half of them related to tumour samples and the other half related 
to normal samples) were recognized of poor quality and are discounted from any 
further analysis based on these QC data. This was because OCS21, OCS23 had 
higher scale factors than any of other groups of samples and lower % present calls.  
These observations suggested a possibility of degraded RNA presents within the 
samples or that the amplification protocol had not worked successfully for the 
samples, resulting in less RNA hybridised to the chip. Furthermore, other chips 
(OCS19, V6_1, V2A_1, and KN1) were excluded as it had lower “percent” present 
call and average background which significantly exceed the accepted upper limit for 
background signal. The QC plots for the new data set are shown in Figure 4.1and 
Figure 4.2. 
Although a spread in the average background can still observed, because generally, 
the remaining QC metrics fall within the current guidelines (specifically the scale 
factors for all chips are within 3-fold of one another), this was not considered 
significant enough to reject arrays. Similarly, tumour samples have higher β-Actin 
and GAPDH ratios, however, this threshold is fairly stringent, and in the context of 
the other QC metrics, it was decided not to fail these arrays. The final decision was 
to include data from 48 tumours and 8 normal arrays and therefore used in the 
subsequent analyses. 





Figure 4.2: Simpleaffy plot displaying the QC of 11 and 8 normal samples from UK and 
Sri Lankan population groups before (top) and after (bottom) removal of bad quality 
microarray chips respectively. 
Each row shows the %present, average background, scale factors and GAPDH / β-actin ratios for an 
individual chip. GAPDH 3’:5’ values are plotted as circles. According to Affymetrix they should be 
about 1. GAPDH values that are considered potential outliers (ratio > 1.25) are coloured red, 
otherwise they are blue. β -actin, 3’:5’ ratios are plotted as triangles. 3’:5’ ratios recommended to be 
below 3; values below 3 are coloured blue, those above, red. The blue stripe in the image represents 
the range where scale factors are within 3-fold of the mean for all chips. Scale factors are plotted as a 
line from the centre line of the image. A line to the left corresponds to a down-scaling, to the right, to 
an up-scaling. If any scale factors fall outside this ‘3-fold region’, they are all coloured red, otherwise 
they are blue. %present and average background, are listed to left of the figure. 
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4.4.3 Filtration and pre-processing data 
Following normalization, the huge number of probe sets was reduced by Nonspecific 
Filtering using the function rowSds/ genefilter in R statistical software package 
available on Bioconductor 
(www.bioconductor.org/packages/release/bioc/vignettes/genefilter/inst/doc/howtoge
nefilter.pdf). By applying the filtration method, not only a reduction in the non-useful 
un-diagnostic probe sets was observed, but improvement in the sample 
discrimination ability of the subsequent analysis. 
4.4.4 Gene expression profile of OSCC versus normal oral 
mucosa from both population groups 
Following data normalization, probe sets filtering, and removal of microarray chips 
having  poor quality, unsupervised analysis of all tumour and normal samples from 
both populations altogether were performed using Pearson correlation comparison. 
The normal samples clearly clustered together away from the tumour samples. 
Moreover, the normal samples of each population were separated from each other as 
seen clearly from the hierarchical clustering (Figure 4.3). Examination of tumour 
groupings in the hierarchical clustering showed the majority but not all tumours that 
associated with metastasis and recurrence tend to group together. A supervised 
analysis of all tumour and normal samples from both populations was carried out 
using significance analysis of microarrays (SAM) with a false discovery rate (FDR) 
≤ 0.001 and fold change above or below 1.5 (Figure 4.4). 




Figure 4.3: Unsupervised Pearson correlation hierarchical clustering of all normalized 
genes clearly discriminating normal oral mucosal samples (N=8) from OSCC samples 
(N=48) of both UK and Sri Lankan populations. 
Heatmap represents samples distribution according to the mean-centred expression of genes. 
Expression (red= 1, yellow= lower than 1, white= lowest value than 1). 
 




Figure 4.4: Hierarchical clustering of the 1222 most differentially expressed genes separating UK and Sri Lankan normal oral mucosa (N=8) 
and patient OSCC specimens (N=48) using SAM supervised analysis at FDR≤0.001. 
Red and blue bars represent cancerous and normal samples, respectively. Heatmap represents mean-centred expression of genes in rows and samples in columns. 
Expression (red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. Gene expression values were either above or below fold change 
magnitudes equal ± 1.5.
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4.4.5 Gene expression profile of tumour versus normal 
samples from UK 
Using both supervised and unsupervised analysis for this comparison as mentioned in 
materials and methods section, both analysis separated normal (N=5) from tumour 
(N=21) samples clearly. The supervised analysis of the 26 samples was undertaken 
under different levels of false discovery rates using SAM. Supervising the analysis in 
two groups according to sample type; OSCC and normal mucosa identifying 925, 
896, 819, and 185 differentially expressed genes with a fold change cut-off value 
equal to ±1.5 and FDR levels of ≤0.005, ≤0.001, ≤ 0.0001, and = 0.00 respectively. 
At FDR level ≤ 0.005, 60 genes were upregulated and 866 genes were downregulated 
in OSCC compared to normal mucosa from UK individuals (Table 4.5 and 
Supplementary file 7). Altering the stringency of the SAM analysis to accept only 
FDR level ≤ 0.0001 reduced the profile to 30 upregulated and 779 downregulated 
genes (Figure 4.5). At FDR level=0.0 a set of 185 genes appeared all downregulated 
within OSCCs in relative to their normal comparators with a fold change magnitude 
≥2 (Figure 4.6). 
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Table 4.5: Significantly differentially expressed genes discriminating UK tumour 
from normal samples. * 
* FDR value < 0.005.The complete lists of upregulated and downregulated genes in OSCCs were 
presented in Supplementary file 7. 
Gene 
Symbol                    
  Gene ID      Fold 
Change 
 Gene Symbol                    Gene ID       Fold 
Change 
Genes higher expressed in OSCCC                                Genes lower  expressed in OSCC 
 
MMP1 204475_at 4.4  CRNN 220090_at -5.7 
MMP3 205828_at 3.2  MAL 204777_s_at    -5.3 
HMGA2 208025_s_at    2.9  KRT13 207935_s_at -5.1 
BMP15 221332_at 2.3  KLF5 209211_at -4.9 
REL 206035_at 2.3  SCEL 206884_s_at -4.6 
POSTN 210809_s_at 2.2  CLCA4 220026_at -4.5 
CXCL10 204533_at 2.2  TGM3 206004_at -4.4 
MMP10 205680_at 2.2  EMP1 201324_at -4.2 
SPP1 209875_s_at 2  CLEC3B 205200_at -4.2 
GRIN1 205914_s_at 1.9  RHCG 219554_at -4.2 
LAMC2 202267_at 1.9  CD24 208650_s_at -3.7 
IFI6                              204415_at 1.7  SERPINB13                     211362_s_at -3 
SLC6A2 215715_at 1.7  CDKN2C 204159_at -2.9 
COL11A1 37892_at 1.6  FGFR2 208228_s_at -2.8 
CXCL11 210163_at 1.5  CLU 208792_s_at -2.8 
PTGS2 204748_at 1.5  CRABP2 202575_at -2.7 
TNC 201645_at 1.5  EHF 219850_s_at -2.6 
    HSP90AB1 214359_s_at -2.5 
    YES1 202933_s_at -2.5 
    CDKN1B 209112_at -2.5 
    IGFBP2 202718_at -2.5 
    RPS6KB1 204171_at -2.4 
    SMAD4 202527_s_at -2.3 
    JUP 201015_s_at -2.3 
    VEGFA 210512_s_at -2.2 
    FGFR3 204379_s_at -2.2 
    HRAS 212983_at -2.1 
    CRYAB 209283_at -2.1 
    DUSP1 201041_s_at -2.1 
    RAD21 200608_s_at -2 
    RAF1 201244_s_at -1.9 
    HSPA1A//HSPA1B 202581_at -1.9 
    KRT19 201650_at -1.9 
    CDH1 201131_s_at -1.8 
    INS-IGF2 202409_at -1.8 
    WNT5A 205990_s_at -1.8 
    ID2 201565_s_at -1.8 
    PTPRC 212588_at -1.8 
    MAPK9 203218_at -1.7 
    MAPK13 210058_at -1.7 
    TNFSF10 202688_at -1.7 
    KRT5 201820_at -1.7 
    EZH2 203358_s_at -1.7 
    TP53 201746_at -1.7 
    RB1 203132_at -1.5 




Figure 4.5: Hierarchical clustering of the 896 most differentially expressed genes separating 5 UK normal oral mucosal and 21 patient OSCC specimens 
using SAM supervised analysis at FDR≤0.001. 
Red and blue bars represent cancerous and normal samples, respectively. Heatmap represents mean-centred expression of genes in rows and samples in columns. 
Expression (red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. Gene expression values were either above or below fold 
change magnitudes equal ± 1.5. 




Figure 4.6: Hierarchical clustering of the 185 most differentially expressed genes 
separating 5 UK normal oral mucosal and 21 OSCC specimens using SAM supervised 
analysis at FDR=0.00 
Red and blue bars represent cancerous and normal samples, respectively. Heatmap represents mean-
centred expression of genes in rows and samples in columns. Expression (red= high, green= low, 
black= not changed) is represented on a log2 mean- centred scale. All genes had fold change 
magnitudes less than 2, relative to normal samples. 
Among the differentially expressed genes of UK tumour samples, several potential 
diagnostic biomarkers were identified which have previously been reported in OSCC 
and HNSCC (Figure 4.4). Of high concern, several of the above biomarkers are 
uniquely expressed in UK but not Sri Lankan tumour samples with their up- or 
downregulation reported substantially associated with tumour invasion, metastasis, 
and recurrence. This includes upregulation of MMP3, COX2, LAMC2, POSTN, 
COL11A1, and TNC along with downregulation of DUSP1 and SLPI (Wen et al., 
2011, Tomasi et al., 2010, Jones and Jones, 2000, Ziober et al., 2006, Schmalbach et 
al., 2004, Kudo et al., 2007, Yan and Shao, 2006, Siriwardena et al., 2006, Shao et 
al., 2004, Bao et al., 2004, Ouyang et al., 2009, Sasaki et al., 2003, Sasaki et al., 
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2001b, Sasaki et al., 2002, Sasaki et al., 2001a, Hensen et al., 2008, Mohan and 
Epstein, 2003, Wang, 2005, Zhi et al., 2003, Kosmehl et al., 1999, Malinoff et al., 
1984, Hintermann and Quaranta, 2004, Liotta et al., 1988, Jeng et al., 2000, Grosch 
et al., 2001, Dannenberg et al., 2001, Brown et al., 2001, Nelson et al., 2000, 
Masferrer et al., 2000, Mohammed et al., 1999, Itoh et al., 2003, Gallo et al., 2002, 
Wiegand et al., 2005, Ye et al., 1996, Gallo et al., 2001).         
Three members of Matrix Metalloproteinase family (MMP1, MMP3, and MMP10) 
are among the genes most significant upregulated, which may contribute to the 
aggressive nature of OSCC in UK samples. MMPs are well known as a large family 
of proteinases which remodel extracellular matrix components and play important 
role in tumour development, invasion and metastasis (Fingleton, 2006, Rosenthal and 
Matrisian, 2006, Moilanen et al., 2003). Several members of MMP family considered 
as important biomarkers for diagnosis and prognosis as well as potential therapeutic 
targets for many types of cancers, including HNSCC (Jordan et al., 2004). 
Another observation in UK tumours was upregulation of genes related with 
tumorigenic transformation including; GREM1, downregulation of E-Cadherin, 
several members of Tight Junctions including CLDN1, CLDN4, CLDN5, and 
CLDN7. This result reflected the activation of the Hedgehog pathway which leads to 
an increase in Snail protein expression and a decrease in E-Cadherin and Tight 
Junctions (Yook et al., 2005). Hedgehog signalling appears a crucial regulator of 
angiogenesis and thus metastasis (Velcheti, 2007). 
Central to many of the pathways (Figure 4.7) is PTGS2 (COX2); this gene has been 
frequently associated with OSCC and HNSCC in previous publications (Hunter et 
al., 2005, Chang et al., 2004, Banerjee et al., 2002, Sudbo and Reith, 2003, Nathan et 
al., 2001, Atula et al., 2006, Lee et al., 2002, Chan et al., 1999, Mohan and Epstein, 
2003, Ye et al., 2008, Tsai et al., 2004, Wang, 2005) and suggested responsibility for 
the prostanoid biosynthesis involved in inflammation and mitogenesis. COX2 
enzyme linked to tumour angiogenesis, prognosis, recurrence, metastasis and micro 
vessel density as well as postoperative disease-free survival of patients with OSCCs 
after surgical removal (Gallo et al., 2001, Itoh et al., 2003). Moreover, COX2 protein 
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expression tended higher in those tumours in advanced stage with vascularization 
and loss of differentiation (Gallo et al., 2002). Several theories explained the role of 
COX2 in a wide range of tissues including oral cancer and OSCC pre-malignancy 
suggesting that the effects of COX2 on tumour development and progression are 
most likely multifactorial and include different pathways including: Inhibition of 
Apoptosis, Stimulation of Angiogenesis, Immunosuppression, Enhanced 
Invasiveness, modulating xenobiotic metabolism, and Increased Mutagenesis (Jeng 
et al., 2000, Grosch et al., 2001, Dannenberg et al., 2001, Brown et al., 2001, Nelson 
et al., 2000, Masferrer et al., 2000). The pattern of gene expression profile in tumour 
samples of UK, suggesting the role of COX2 lies mainly on “Stimulation of 
Angiogenesis”, “Inhibition of Apoptosis” by increased expression of anti-apoptotic 
proteins and decreased expression of pro-apoptotic proteins, and “Enhanced 
Invasiveness” by increased expression of various matrix metalloproteinases, a family 
of degradative enzymes and would play a key role in the cancer invasiveness and 
metastasis.  




Figure 4.7: Master molecular network of significant genes of tumour samples from UK.  
Master network built by connecting significant genes involved in OSCC, HNSCC, and SCC identified by IPA tool (version 8.5) from up- and down-regulated genes 
using overlapping core analysis. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationship between the nodes). The 
tumours relative to normal overexpressed genes are shaded in red and downregulated genes in green. The nodes are represented using various shapes that represent the 
functional class of the gene products. Highly interconnected nodes (‘hub genes’) are highlighted with blue edges as potential key regulators of the master network. The 
network represents significant genes at FDR level ≤ 0.005 and fold change cut-off value ± 1.5.For clearer view of the network, see supplementary file 8.
  Chapter 4 
142 
 
Although increased expression of COX2 enzyme linked to the influence of tobacco 
use (a major risk factor with alcohol in UK samples) and heavy consumption of betel 
quid (a major risk factor in Sri Lankan samples) (Neville and Day, 2002, Jeng et al., 
2000, Ayan et al., 2000, Sharan, 1996, Mashberg et al., 1993), COX2 appeared 
upregulated in UK but not Sri Lankan samples. This observation could be important 
because pathway analysis displays it at the centre of many of the associated 
transcriptional pathways aberrantly expressed in UK OSCC. Upregulation of PTGS2 
has been reported in association with colorectal, bladder, and gastric cancer (Sudbo 
and Reith, 2003) as well as head and neck and OSCC (Tsai et al., 2004, Hunter et al., 
2005, Chan et al., 1999). PTGS2 upregulation may considered as important 
contributor to the phenotypic behaviour of OSCC and this may be exclusive to that 
seen in western countries (where betel quid chewing is not habitual and not an 
aetiological agent in the pathogenesis of OSCC). In fact topical use of COX2 
inhibitors on oral dysplastic lesions and early carcinoma is beginning in early clinical 
trials (Nelson, 2006) and represents a positive step forward in the molecular 
prevention and treatment of OSCC. Therefore, substantial evidence were existed for 
the role of PTGS2 in tumour progression and metastasis confirming the importance 
of its differential upregulation in UK but not Sri Lankan OSCC compared to normal 
mucosa. 
Nuclear Factor Kappa B (NFKB) signalling pathway is also implicated in tumour 
transformation and CXCL10 is more highly expressed in tumours than normal tissues 
appear to act with NFKB1 to promote COX2 upregulation. However, NFKB1 itself 
is not upregulated in the SAM analysis. It has been shown that a feedback-loop 
requiring constitutive NFKB1 expression for the IFNγ induced expression of 
CXCL10 (Hiroi and Ohmori, 2003).  
Upregulation of LAMC2 (a subunit gamma 2 of laminin 5) is another relevant 
observation. Laminin was reported frequently associated with aggressiveness, 
metastasis and poor prognosis of cancer in several studies (Barsky et al., 1984a, 
McCarthy et al., 1985, Hintermann and Quaranta, 2004, Yamamoto et al., 2001, 
Yamamoto et al., 2009, Kagesato et al., 2001, Aishima et al., 2004, Soini et al., 1996, 
Olsen et al., 2003, Malinoff et al., 1984, Barsky et al., 1984b, Haslam and 
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Woodward, 2003, Kaklamani and Gradishar, 2006, Gontero et al., 2004). 
Interestingly, this specific subunit of laminin 5 was previously reported in the 
cytoplasm of budding carcinoma cells at the invasive front of OSCC (Franz et al., 
2010, Kosmehl et al., 1999). This gene encodes for protein that act on cell- matrix, 
cell-cell interaction, and cellular migration or invasion (Chen et al., 2008a). 
Following attachment to laminin in the basement membrane, malignant cells secrete 
collagenase IV that specifically breaks down type IV collagen thus facilitate cell 
spreading and migration (Liotta et al., 1988). Moreover, laminin fragments generated 
by post-translational proteolytic cleavage bind to cell surface integrins and other 
proteins to trigger and modulate cellular movement(Hintermann and Quaranta, 
2004). Another study recruited mouse models showed that tumour cells with high 
levels of laminin and low level of unoccupied laminin receptor are resistant to killing 
by natural cytotoxic T cells, show high malignant behaviour (Malinoff et al., 1984), 
and by injecting laminin receptor’s blockers stop lung metastasis of 
hematologenously introduced tumour cells (Barsky et al., 1984a). Furthermore, 
several types of cancers distinguished with abundance of unoccupied laminin 
receptors (Liotta et al., 1988).  
Upregulation of Periostin (POSTN) in UK tumours relative to normal tissues is 
consistent with suggestions that it is a candidate for early prediction of malignant 
behaviour of UK cancer. Clinicopathological studies revealed that Periostin 
overexpression is well correlated with metastasis and poor prognosis in various 
cancers (Siriwardena et al., 2006, Bao et al., 2004, Sasaki et al., 2003, Sasaki et al., 
2001b, Sasaki et al., 2002, Sasaki et al., 2001a). Moreover, in vivo studies revealed 
Periostin displaying a striking phenotype of greatly accelerated tumour metastatic 
growth by using the animal model system of metastasis (Yan and Shao, 2006, Kudo 
et al., 2007, Shao et al., 2004, Bao et al., 2004).  
Invasion and angiogenesis promoted by Periostin may lead to metastasis of OSCC 
through the following steps: (I) Periostin-overexpressing OSCC cells secrete 
Periostin, (II) secreted Periostin binds to integrins both in OSCC cells and 
endothelial cells, (III) interaction between Periostin and integrins promotes invasion 
through inhibition of interaction between integrins and ECM and/or activation of 
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intracellular signal in OSCC cells, (IV) interaction between Periostin and integrins 
promotes angiogenesis in endothelial cells and (V) invasion and angiogenesis leads 
to metastasis. Overall, these findings suggest that Periostin can be a useful marker to 
predict metastasis in OSCC. Furthermore, it has been reported that serum levels of 
Periostin were elevated in patients with breast cancer, non-small-cell lung cancer and 
thymoma (Chen et al., 2008a, Suhr et al., 2007, Sasaki et al., 2003, Sasaki et al., 
2001b, Sasaki et al., 2001a). 
MMP3 also noticed highly expressed in UK tumours than normal tissue which 
encodes a secreted protease, matrix metalloproteinase-3, whose action is to degrade 
the major components of the extracellular matrix, and is thought associated with 
cervical lymph node metastases in HNSCC (Ye et al., 1996, Wiegand et al., 2005). 
MMP3 also reported upregulated in previous microarray studies which used the same 
criteria as this study (Nagata et al., 2003, Tsai et al., 2004, Ye et al., 2008, Suhr et al., 
2007). TNC also showed overexpression which encodes an ECM protein, tenascin-C, 
that regulates cell adhesion, migration, and growth (Jones and Jones, 2000). 
Furthermore, COL11A1 demonstrated the greatest differential expression between 
metastatic and non- metastatic tumour (Ziober et al., 2006, Schmalbach et al., 2004).  
Significantly lower expression of SLPI was observed in UK OSCCs compared to 
normal controls and may correlate with the invasive nature of this population group. 
According to a previous report, this gene showed an inverse correlation between its 
expression and histological parameters associated with tumour progression, including 
stage and pattern of invasion as well as invasive cell grade. Data suggested that SLPI 
may possess anti-tumorigenic activity via its ability to interfere with multiple 
requisite proteolytic steps underlying tumour cell invasion and may provide insight 
into potential stratification of oral cancer according to risk of occult metastasis, 
guiding treatment strategies (Abdel-fattah, Wen et al., 2011).  
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Additional observations that may reflect the invasive phenotypic behaviour of UK 
cases is reduced expression  of DUSP1, a transcriptional target of tumour suppressor 
p53, inducing cell cycle arrest or apoptosis (Li et al., 2003) with a role in protein 
modification; signal transduction and oxidative stress (Markopoulos et al., 2010). It 
was reported that the expression of DUSP1 is decreased in primary ovarian tumours 
compared with corresponding normal tissues (Denkert et al., 2002). A previous 
microarray study showed that the expression of DUSP1 gene is decreased in OSCC 
and a candidate for tumour suppression, mediating PTEN signalling pathways in 
OSCC (Tomioka et al., 2006). In many human cancers, increased DUSP1 expression 
was significant in early carcinogenic stage but fell progressively with higher 
histologic grade and metastasis. The downregulation of DUSP1 occurs 
predominantly as the tumour progresses from localized to advanced disease (Tomasi 
et al., 2010). 
To obtain biological background knowledge of the expressed genes in UK OSCCs in 
relative to the corresponding normal samples, IPA system was used to examine gene 
molecular function, biological process, canonical pathways, and transcriptional 
regulators analysis. 926 genes differentiating between UK tumour and normal 
mucosa at FDR level ≤ 0.005 and fold change cut off equal ± 1.5 were uploaded to 
IPA system resulted in 925 mapped genes after correction/ conversion processes of 
the uploaded genes. The most relevant activated and inhibited functions at 
FDR<0.001 are reported in Figure 4.5. Tumourigenesis, cellular growth, 
proliferation, transformation, movement, migration, invasion, metastasis, and ECM 
degradation, functions were appeared in the top of highest-level functions. 
Altogether these functions might influence the phenotypic behaviour of UK OSCCs 
related to tumour invasiveness, recurrence, and metastasis. 
Utilizing the canonical pathway analysis tool, determined fatty acid metabolism, 
glycolysis/ gluconeogenesis, citrate cycle, xenobiotic metabolism signalling, and 
NRF2-mediated oxidative stress response as the main relevant significant pathways 
associated with UK tumours along with a significant deregulation of Arachidonic 
Acid Metabolism pathway.  
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Next, investigation of the biological relationships between genes and gene products 
were carried out by performing a network analysis for the genes altered in UK 
tumour samples. Significant genes were uploaded to IPA system (n=926). At FDR = 
0.001, setting a cut off value of FC =1.5, 896 genes were mapped and considered 
eligible for network analysis. This network shows higher expression of essential 
central nodes, transcription regulators, and OSCC biomarkers including MMP1, 
PTGS2 (COX2), POSTN, MMP3, SPP1, HMGA2, LAMC2, TNC, GRIN1, REL, 
and SLC6A2 along with downregulation of TP53, RB1, HRAS, CDKN1B, DUSP1, 
CDH1, VEGFA,IGF2, NR3C1, PARP1, RPS6KB1, RAF1, SOD2, EZH2, SMAD4, 
ID2, JUP, TNFSF10, BAG1, SAT1, CASP4, CD24, KLF5, LGALS7, CDKN2C, 
CRYAB, MAPK9, MAPK13, FGFR2, FGFR3, HSP90, YES1, EHF, RAD21, 
COL18A1, PTPRC, WNT5A, KRT5, and MUC1 (Figure 4.7) highlighting MMP1, 
MMP3, and PTGS2 upregulation and downregulation of  TP53, RB1, CDH1, and 
HRAS at the centre of the network. Overlapping these genes over canonical pathway 
tool displayed the top perturbed pathways in the following ranking; molecular 
mechanism of cancer, Glucocorticoid receptor signalling, axonal guidance signalling, 
RAR activation, IL8 signalling, PIK/ AKT signalling, PTEN signalling, and B-cell 
receptor signalling. 
Some of the expressed genes have a special importance in the tumorigenic process 
acting as transcription regulators. Of the common perturbed transcription regulators, 
deregulation of MYC, TP53, NR3C1, and NFE2L2 were observed consistently in 
both populations which will be explained later on in the common gene comparison 
section. Activation of ESR1, SMAD3, and SMAD4 transcription regulators in UK 
tumour cases confirming the phenotypic behaviour of OSCCs from UK. Oestrogen 
receptors are over-expressed in around 70% of breast cancer cases. Two hypotheses 
have been proposed to explain why this causes tumourigenesis, and the available 
evidence suggests that both mechanisms contribute: First, binding of Oestrogen to 
the ER stimulates proliferation of mammary cells, with the resulting increase in cell 
division and DNA replication, leading to mutations. Second, Oestrogen metabolism 
produces genotoxic waste (Deroo and Korach, 2006). Oestrogen and the ERs have 
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also been implicated in breast, ovarian, colon, prostate, and endometrial cancer 
(Harris et al., 2003).  
Activation of SMAD proteins that accumulate in the nucleus can control 
transcription of a large number of target genes. The ability of SMADs to target a 
particular gene and the decision to activate or repress gene transcription are 
determined by cofactors that confer discriminating properties to the SMAD complex. 
The upregulation of common TGF-β pathway genes is Trans activated by 
SMAD2/3/4. However, SMAD signalling is essential for most, but not all, TGF-β 
gene responses (Siegel and Massague, 2003). Induction of CTGF and IL11 by TGF-β 
in tumour cells involves the binding of a SMAD complex to the promoter region of 
these genes, indicating that the SMAD pathway can involve in metastasis of breast 
cancer to bone by upregulation of pro-metastatic genes (Sethi et al., 2011). 
Furthermore, migratory ability of epithelial cells relies on loss of cell to cell contacts 
and acquisition of fibroblastic characteristics, a process that is commonly referred to 
as the epithelial mesenchymal transition (EMT). Several signalling pathways have 
been implicated in TGF-β-induced EMT, including SMADs, PI3K–AKT, RHOA and 
p38 MAPK78. Experiments showed that SMADs are indispensable for the EMT 
process (Hocevar et al., 1999, Yu et al., 2002). 
Inhibition of AP-1 complex (FOS) was noticed being significant in UK tumours and 
has been implicated in the transformation and progression of cancer.  It regulates 
gene expression in response to a variety of stimuli, including cytokines, growth 
factors, and stress (Hess et al., 2004) and in turn controls a number of cellular 
processes including differentiation, proliferation, and apoptosis (Ameyar et al., 
2003). Observations in human hepatocellular carcinoma cells indicate that c-Fos is a 
mediator of c-myc-induced cell death and might induce apoptosis through the p38 
MAP kinase pathway (Kalra and Kumar, 2004). This result confirmed that loss of c-
FOS expression is significantly and independently associated with reduced 
progression-free and overall survival in a cohort of optimally treated patients with 
epithelial ovarian cancer which suggest that c-FOS might have a function in tumour 
suppression in ovarian cancer. Moreover,  increase evidence that AP-1 might also 
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have an important function in cell death (Shaulian and Karin, 2001) and the ability of 
AP-1 to participate in several different cellular processes requires activation of 
different target genes under different conditions (Mahner et al., 2008). 
4.4.6 Gene expression profile of tumour versus normal 
samples from Sri Lanka 
The analysis were supervised in two groups according to sample type; OSCC and 
normal mucosa identifying 2070, 1966, 480, and 28 differentially expressed genes 
with a fold change cut-off value equal to ±1.5 and FDR levels of ≤0.005, ≤0.001, ≤ 
0.0001, and equal 0.00 respectively. At FDR level ≤ 0.005, 98 genes were 
upregulated and 1972 genes were downregulated in OSCC compared to normal 
mucosa (Table 4.6, Figure 4.8, and Supplementary file 9). Altering the stringency of 
SAM analysis to accept only FDR level ≤ 0.0001 reduced the profile to 480 all 
downregulated genes (Supplementary file 10). At FDR level=0.0 a set of 28 genes 
appeared all downregulated within Sri Lankan tumours relative to their normal 
comparators with a fold change magnitude ≥2 (Supplementary file 11). Among the 
differentially expressed genes represented tumour samples of Sri Lanka, Potential 
biomarkers were identified which previously reported a relation to OSCC and 
HNSCC (Table 4.6). Several of the above were significantly higher or lower in Sri 
Lankan but not UK tumour samples relative to normal oral tissues from the same 
country (Elevated expression of CD80, IL1RL1, GML, CYP27B1, SCN10A, 
HOXC10, and SH2D2A along with reduced expression of TWIST1, RECK, PSPH, 
GNG11, LSM7, and ERAP2). Interestingly, higher expression of CD80, IL1RL1 
which mediate anti-tumour immunity (Tajima et al., 2003, Thomas and Wen, 2006, 
Vesosky and Hurwitz, 2003, Chen et al., 1993), and GML upregulation which play a 
role in tumour suppression (Kimura et al., 1997) along with downregulation of PSPH 
and TWIST1 over expression is critical in SCC proliferation and metastasis (Yang et 
al., 2008, Yang and Wu, 2008, Yuen et al., 2007, Niu et al., 2007, Bachelor et al., 
2011) and might presumably accountable in resisting tumour invasion and metastasis 
of Sri Lankan tumour cases.  




Figure 4.8: Hierarchical clustering of the1065 most differentially expressed genes separating 3 Sri Lankan normal oral mucosal and 27 patient-
paired OSCC specimens using SAM supervised analysis at FDR≤0.001. 
Red and blue bars represent cancerous and normal samples, respectively. Heatmap represents mean-centred expression of genes in rows and samples in columns. 
Expression (red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. All gene expression values were either above or below fold 
change magnitudes equal to 2. For clearer view of the figure, see supplementary file 12. 
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Table 4.6: Significantly differentially expressed genes discriminating Sri Lankan 
tumour from normal samples.* 
Gene Symbol                      Gene ID    Fold 
Change 
 Gene 
Symbol                    
  Gene ID    Fold 
Change 
Genes higher expressed in OSCCC          
HMGA2 208025_s_at 2.8  SLC6A2 215715_at 1.9 
REL 206035_at 2.8  SPP1 209875_s_at 1.9 
CXCL10 204533_at 2.8  CXCL11 210163_at 1.8 
BMP15 221332_at 2.6  RARB 205080_at 1.8 
SCN10A 208578_at 2.2  OPRM1 211359_s_at 1.8 
MMP1 204475_at 2.1  MMP10 205680_at 1.7 
CHRM2 221330_at 1.9  CNR2 206586_at 1.5 
Genes lower expressed in OSCC       
CLEC3B 205200_at -5.3  CRYAB 209283_at -2.4 
CRNN 220090_at -5.2  ID2 201565_s_at -2.4 
KLF5 209211_at -4.8  TGFBR3 204731_at -2.4 
MAL 204777_s_at -4.8  CASP4 209310_s_at -2.3 
KRT13 207935_s_at -4.7  FGFR1 211535_s_at -2.3 
SCEL 206884_s_at -4.3  TP53 201746_at -2.3 
CLCA4 220026_at -4.2  BAG1 211475_s_at -2.2 
TGM3 206004_at -4.1  EHF 219850_s_at -2.1 
CDKN2C 204159_at -4  MAPK9 203218_at -2.1 
CLU 208792_s_at -4  PTPRC 212588_at -2.1 
EMP1 201324_at -4  RB1 203132_at -2.1 
PDGFRA 203131_at -4  EZH2 203358_s_at -2 
RHCG 219554_at -4  LGALS7 206400_at -2 
TWIST1 213943_at -4  PTCH1 209815_at -2 
CD24 208650_s_at -3.7  RAF1 201244_s_at -2 
SERPINB13 211362_s_at -3.3  SOD2 216841_s_at -2 
INS-IGF2 202409_at -3.1  LGALS3 208949_s_at -1.9 
HSPA1A//HSPA1B 200800_s_at -3  PARP1 208644_at -1.9 
IGFBP2 202718_at -3  BCL2 203685_at -1.8 
RPS6KB1 204171_at -3  CDC42 208728_s_at -1.8 
KRT19 201650_at -2.9  SMARCB1 212167_s_at -1.8 
SMAD4 202527_s_at -2.9  WNT5A 205990_s_at -1.8 
HRAS 212983_at -2.8  MAPK13 210058_at -1.7 
CDKN1B 209112_at -2.7  LGALS1 201105_at -1.7 
VEGFA 210512_s_at -2.7  PIK3CA 204369_at -1.7 
RAD21 200608_s_at -2.6  TIMP1 201666_at -1.7 
YES1 202933_s_at -2.6  TNFRSF10B 209295_at -1.7 
CRABP2 202575_at -2.5  CCND1 208712_at -1.6 
HSP90AB1 214359_s_at -2.5  JUP 201015_s_at -1.6 
NR3C1 216321_s_at -2.5  COL1A2 202403_s_at -1.5 
* FDR value < 0.005.The complete lists of upregulated and downregulated genes in OSCCs were 
presented in Supplementary file 9. 
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The most relevant activated and inhibited functions using IPA system are reported in 
Figure 4.8 at FDR<0.001. Cell cycle progression, tumour development and colony 
formation, epithelial cell proliferation, and cell ploidy and mitosis, appeared in the 
top of highest-level functions. Altogether these functions show no correlation with 
aggressive behaviour and metastasis of cancer which might influence and confirm 
the phenotypic behaviour of Sri Lankan OSCCs being non-invasive with no 
metastasis or recurrence of the disease reported. 
By utilizing canonical pathway analysis tool, mitochondrial dysfunction, oxidative 
phosphorylation, and ubiquinone biosynthesis are exhibited as the most common 
perturbed pathways involved in the process of tumour transformation in Sri Lankan 
group. 
Mitochondrial mutations may contribute to the development of a malignant 
phenotype by direct effects from increased reactive oxygen species production as 
well as induction of aerobic glycolysis and growth promotion (Zhou et al., 2007). 
While normal mitochondrial function can reduce tumourigenesis, various studies 
showed that tumour mitochondria are structurally and functionally abnormal and 
unable to generate normal levels of energy (Seyfried and Shelton, 2010). 
As RTG response is “off” in healthy cells with normal mitochondrial function, It 
turned “on” following impairment in mitochondrial energy production  where 
transcription and signalling commences for multiple energy and anti-apoptotic 
related genes and proteins to include MYC, TOR, p53, RAS, CREB, NFκB, and 
CHOP (Wolfman et al., 2006, Kulawiec et al., 2009, Kulawiec et al., 2008, Singh et 
al., 2005, Miceli and Jazwinski, 2005, Butow and Avadhani, 2004). The RTG 
response also takes a part in the participation of multiple negative and positive 
regulators, which facilitate the bioenergetics’ transition from respiration to substrate 
level Phosphorylation (Butow and Avadhani, 2004). Most cancer types are similar in 
expressing mitochondrial dysfunction and elevated substrate level Phosphorylation. 
When loss of respiration leads to glycolysis, dedifferentiation, and unbridled 
proliferation (Szentgyorgyi, 1977), it is expected that the presence of normal 
mitochondria in tumour cells would restore the cellular redox status, turn off the 
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RTG response, and reduce or eliminate the need for glycolysis (Warburg effect) and 
glutaminolysis to maintain viability. In other words, normal mitochondrial function 
would facilitate expression of the differentiated state thereby suppressing the 
tumorigenic or undifferentiated state (Seyfried and Shelton, 2010). 
Mitochondria and mitochondrial functions reported an involvement in apoptotic cell 
death (Jacobson et al., 1994, Nguyen et al., 1993, Hockenbery et al., 1990, Hennet et 
al., 1993, Newmeyer et al., 1994, Schulzeosthoff et al., 1992). Moreover, recent 
studies suggest that mitochondrial function may play substantial role behind the 
commitment of cells to undergo apoptosis (Heerdt et al., 1997, Krippner et al., 1996, 
Liu et al., 1996, Zhang et al., 1996, Marchetti et al., 1996, Zamzami et al., 1996, 
Vayssiere et al., 1994, Hennet et al., 1993, Schulzeosthoff et al., 1992).  
Alternative oxidations of fatty acids, ketone bodies, short-chain carboxylic acids, 
propionate, acetate and butyrate in tumour cells may contribute to ATP supply by 
oxidative phosphorylation (OXPHOS)(Ralph et al., 2010). Tumour cells maintain a 
significant level of OXPHOS capacity to rapidly switch from glycolysis to OXPHOS 
during carcinogenesis. The more realistic theory considers that OXPHOS and 
glycolysis cooperate to enhance energy demands along tumourigenesis (SmolkovÃ¡ 
et al., 2011). 
According to the previous studies, glycolysis appeared a feature of several tumours 
associated with faster growth in high glucose environment; however, active 
OXPHOS is also a significant  feature of other tumours occurred at a particular stage 
of carcinogenesis which might be more beneficial than a “glycolysis-only” 
metabolism in conditions of intermittent shortage in glucose supply. The metabolism 
of cancer cells is not constant during carcinogenesis and might depend on both the 
activated oncogenes and the tumour cell microenvironment (Jose et al., 2011). 
Moreover, several studies concluded that aerobic glycolysis is more a consequence 
of hypoxia rather inherent to cancer (Zu and Guppy, 2004).  
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Recent studies considered mitochondria as therapeutic targets for cancer 
chemotherapy suggested a combined strategies involving modulation of both 
glycolytic and mitochondrial pathways which might be required for more efficient 
elimination of malignant cells (Rodriguez-Enriquez et al., 2009, Galluzzi et al., 
2006). As tumour cells shift among different patterns of energy metabolism 
(Pedersen, 1978, SmolkovÃ¡ et al., 2011, Nadege et al., 2009, Rodriguez-Enriquez et 
al., 2009), variant pharmacological trials could provide drug specificity via variable 
interference with distinctive steps of cancer energy production pathways.  
Another identified observation is the relatively severe downregulation of p53 in Sri 
Lankan tumour samples along with the absence of COX2, raised the previous 
reported evidence stated that carcinogenic p53 deficiency results in a decreased level 
of COX2 and triggers a shift toward anaerobic metabolism. Where lactate synthesis 
is increased, cellular ATP levels remain stable (Zhou et al., 2003). This evidence is 
further confirmed by results of current study highlighting mitochondrial dysfunction, 
oxidative phosphorylation, citrate cycle suppression, and glycolysis/ gluconeogenesis 
on the top canonical pathways perturbed in Sri Lankan tumour cases. 
Briefly any unspecific condition that damages a cell’s oxidative phosphorylation, but 
is not severe enough to induce apoptosis, can potentially initiate the path to a 
malignant cancer. Impaired mitochondrial function can induce abnormalities in 
tumour suppressor genes and oncogenes. The accumulation of mitochondrial damage 
over time is what ultimately leads to malignant tumour formation.  An increased 
dependency on substrate level phosphorylation for survival would follow each round 
of metabolic and genetic damage thus initiating uncontrolled cell growth and 
eventual formation of a malignant neoplasm. Basically the well-documented tumour-
associated abnormalities in oncogenes, tumour suppressor genes, and chromosomal 
imbalances can arise as a consequence of the progressive impairment of 
mitochondrial function (Seyfried and Shelton, 2010). 
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The master network of Sri Lankan tumour samples displayed upregulation of MMP1, 
SPP1, HMGA2, RARB, REL, OPRM1, CNR2, SCN10A, and CHARM2 along with 
downregulation of TP53, BCL2, VEGFA, CDKN1B, SMAD4, LGALS1, CDKN2C, 
LGALS3, RB1, RAF1, HRAS, COL1A2, CDC42, PIK3CA, PTCH1, TWIST1, 
PDGFR, SOD2, KLF5, CASP4, BAG1, ID2, RAF1, MAPK9, TGFBR, TIMP1, 
CCND1, WNT5A, SMARCB1, TNFRSF10, KRT19, FGFR, JUP, YES1, and 
COL18A1 as major key players with MMP1 upregulation along with TP53,BCL2, 
RB1, CCND1, and HRAS downregulation at the centre of the network (Figure 4.9). 
Overlapping these genes with canonical pathway tool displayed the top affected 
pathways by the following rank; molecular mechanism of cancer, PTEN signalling, 
axonal guidance signalling, PIK/ AKT signalling, NFκB signalling, Glucocorticoid 
receptor signalling, RAR activation, B-cell receptor signalling, and telomerase 
signalling pathway as the top relevant pathways in the process of tumour 
transformation in Sri Lankan cases.  




Figure 4.9: Master molecular network of significant genes of tumour samples from Sri Lanka.  
Master network built by connecting significant genes involved in OSCC, HNSCC, and SCC identified by IPA tool (version 8.5) from up- and down-regulated genes 
using overlapping core analysis. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationship between the nodes). The 
tumours relative to normal upregulated genes are shaded in red and downregulated genes in green. The nodes are represented using various shapes that represent the 
functional class of the gene products. Highly interconnected nodes (‘hub genes’) are highlighted with blue edges as potential key regulators of the master network. The 
network represents significant genes at FDR level ≤ 0.005 and fold change cut-off value ± 1.5. For clearer view of the network, see supplementary file 13.
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4.4.7 Common gene expression profile of tumour versus 
normal samples from both UK and Sri Lanka 
Out of the total number of supervised differentially expressed genes at FDR ≤ 0.005 
and fold change cut-off values equal to 2.0, 846 genes (807 downregulated and 39 
upregulated) were observed commonly expressed in tumours versus controls for the 
cases from the two populations together (Table 4.7 and Supplementary file 14). The 
common significant biomarkers which previously reported in relation to OSCC and 
HNSCC are shown in Table 4.7. 
MMP1 was more highly expressed in UK OSCCs compared to normal tissues and 
also higher, although to a lesser degree, in Sri Lankan cases. MMP1 facilitates the 
infiltration of tumour cells by physically destroying connective tissue and involved in 
the breakdown of the ECM during angiogenesis, invasion and metastasis (Seiki, 
2003, Franchi et al., 2002, Thomas et al., 1999). MMP1 has been significantly 
associated with tumour metastasis and is widely reported in gene expression 
signatures of OSCC compared to normal mucosa in several studies (Alevizos et al., 
2001, Mendez et al., 2002, Nagata et al., 2003, Tsai et al., 2004, Choi and Chen, 
2005, Suhr et al., 2007, Ziober et al., 2006, Ye et al., 2008, Estilo et al., 2009). It is 
also upregulated in studies used laser capture micro dissection (LCM) to isolate pure 
populations of keratinocytes (Alevizos et al., 2001, Toruner et al., 2004) indicating 
that MMP1 is upregulated in malignant cells and therefore reinforcing its 
contribution to the biological behaviour of OSCC. 
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Table 4.7: The common significantly differentially expressed genes discriminating 
tumour from normal samples of both UK and Sri Lankan population groups. * 
Gene Symbol                      Gene ID    Fold 
Change 
 Gene 
Symbol                    
  Gene ID    Fold 
Change 
Genes lower expressed in OSCC than normal 
 
       
MMP1 204475_at 3.2  REL 206035_at 2.3 
MAGEA3 209942_x_at 2.9  CXCL10 204533_at 2.2 
HMGA2 208025_s_at 2.8  AIM2 206513_at 2.1 
BMP15 221332_at 2.3  SPP1 209875_s_at 2 
 
Genes lower expressed in OSCC than normal 
  
CRNN 220090_at -5.7  SMAD4 202527_s_at -2.6 
MAL 204777_s_at -5.4  CDKN1B 209112_at -2.6 
KRT13 207935_s_at -5.2  CRABP2 202575_at -2.5 
KLF5 209211_at -5  INS-IGF2 202409_at -2.5 
SCEL 206884_s_at -4.7  HRAS 212983_at -2.5 
CLCA4 220026_at -4.6  VEGFA 210512_s_at -2.5 
TGM3 206004_at -4.5  Rgs5 209071_s_at -2.5 
EMP1 201324_at -4.3  KRT19 201650_at -2.4 
CLEC3B 205200_at -4.2  EHF 219850_s_at -2.3 
RHCG 219554_at -4.2  NR3C1 216321_s_at -2 
CD24 208650_s_at -3.8  ID2 201565_s_at -2 
CDKN2C 204159_at -3.5  TP53 201746_at -2 
CLU 208792_s_at -3.4  CASP4 209310_s_at -1.9 
SERPINB13 211362_s_at -3.2  SOD2 216841_s_at -1.8 
HSPA1A//HSPA1B 200800_s_at -3  LGALS3 208949_s_at -1.8 
IGFBP2 202718_at -2.7  TNFSF10 202688_at -1.7 
* FDR value < 0.005. The complete lists of upregulated and downregulated genes in OSCCs were 
presented in Supplementary file 14. 
Several investigations into tumour progression have established that AGR2 has a role 
in promoting cell migration and invasion (Wang et al., 2008, Maresh et al., 2010, Liu 
et al., 2005, Zhang et al., 2010). Recent study confirmed association of AGR2 with 
metastasis of HNSCC in vivo with findings indicated both CD147 and AGR2 play a 
role in tumourigenesis (Sweeny et al., 2012). Of specific finding is the upregulation 
of MAGEA3 which could be a novel biomarker in OSCC especially it’s highly 
upregulation in both populations. Reviewing this gene uncovered its involvement in 
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early prediction of the relapse and prognosis in patients with hepato-cellular 
carcinoma (Mou et al., 2002) as well as metastasized melanoma (Roeder et al., 
2005). Moreover, it considered a target in diagnosis and immunotherapy of lung 
cancer (Sienel et al., 2004, Vansteenkiste et al., 2007a, Vansteenkiste et al., 2007b). 
The most highly downregulated gene was Cornulin (CRNN) followed by a putative 
tumour suppressor gene T-cell differentiation protein (MAL). CRNN functions as 
survival factor that participates in the clonogenicity of squamous oesophageal 
epithelium cell lines, attenuates deoxycholic acid (DCA)-induced apoptotic cell 
death. Another downregulated gene KRT13 was suggested a promising tumour 
marker for detecting the micro metastases in cervical lymph nodes of oral cancer 
(Hamakawa et al., 2000). Loss of KRT13 expression indicates tumours with a high 
potential for recurrence (Yanagawa et al., 2007). Several genes were similarly 
downregulated in both UK and Sri Lankan OSCC including the tumour suppressor 
gene CLU which has been associated with programmed cell death (apoptosis) 
(Buttyan et al., 1989). Downregulation of CLU is associated with poor outcome in 
breast cancer (Zhang et al., 2006) as well as OSCCs (Chin et al., 2005, Ye et al., 
2008).  
CRABP2 (cellular retinoic acid binding protein 2) which has been reported  
downregulated in prostate cancer (Okuducu et al., 2005) is also showed 
downregulation in both UK and Sri Lankan tumours. Retinoids have shown 
promising agents in the treatment of oral dysplastic lesions although toxicity has 
limited their clinical usefulness; retinoids may still have utility in the treatment of 
OSCC as they can suppress squamous differentiation in OSCC (Shalinsky et al., 
1995). 
RGS5 (Regulator of G-protein signalling 5) is another key player shown 
downregulated in Sri Lankan but not UK tumours relative to their normal controls 
and has been reported to play an important roles in the development of vasculature. 
A recent study demonstrated that levels of RGS5 inversely related to tumour 
metastasis in non-small cell lung cancer (Huang et al., 2012). Furthermore, RGS5 
downregulation identified  one of the genes capable of discriminating between lymph 
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node positive (N+) and lymph node negative (N0) individuals in HNSCC (Roepman 
et al., 2005). 
846 genes differentiating between both UK and Sri Lankan OSCCs and their normal 
mucosa at FDR level ≤ 0.005 and fold change cut off value equal ± 1.5 were 
uploaded to IPA system resulted in 845 mapped genes after correction/ conversion 
processes of the uploaded genes with 841 genes eligible for subsequent IPA analysis. 
The common key players of the comprehensive network generated by IPA system, 
those related to OSCC and HNSCC include upregulation of MMP1, SPP1, HMGA2, 
REL, and SLC6A2 along with downregulation of TP53, CLU, CDKN1B, CDKN2C, 
HSPA1A, CASP4, SMAD4, PARP1, PDGFRA, FGFR2, SOD2, LGALS3, KLF5, 
TNFSF10, NR3C1, ID2, RAF1, IGFBP2, CD24, RB1, HRAS, KRT1, WNT5A, 
EZR, YES1, BAG1, JUP, MAPK13, KRT19, and VEGFA (Figure 4.10).  




Figure 4.10: Master molecular network of common genes existed in both UK and Sri Lankan tumour samples.  
Master network built by connecting significant genes involved in OSCC, HNSCC, and SCC identified by IPA tool (version 8.5) from up- and down-regulated genes 
using overlapping core analysis. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationship between the nodes). The 
tumours relative to normal upregulated genes are shaded in red and downregulated genes in green. The nodes are represented using various shapes that represent the 
functional class of the gene products. Highly interconnected nodes (‘hub genes’) are highlighted with blue edges as potential key regulators of the master network. The 
network represents significant duplicated genes existed in both populations at FDR level ≤ 0.005 and fold change cut-off value ± 1.5.
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Comparison core analysis of Sri Lankan and UK tumours versus normal comparators 
displayed an obvious contrast in specific bio functions. This reflected by relatively 
higher activation of cellular compromise in Sri Lankan samples with defect and 
suppression of organismal function (which implements healing of lesion, wound, and 
oxygenation of lipid) in UK groups. 
Fatty acid metabolism pathway followed by Propanoate, Butanoate metabolism, 
glycolysis/ gluconeogenesis, Arginine and Proline metabolism, citrate cycle, NRF2-
Mediated oxidative stress response, EIF2 Signalling, Glucocorticoid receptor 
signalling, xenobiotic metabolism signalling are the most common perturbed 
pathways in the cases from the two populations. This indicates that the development 
of OSCCs is mediated mostly by similar biological pathways despite the differences 
related to racing, ethnicity, lifestyle, and/or exposure to environmental carcinogens 
(Gmeiner et al., 2008). 
From the above mentioned pathways that not discussed in the previous sections of 
this study is the deregulation of NRF2-mediated oxidative response pathway. 
Nuclear factor (erythroid-derived 2)-like 2(NRF2)-mediated oxidative stress 
response pathway and genes were detected at all-time points of hypoxia suggesting 
activation of NRF2 are antioxidant defence system. The activation of Nrf2 results in 
transcriptional expression of a broad spectrum of protective enzymes including those 
involved in xenobiotic detoxification, antioxidative response, and proteome 
maintenance (Kensler et al., 2007). Low levels of Nrf2 or loss of Nrf2 activity 
appears to increase ROS production and DNA damage and predisposes cells to 
tumourigenesis (Hayes and McMahon, 2006, Klaunig et al., 2010). 
Of the common perturbed transcription regulators observed consistently in both 
populations is MYC (v-myc myelocytomatosis viral oncogene homolog). MYC 
regulates the transcription of many genes including those that encode proteins 
involved in the control of cell adhesion, differentiation, cell cycle regulation, 
angiogenesis and apoptosis. The ability of MYC to modulate protein synthesis 
globally suggests that it has multiple roles in orchestrating cellular processes in 
regulating specific physiological functions (van Riggelen et al., 2010). 
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The MYC network can also regulate the transactivation and repression of many 
genes through the remodelling of chromatin structure (Knoepfler, 2007). The 
suppression of MYC results in global changes to chromatin structure and therefore 
gene expression (Knoepfler et al., 2006, Wu et al., 2007, van Riggelen et al., 2010). 
A recent study demonstrated that more aggressive phenotypes of OSCC are probably 
the consequences of multiple deregulations of multiple copies number of amplified 
genes in MYC module and that MYC centred regulatory network may explain the 
observed differences in clinical outcomes of OSCC patients instead of direct 
consequences of MYC expression itself. Speculation explained that beyond MYC , 
multiple copy number amplified genes and abundant dysregulated genes in the MYC 
module may ultimately lead to dysfunction of the cell cycle, cell proliferation, and 
invasion in OSCC tumours (Peng et al., 2011).  
NFE2L2 showed the lowest expression in tumours compared to normal controls 
among the transcriptional regulators distinguished in both population groups. 
NFE2L2 induces the expression of various genes including those that encode for 
several antioxidant enzymes, and it may play a physiological role in the regulation of 
oxidative stress.  
Inhibition of NR3C1regulator was another finding. NR3C1is receptor of 
Glucocorticoids regulates carbohydrate, protein and fat metabolism; modulates 
immune responses through suppression of chemokine and cytokine production. The 
observation of TP53, a transcription factor, with lower expression tumours in both 
populations compared to normal tissue was not surprising as it is often reported to 
regulate the expression of genes involved in a variety of cellular functions, including 
cell-cycle arrest, DNA repair, and apoptosis (Kho et al., 2004, Cawley et al., 2004, 
Kannan et al., 2001b, Kannan et al., 2001a, Zhao et al., 2000, Yu et al., 1999).
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4.4.8 Gene expression profile of perineural invasive versus 
non- invasive tumour samples from UK 
Using SAM supervised analysis at FDR≤0.05, only three genes separating 6 
perineural invasive and 15 non-invasive OSCCs (Figure 4.11). All three genes 
appeared upregulated in perineural invasive tumours; two genes (PGM1, ENO2) with 
log2 fold change magnitudes above 1 and ILK within (0.556). 
   
Figure 4.11: Hierarchical clustering of three differentially expressed genes separating 6 
perineural invasive OSCC and 15 non-invasive OSCC samples using SAM supervised 
analysis at FDR≤0.05 
Red and blue bars represent perineural invasive and non-invasive UK tumour samples, respectively. 
Heatmap represents mean-centred expression of genes in rows and samples in columns. Expression 
(red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. All genes 
appeared over-expressed in perineural invasive tumours, two genes (PGM1, ENO2) with fold change 
magnitudes above 1 and ILK within 0.556 fold change magnitude. 
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4.4.9 Gene expression profile of high-stage versus low- stage 
tumour samples from both UK and Sri Lankan tumours 
Using SAM supervised analysis at FDR≤0.05, 12 genes separating 15 “high stage” 
from 35 “low stage” OSCCs of both population groups. Most of genes appeared 
over-expressed in high stage tumours with fold change log2 magnitudes above or 
equal to 1 (Figure 4.12) and appeared associated with different cancer types and 
cellular processes associated with tumours. 
Most of differentially upregulated genes in high stage tumours exhibited involvement 
in variant biological processes crucial in driven tumour lesion to late stage and 
metastasis with distinct roles in cellular migration, remodelling, outgrowth, invasion, 
differentiation, colony formation, cell cycle progression, activation, proliferation, and 
angiogenesis.  




Figure 4.12: Hierarchical clustering of 12 differentially expressed genes discriminating 
high stage (N=15) from low stage tumours (N=33) of UK and Sri Lankan OSCCs using 
SAM supervised analysis at FDR≤0.05 
Pink and blue bars represent high stage and low stage tumour samples, respectively. Heatmap 
represents mean-centred expression of genes in rows and samples in columns. Expression (red= high, 
green= low, black= not changed) is represented on a log2 mean- centred scale. The majority of 12 
genes appeared to be over-expressed in almost high stage than low stage tumour samples within 
expression values fold change magnitudes ≥ 0.5. 
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4.4.10 Gene expression profile between UK and Sri Lankan 
tumour samples 
Using SAM supervised analysis at FDR≤0.05, 21 differentially expressed genes 
separating all Sri Lankan (N=27) and UK (N=21) OSCCs. Although gene expression 
values were only above or below log2 fold change magnitudes equal to 1, the 
discriminating power of these genes was weak (Figure 4.13). Altering the stringency 
of the SAM analysis to accept only FDR level ≤ 0.01 reduced the profile to 10 
upregulated and 2 downregulated genes in Sri Lankan relative to UK cases with more 
powerful discrimination (Figure 4.14).  
Better improvement in discrimination was observed when comparing cases from one 
disease stage separately. Comparing high stage cases only identified 11 upregulated 
genes (Figure 4.15) whereas cases of low stage separated by 31 genes, 25 up- and 6 
downregulated genes in Sri Lankan versus UK tumours (Figure 4.16).  




Figure 4.13: Hierarchical clustering of 21 differentially expressed genes separating Sri 
Lankan (N=27) and UK (N=21) oral squamous cell tumour samples using SAM 
supervised analysis at FDR≤0.05. 
Red and blue bars represent UK and Sri Lankan cancerous samples, respectively. Heatmap represents 
mean-centred expression of genes in columns and samples in rows. Expression (red= high, green= 
low, black= not changed) is represented on a log2 mean- centred scale. All gene expression values 
were either above or below fold change magnitudes equal to 1. 




Figure 4.14: Hierarchical clustering of 12 differentially expressed genes separating Sri 
Lankan (N=27) and UK (N=21) OSCC samples using SAM supervised analysis at 
FDR≤0.01 
Red and blue bars represent UK and Sri Lankan cancerous samples, respectively. Heatmap represents 
mean-centred expression of genes in columns and samples in rows. Expression (red= high, green= 
low, black= not changed) is represented on a log2 mean- centred scale. All gene expression values 
were either above or below fold change magnitudes equal to 1. 
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Comparing UK and Sri Lankan OSCCs, some of the gene expression differences are 
attributed to cancer-associated genes, many of them are not. This comparison was 
carried out at a reduced fold change cut off value compared to the other supervised 
analyses (log2 fold change magnitudes equal to 1 at FDR level ≤ 0.01). This 
observation tends to support the notion that only small numbers of (tumour related) 
gene expression differences between UK and Sri Lankan OSCCs. 
CDKN1B is only one among the genes downregulated in UK relative to Sri Lankan 
OSCCs which defined as being lower in high-risk tumours and is associated with 
poor prognosis (Chu et al., 2008). CDKN1B has already been shown as tumour 
suppressor gene that is downregulated in UK OSCC when compared to normal 
tissue, and is perhaps an important contributor to the phenotypic differences 
observed between UK and Sri Lankan tumours. PSIP1, SAMSN1, CCNG2, and 
NCOA2 play a protective role in tumorigenic process and their downregulation can 
favour cancer transformation (Chylack et al., 2004, Tian et al., 2002). Likewise, 
upregulation of CCT2 and DHCR24 in UK OSCCs contributed in rapidly 
proliferating tumour and melanoma metastases respectively (Yokota et al., 2001, Di 
Stasi et al., 2005).  




Figure 4.15: Hierarchical clustering of 11 differentially expressed genes separating 
“High Stage” Sri Lankan (N=3) and UK (N=12) oral squamous cell tumour samples 
using SAM supervised analysis at FDR≤0.05 
Red and blue bars represent UK and Sri Lankan high stage tumour samples, respectively. Heatmap 
represents mean-centred expression of genes in rows and samples in columns. Expression (red= high, 
green= low, black= not changed) is represented on a log2 mean- centred scale. All 11 gene expression 
values were over expressed in Sri Lankan tumours samples above fold change magnitudes equal to 1. 
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Figure 4.16: Hierarchical clustering of 11 differentially expressed genes separating 
“Low Stage” Sri Lankan (N=24) and UK (N=9) oral squamous cell tumour samples 
using SAM supervised analysis at FDR≤0.05 
Red and blue bars represent UK and Sri Lankan low stage tumour samples, respectively. Heatmap 
represents differential mean-centred expression of genes in rows and samples in columns. Expression 
(red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. Gene 
expression values were either above or below fold change magnitudes equal to1. 
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Running IPA core analysis identified activated immune response functions in Sri 
Lankan relative to UK tumours. These include; development and mitosis of 
thymocytes; activation, development, differentiation, cell movement, migration, and 
chemotaxis of T, B-lymphocytes, leukocytes, monocytes, and other immune system 
cells. Curcumin consumed by Sri Lankan people for centuries as a frequent dietary 
component could play a role in the above observation (Pirasath et al., 2010, 
Jayasekera et al., 2004).  
These findings might has an impact on the clinical behaviour of the two tumour 
groups which mainly reflected in resistant of Sri Lankan patients to the invasiveness, 
metastasis, and recurrence of disease as well as survival of the patient with lower 
morbidity and mortality relative to UK patients. The same findings are observed 
between Sri Lankan and UK normal groups and will be explained in details.  
4.4.11 Gene expression profile between UK and Sri Lankan 
normal mucosa  
Following the same analysis strategy used in the previous comparison categories of 
this study, both supervised and unsupervised analysis are used as mentioned in 
materials and methods section. Both analysis separated normal Sri Lankan (N=3) 
from normal UK (N=5) samples (Figure 4.17). Using SAM supervised method, 1439 
genes were differentially expressed when comparing normal UK and Sri Lankan 
tissue with a fold change cut-off value equal to ±1.5 and FDR levels of ≤0.01 (Table 
4.8, Figure 4.18, and Supplementary file15). Altering the stringency of the SAM 
analysis to accept only FDR level ≤ 0.005 reduced the profile to only 10 upregulated 
and 5 downregulated genes in Sri Lankan compared to UK normal mucosa (Table 
4.9 and Figure 4.19).  




Figure 4.17: A. Unsupervised Pearson correlation hierarchical clustering of all 
normalized genes separating 3 Sri Lankan and 5 UK normal oral mucosal samples. B. 
Supervised Pearson correlation hierarchical clustering of the 205 most differentially 
expressed genes using SAM supervised analysis at FDR≤0.01. 
Red and blue bars represent UK and Sri Lankan normal samples, respectively. Heatmap represents 
samples distribution according to the mean-centred expression of genes. Expression (red= 1, yellow= 
lower than 1, white= lowest value than 1). 
Among the differentially expressed genes discriminating normal samples of Sri 
Lanka from those of UK, potential biomarkers previously involved in different types 
of cancer were identified (Table 4.8). 
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Table 4.8: List of the top upregulated and downregulated genes differentially expressed 
between normal samples of both UK and Sri Lankan groups at FDR level ≤ 0.01.* 
Gene Symbol                    Gene ID    Fold 
Change 
 Gene Symbol                    Gene ID    Fold 
Change 
 Genes higher expressed in Sri Lankan than UK normal samples 
 
PHACTR2 244774_at 4.2  LOC399959 232113_at 2.9 
       SCARA5 229839_at 3.7 POSTN 210809_s_at 2.9
CTHRC1 225681_at 3.5  RECK 205407_at 2.8 
ITGBL1 205422_s_at 3.3  P2RY14 206637_at 2.8 
IGJ 212592_at 3.3  BCAT1 226517_at 2.8 
PSPH 205048_s_at 3.3  COL3A1 232458_at 2.8 
FLJ40330 1569040_s_at 3.2  FERMT2 209210_s_at 2.8 
GLT8D2 227070_at 3.2  TFPI 213258_at 2.8 
FAM46C 226811_at 3.2  LY96 206584_at 2.8 
ZBTB38 225512_at 3.1  SLC25A32 221020_s_at 2.8 
PLN 204939_s_at 3.1  TYRP1 205694_at 2.8 
MGP 202291_s_at 3  MGC29506 223565_at 2.8 
FBN1 202766_s_at 3  LAMB1 201505_at 2.8 
C12ORF23 224759_s_at 3  TMEM47 209656_s_at 2.8 
C13ORF15 218723_s_at 3  LY75//CD302 203799_at 2.8 
MAP1B 226084_at 2.9  POSTN 1555778_a_at 2.7 
ANGPTL1 231773_at 2.9  IKBIP 227295_at 2.7 
DCLK1 229800_at 2.9  EBF1 227646_at 2.7 
EVI2B 211742_s_at 2.9  SELM 226051_at 2.7 
ERAP2 219759_at 2.9     
MALAT1 223940_x_at -4.1  ATP6V0D2 1553153_at -2.2 
       Genes lower expressed in Sri Lankan than UK normal samples 
 
MALAT1 224568_x_at -4  ZNF664 1569935_at -2.2 
EGFR 1565484_x_at -3.6  SNORA71A 1568249_at -2.1 
EGFR 1565483_at -3.6  WHAMML2 1557450_s_at -2.1 
PLEKHA5 1558695_at -3  CUEDC1 1555786_s_at -2.1 
MALAT1 223578_x_at -2.9  LOC100192378 1559966_a_at -2.1 
NEAT1 238320_at -2.8  HNRNPD 236000_s_at -2.1 
DEFB106A//B 1552411_at -2.8  TRIM4 224159_x_at -2.1 
FAM120A 1555944_at -2.7  NBPF1 214693_x_at -2 
LCE1E 1559224_at -2.6  NEAT1 214657_s_at -2 
LOC285708 1564281_at -2.5  CLIP4 242710_at -2 
NEAT1 227062_at -2.4  EHF 241397_at -2 
CADM3 216535_at -2.4  MALAT1 227510_x_at -2 
HIF3A 222124_at -2.3     
*FDR≤ 0.01.The complete lists of upregulated and downregulated genes in Sri Lankan normal 
samples relative to UK normal samples were presented in Supplementary file 15. 
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Table 4.9: List of the top upregulated and downregulated genes differentially expressed 
between normal samples of both UK and Sri Lankan groups at FDR level ≤ 0.005.* 
Gene Symbol       Affymetrix ID           Gene Name / Description                                                                         Average
Fold 
Change 
Genes higher expressed in Sri Lankan than UK normal samples 
 
 
PHACTR2 244774_at phosphatase and actin regulator 2 4.2 
ITGBL1 205422_s_at integrin, beta-like 1 (with EGF-like repeat 
domains) 
3.3 
GLT8D2 227070_at glycosyltransferase 8 domain containing 2 3.2 
C13ORF15 218723_s_at chromosome 13 open reading frame 15 3.0 
SELM 226051_at selenoprotein M 2.7 
NEGR1 229461_x_at neuronal growth regulator 1 2.5 
SEC62 1552790_a_at SEC62 homolog (S. cerevisiae) 2.4 
MTR 203774_at 5-methyltetrahydrofolate-homocysteine 
methyltransferase 
2.4 
POLK 223261_at polymerase (DNA directed) kappa 2.4 
RAB30 229072_at RAB30, member RAS oncogene family 2.3 
Genes lower expressed in Sri Lankan than UK normal samples 
 
 
EGFR 1565484_x_at epidermal growth factor receptor  -3.6 
EGFR 1565483_at epidermal growth factor receptor  -3.6 
PLEKHA5 1558695_at pleckstrin homology domain containing, family A 
member 5 
-3.0 
DEFB106A//B 1552411_at defensin, beta 106A; defensin, beta 106B -2.8 
FAM120A 1555944_at family with sequence similarity 120A -2.7 
LCE1E 1559224_at late cornified envelope 1E -2.6 
*FDR≤ 0.005 




Figure 4.18: Hierarchical clustering of 1439 differentially expressed genes separating 3 Sri Lankan and 5 UK normal oral mucosal samples 
using SAM supervised analysis at FDR≤0.01. 
Red and blue bars represent UK and Sri Lankan normal samples, respectively. Heatmap represents mean-centred expression of genes in rows and samples in columns. 
Expression (red= high, green= low, black= not changed) is represented on a log2 mean- centred scale. All gene expression values were either above or below fold 
change magnitudes equal to ±1.5. 




Figure 4.19: Hierarchical clustering of 16 differentially expressed genes separating 3 
Sri Lankan and 5 UK normal oral mucosal samples using SAM supervised analysis at 
FDR≤0.005. 
Red and blue bars represent UK and Sri Lankan normal samples, respectively. Heatmap represents 
mean-centred expression of genes in rows and samples in columns. Expression (red= high, green= 
low) is represented on a log2 mean- centred scale. All gene expression values were either above or 
below fold change magnitudes equal to 2. 
Running biomarker analysis identified specific biomarkers related to OSCC and 
HNSCC. This include upregulation of COL1A1, COL4A1, H3F3A/B, BCL2, FGF2, 
ATM, IGF1, MGMT, FZD7, LGALS1, SPARKL1, CXCL12, TIMP3, MIB1, NBN, 
NTRK2, and TMEM38B along with downregulation of EGFR and IGF1R.      
Elevated oncogenes were observed in normal samples from Sri Lanka comparing to 
those from UK population group. Example are; BCL2, RUNX1, AXL, ERBB2, 
RAS, MYC, HTERT, KIT, IGF1, MGMT, TRK, and SRC oncogenes plus other 
genes strongly involved in tumourigenesis like POSTN, RECK, COL1A2, COL1A3, 
COL5A2, WISP1, AGR2.Noticeably, suppressed oncogenes receptors, including 
EGFR, IGF1R, RARA, EPOR, THRA, and NMUR2 receptors, were observed which 
might be explained as expected biological tolerance modulation response of the body 
to the long term elevated expression level of oncogenes. This finding could suggest 
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elevated body threshold to oncogenic stimulus as protective mechanism of normal 
cell against tumorigenic signalling. As Sri Lankan normal individuals did not chew 
Betel quid, Curcumin consumed by Sri Lankan people for centuries as a frequent 
dietary component could play a role in the above observation (Pirasath et al., 2010, 
Jayasekera et al., 2004). Curry and turmeric have already been reported as anti-
tumour diets which boost immune surveillance against tumour progression. 
Curcumin (diferuloylmethane) is reported to downregulate various growth regulatory 
pathways and specific genetic targets including genes for NFκB, STAT3, COX2, 
AKT, anti-apoptotic proteins, growth factor receptors, and multidrug-resistance 
proteins. The protective effects of Curcumin appear on its ability to hasten the 
activation of NRF2 and induce the expression of antioxidant enzymes (e.g., 
hemeoxygenase-1, glutathione peroxidase, modulatory subunit of gamma-glutamyl-
cysteine ligase, and NAD(P)H:quinone oxidoreductase 1, increase glutathione (a 
product of the modulatory subunit of gamma-glutamyl-cysteine ligase), directly 
quench free radicals, and inhibit p300 HAT activity (Goel and Aggarwal, 2010).    
A further observation is the upregulation of Selenoproteins in normal Sri Lankan 
samples including SELM, SELK, SEPP1, and SELT provides an additional 
independent explanation of the Sri Lankan population resisting tumour invasiveness. 
The increase in the production of reactive oxygen species (ROS) associated with low 
antioxidant activity has been related to several types of cancer. Selenium, an 
antioxidant micronutrient, may function as an anti-mutagenic agent, preventing the 
malignant transformation of normal cells. The protective effect of selenium is 
especially associated with its presence in the glutathione peroxidase and thioredoxin 
reductase enzymes to protect DNA and other cellular components against oxidative 
damage caused by ROS. The thioredoxin reductase (TrxR) selenoenzyme family is 
also capable of degrading hydroperoxides, as demonstrated by the reduction in 
hydrogen peroxide and is involved in numerous vital processes, such as DNA 
synthesis and regulation of apoptosis (Gromadzinska et al., 2008). Moreover, another 
result reported the role of selenium in inhibition of tumour growth and metastasis 
(Yoo et al., 2006). Several studies have shown reduced expression of these enzymes 
in various types of cancer, especially when associated with low intake of selenium, 
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which may increase the damage. Selenium supplementation appears to reduce the 
risk of some types of cancer by reducing oxidative stress and DNA damage 
(Almondes et al., 2010). 
4.4.12 qPCR validation of Affymetrix GeneChip microarray 
gene expression data 
Three genes (CLU, MAL, PTP313/FAP1) downregulated in both UK and Sri Lankan 
tumours were selected for further investigation and qPCR validation. The Box plot 
relative expression level of these 3 genes is shown in Figure 4.20. 
Samples used in the qPCR were 4 Sri Lankan and 5 UK normal oral mucosa 
samples. These were compared to 12 samples each UK and Sri Lankan OSCC and 
were selected as representative of patient and tumour characteristics. 
The qPCR data presented here were repeated and confirmed over four separate 
rounds of experimental determination consistently confirming the expression array 
findings that, these three genes are downregulated in OSCC compared to normal in 
both UK and Sri Lankan samples. 




Figure 4.20: Box plots displaying results of qPCR analysis for the genes, CLU, MAL, 
and PTPN13 chosen for qPCR validation.  
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4.5 Discussion  
4.5.1 Choice of normal comparator 
The use of non-matched control tissue in this study was an attempt to overcome the 
problem of obtaining macroscopically normal tissue adjacent to a cancer that later 
was determined histologically abnormal; so called field cancerization. Such tissues 
would not display the gene expression pattern of normal mucosa and would be at 
increased risk of malignant transformation (Mao et al., 2004). It is suggested that 
there may be large gene expression differences between normal mucosa samples 
from different individuals that may then confound any attempt to identify expression 
differences between OSCC and normal mucosa.  
Normal mucosa samples were clearly discriminated from OSCC samples in both 
supervised and unsupervised analyses. Whilst there are gene expression differences 
between UK and Sri Lankan normal mucosa, the normal mucosa samples all 
clustered together in an unsupervised comparison of all samples indicating a broad 
similarity of expression profiles. 
Many previous studies used matched normal oral mucosa from the same patient to 
derive discriminatory expression profiles as it is suggested that using matched 
controls reduces variation in expression seen between individuals (Ziober et al., 
2006). However, many patients with OSCC exhibit changes of the mucosa in many 
parts of the mouth with no clinical observations. Such lesions frequently display 
epithelial dysplasia and a proportion will transform to carcinoma (Mashberg, 1977). 
This observation gave rise to the concept of “field cancerization” (Slaughter et al., 
1953). 
Frequently second primary cancers that occur in OSCC share genetic similarities to 
the first primary tumour; a proportion of such similarities are also seen in normal 
tissue within field cancerization area adjacent to a cancer (Mao et al., 2004). This 
finding therefore raises a crucial question of how normal is “normal” oral mucosa in 
a patient with OSCC. 
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4.5.2 Data uploading, Functional, Networks, Canonical 
pathways analysis using IPA system 
It is worth notable here to mention a problem experienced during uploading the gene 
sets to IPA system. Example for this is the uploading of 1439 genes differentiating 
between UK and Sri Lankan normal mucosa to IPA system resulted in 95 unmapped 
genes. As mentioned in previous chapters, IPA cannot map pseudogenes, 
hypothetical genes, ESTs and ambiguous (mapping to multiple) genes as well as 
duplicates of multiple IDs snapped in one molecule or multiple molecules snapped in 
one ID. After re-arrange the unmapped genes by converting them using David 
conversion tool (Huang et al., 2009a, Huang et al., 2009b) and deletion of duplicates 
Ids, gene names / symbols,  54 mapped out of the 95 unmapped genes were obtained, 
end with total of 1398 genes recognized by IPA, with 1154 eligible genes for 
network analysis and 982 eligible genes for functional, pathway, and list analysis 
.Some of these genes are substantial key players contributed in the tumorigenic 
process and in the master networks of the analysis. The same procedure was repeated 
in all gene sets for study comparisons. After communication with IPA technical 
support, the system seems override this problem with the new version release as the 
subsequent IPA analysis experienced very rare unmapped genes in the system which 
not recognized in other genomic tools as well. However, double check of the 
unmapped genes before proceed the analysis is recommended as some of these genes 
might be study targets.  
4.5.3 Gene expression profile of tumour versus normal 
samples from UK 
 Several differentially expressed genes between tumour and normal tissues from UK 
are related to arachidonic acid (AA) metabolism, such as S100A10, glutathione 
peroxidase-3 (GPX3), phosphatidylcholine transfer protein, aldo-keto reductase 
family 1 (AKR1A1), and COX2. Arachidonic acid is metabolized in mammalian 
cells by a free radical reaction to cyclic endoperoxides via the cyclooxygenase 
system (Hamberg et al., 1974). The cyclooxygenase pathway converts arachidonic 
acid to prostaglandins and thromboxanes. These metabolites regulate diverse 
intracellular and extracellular biological processes in various cell types via specific 
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receptor molecules (Hammarstrom, 1983). Prostaglandins produced by COX2 may 
play an important role in the tumorigenic process of OSCCs from UK. 
Previous epidemiologic studies have reported the association between the frequent 
usage of non-steroidal anti-inflammatory drugs (NSAIDs) and the decreased risk of 
oesophageal cancer (Shureiqi et al., 2001) ,the main mechanism detected is the 
inhibition of COX2 activity. UK tumour samples showed significant over-expression 
of COX2  consistent with previous studies (Banerjee et al., 2002, Nathan et al., 2001, 
Atula et al., 2006, Lee et al., 2002, Chan et al., 1999, Chang et al., 2004, Mohan and 
Epstein, 2003, Wang, 2005, Tsai et al., 2004, Ye et al., 2008, Ratnasinghe et al., 
1999, Zimmermann et al., 1999). 
Further study indicates a key role for arachidonic acid metabolites in metastasis. The 
study determined that intracellular pathways involving metabolites of arachidonic 
acid are required for both tumour cell invasion through basement membranes in 
vitro, and for their metastasis in vivo and are required for the invasive activity of 
several lines of malignant cells (Reich and Martin, 1996). 
4.5.4 Gene expression profiling of Sri Lankan OSCCs 
compared to normal oral tissues 
Higher expression of CD80, IL1RL1 which mediate anti-tumour immunity (Tajima 
et al., 2003, Thomas and Wen, 2006, Vesosky and Hurwitz, 2003, Chen et al., 1993), 
and GML upregulation which play a role in tumour suppression (Kimura et al., 1997) 
along with downregulation of PSPH and TWIST1 which their over expression is 
critical in SCC proliferation and metastasis (Yang et al., 2008, Yang and Wu, 2008, 
Yuen et al., 2007, Niu et al., 2007, Bachelor et al., 2011) and might presumably 
contribute in resisting tumour invasion and metastasis of Sri Lankan tumour cases. 
Additionally, several genes and transcription regulators which reported a role in 
tumour invasive behaviour, recurrence, and metastasis were upregulated in UK but 
not Sri Lankan tumour cases relative to their normal comparators. These include 
COX2, POSTN, MMP3, and LAMC2 gene biomarkers of OSCC along with 
activation of ESR1, SMAD3, and SMAD4 transcription regulators. 
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The most relevant activated and inhibited functions using IPA system are reported in 
Figure 4.8 at FDR<0.001. Cell cycle progression, tumour development and colony 
formation, epithelial cell proliferation, and cell ploidy and mitosis, appeared to be in 
the top of highest-level functions. Altogether these functions show no correlation 
with aggressive behaviour and metastasis of cancer which might influence and 
confirm the phenotypic behaviour of Sri Lankan OSCCs being less invasive with no 
metastasis or recurrence of the disease reported. 
Most cancer types are similar in expressing mitochondrial dysfunction and elevated 
substrate level Phosphorylation, when loss of respiration leads to glycolysis, 
dedifferentiation, and unbridled proliferation (Szentgyorgyi, 1977). Mitochondrial 
mutations may contribute to the development of a malignant phenotype by direct 
effects from increased reactive oxygen species production as well as induction of 
aerobic glycolysis and growth promotion (Zhou et al., 2007). While normal 
mitochondrial function can reduce tumourigenesis, various studies show that tumour 
mitochondria are structurally and functionally abnormal and unable to generate 
normal levels of energy (Seyfried and Shelton, 2010). 
4.5.5 Common gene expression profile of tumour versus 
normal samples from both UK and Sri Lanka 
Among the common upregulated genes is SPP1 which is described essential in the 
pathway leads to type I immunity. Osteopontin is expressed and secreted by various 
cells, and has a role in cell adhesion, chemotaxis, prevention of apoptosis, invasion, 
migration and anchorage-independent growth of tumour cells. It has also been shown 
that SPP1 is upregulated in cervical carcinoma (Wong et al., 2006) and associated 
with progression from premalignancy to OSCC (Devoll et al., 1999). Although 
previous study has demonstrated that tumour derived SPP1 is able to inhibit 
macrophage function and enhance survival of SCC and metastases (Crawford et al., 
1998), further study concluded that elevated expression of SPP1 was by DNA 
damage-induced Tp53 activity and by adenovirus-mediated transfer of the human 
TP53 gene and this gene has a functional Tp53-responsive element in its promoter 
region which suggests SPP1 a direct transcriptional target of TP53. TP53-directed 
  Chapter 4 
185 
 
regulation of SPP1 expression suggests a novel model of TP53 participation in 
immunosurveillance, involving interaction with the host immune system to prevent 
damaged cells from undergoing malignant transformation (Morimoto et al., 2002). 
MMP10 was also upregulated in both populations’ tumours which already reported 
to promote invasion in HNSCC and that MMP10 mediates the Periostin and Wnt-5b-
induced invasion (Deraz et al., 2011). Moreover, Wnt-5a which is upregulated in UK 
samples reported being involved in the invasion of various cancers including 
melanoma, breast cancer, gastric cancer, pancreatic cancer and osteosarcoma 
(Weeraratna et al., 2002, Pukrop et al., 2006, Kurayoshi et al., 2006, Ripka et al., 
2007, Enomoto et al., 2009, Yamamoto et al., 2009, Yamamoto et al., 2010). 
Notably, some MMPs (upregulated in this study) are involved in Wnt-5a mediated 
invasion of cancer cells (Kurayoshi et al., 2006, Enomoto et al., 2009, Dissanayake et 
al., 2007, Masckauchan et al., 2006). 
Previous studies reported MAL gene frequently extinguished in oesophageal 
carcinoma and other gastrointestinal cancer tissues relative to normal corresponding 
epithelium. The anti-tumour effect of MAL was confirmed in vitro and in vivo 
(Mimori et al., 2003). Recent study showed that MAL is able to suppress malignant 
phenotypes of OSCC, such as proliferation, apoptosis and invasion, and inhibit 
tumorigenicity in vivo by transient and stable transfection and suggested MAL might 
be a candidate for  tumour suppression gene (Cao et al., 2010). Previous microarray 
studies showed frequent MAL repression in OSCC and HNSCC samples which 
support the existing findings (Alevizos et al., 2001, El-Naggar et al., 2002, Mendez 
et al., 2002, Toruner et al., 2004, Belbin et al., 2005, Tomioka et al., 2006, Ye et al., 
2008, Choi and Chen, 2005). 
NFE2L2 showed the lowest expression in tumours compared to normal controls 
among the transcriptional regulators distinguished in both population groups. 
NFE2L2 induces the expression of various genes including those that encode for 
several antioxidant enzymes, and it may play a physiological role in the regulation of 
oxidative stress. Genetic polymorphisms in glutathione peroxidase enzymes and their 
altered expressions and activities are associated with oxidative DNA damage and, as 
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a result, the individual’s risk of cancer susceptibility (Itoh et al., 1999).
 
Indeed, 
GPX3, whose main biological role is to protect the organism from oxidative damage, 
was massively downregulated in tumour cases of both populations. 
Inhibition of NR3C1regulator was another finding, a receptor of Glucocorticoids. 
The major signalling pathway used by Glucocorticoids receptors is via direct DNA 
binding and transcriptional regulation of target genes. They can also signal by 
binding to other proteins, mainly with transcription factors such as NFκB, AP-1 or 
STAT (Lu et al., 2006, Rhen and Cidlowski, 2005, Pratt et al., 2006, Ray and 
Prefontaine, 1994, Lerner et al., 2003, Zhang et al., 1997, Stocklin et al., 1996). It’s 
noteworthy that Glucocorticoids enhance glucagon action (McMahon et al., 2010) 
which inhibits glycolysis (a significant molecular function activated in this study) 
and mobilizes fats and stress response. Suppression of NR3C1 may implement in the 
tumorigenic process for both populations of the study. 
As molecular relationships represented on the network include not only activation or 
inhibition of expression, but also protein-protein interactions, DNA-protein 
interactions and activation, localization, inhibition of the corresponding proteins 
(Debily et al., 2009), it is not surprising that microarrays may fail to identify some of 
the hub genes significantly differentially expressed among the tumour versus normal 
samples. These genes might play a major role through protein activation for instance. 
Alternatively, their modulations may be very subtle and below the threshold for 
reliable detection of differences of the microarray platform despite its high 
sensitivity. 
4.5.6 Gene expression differences between UK and Sri 
Lankan tumour samples 
It is notable that the overall number of gene expression differences between UK and 
Sri Lankan OSCC is smaller than that observed in either of the two other supervised 
analyses comparing each tumour population to its normal, suggesting that a greater 
gene expression differences between the cancer samples and their respective normal 
comparators than between the two cancer populations. IPA core analysis revealed 
activated immune response functions in Sri Lankan relative to UK tumours. These 
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include; development and mitosis of thymocytes; activation, development, 
differentiation, cell movement, migration, and chemotaxis of T, B-lymphocytes, 
leukocytes, monocytes, and other immune system cells. Curcumin consumed by Sri 
Lankan people for centuries as a frequent dietary component could play a role in the 
above observation (Pirasath et al., 2010, Jayasekera et al., 2004). More discussion 
will be conducted under normal samples comparison of the two population groups. 
These findings might have an impact on the significant differences in the clinical 
behaviour of the two tumour groups which mainly reflected in resistant of Sri Lankan 
patients to the invasiveness, metastasis, and recurrence of disease as well as survival 
of the patient with lower morbidity and mortality relative to UK patients.  
4.5.7 Gene expression differences between UK and Sri 
Lankan normal mucosa and its impact on the observed 
phenotypic differences of the two tumour populations  
First observed finding is suppressed oncogenes receptors, including EGFR, IGF1R, 
RARA, EPOR, THRA, and NMUR2 receptors in Sri Lankan normal controls. 
Further potential finding is the highly activated cell mediated immune response in Sri 
Lankan relative to UK normal controls. As Sri Lankan normal individuals did not 
chew Betel quid, as previously mentioned (4.3.1), frequent consumption of curcumin 
by Sri Lankan people could play a role in the above observation (Pirasath et al., 
2010, Jayasekera et al., 2004). Curry and turmeric have already been reported as anti-
tumour diets which boost immune surveillance against tumour progression. 
Curcumin (diferuloylmethane) is reported to downregulate various growth regulatory 
pathways and specific genetic targets including genes for NFκB, STAT3, COX2, 
AKT, anti-apoptotic proteins, growth factor receptors, and multidrug-resistance 
proteins. The protective effects of Curcumin appear mediated through its ability to 
induce the activation of NRF2 and induce the expression of antioxidant enzymes 
(e.g., hemeoxygenase-1, glutathione peroxidase, modulatory subunit of gamma-
glutamyl-cysteine ligase, and NAD(P)H:quinone oxidoreductase 1, increase 
glutathione (a product of the modulatory subunit of gamma-glutamyl-cysteine 
ligase), directly quench free radicals, and inhibit p300 HAT activity (Goel and 
Aggarwal, 2010).    
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Genes detected are involved predominantly in processes such as cell mediated 
immune response, antigens presentation,  cell differentiation, small molecule 
biochemistry, cell-to-cell signalling and interaction, binding of phagocytes and B-
lymphocytes, elevated quantity, development and migration of lymphatic system 
cells, adhesion of immune cells, cell movement of T-lymphocyte, leukocytes, 
phagocytes, monocytes, neutrophils, mast cells, T-cell development and 
differentiation (Figure 4.18). The above observation might underlie differences in 
clinical behaviour of the two tumour groups. Indeed, the highly activated Cell-
mediated Immune Response in Sri Lankan normal group presumably plays a key role 
in resistant of Sri Lankan patients to the invasiveness, metastasis, and recurrence of 
disease as well as survival of the patient with lower morbidity and mortality relative 
to UK patients. Previous studies on HNSCC suggested that a peri-tumoural 
lymphocyte infiltrate was associated with a better prognosis when compared with 
tumours not exhibiting immune infiltration (Wolf et al., 1986, Hiratsuka et al., 1984, 
Guo et al., 1987, Hirota et al., 1990, Slootweg et al., 1994). Furthermore, higher peri-
tumoural lymphocyte infiltration correlated with lower stage and less invasive 
tumour growth (Guo et al., 1987, Slootweg et al., 1994). Other studies concluded that 
tumour-infiltrating lymphocytes in HNSCC acquire defects in T-cell receptor 
signalling and subsequent apoptotic death (Kuss et al., 1999, Gastman et al., 1999). 
Interestingly, circulating T lymphocytes from individuals with HNSCC exhibit 
defects in tumour directed cell killing suggesting that immune function modulation in 
the local tumour bed may extend to systemic immune system disruption in 
individuals with HNSCC (Reichert et al., 2002). Ginos group noticed that their 
tumour samples demonstrated a marked absence of an immune response signature 
suggesting that modulation of tumour-specific immune responses may play a role in 
local treatment failure of HNSCC (Ginos et al., 2004). 
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4.5.8 Gene expression profile of perineural invasive versus 
non- invasive tumour samples from UK 
Three genes appeared upregulated in perineural invasive tumours; PGM1, ENO2, 
and ILK. ENO2 (enolase2) reported  a prognostic biomarker in metastatic, high 
grade, and invasiveness of various types of cancer, including breast, lung, bladder, 
renal, prostate, colorectal cancer, and OSCC (Abba et al., 2005, van Zandwijk et al., 
1992, Di Carlo et al., 1990, Vandepol et al., 1994, Buzaid et al., 1994, Rasmuson et 
al., 1993, Jacobsen et al., 1990, Nishihara et al., 2009, Zufferey et al., 2001, 
Famulski et al., 2001). ILK has been associated with multiple cellular functions 
including cell migration, proliferation, and signal transduction. Recent studies 
reported ILK as a biomarker associated with laryngeal, lung, colon, ovarian cancer as 
well as metastatic behaviour of gastric carcinoma (Ito et al., 2003, Wu et al., 2006, 
Takanami, 2005, Bravou et al., 2006, Du et al., 2008, Loessner et al., 2009).  
GO term (Gene Ontology, www.geneontology.org/) showed both PGM1 and ENO2 
enzymes involved in magnesium ion binding whereas the all three genes involved in 
phosphorylation and interconversion activities of certain proteins and amino acids 
like phosphopyruvate hydratase, lyase, phosphoglucomutase, isomerase, and 
phosphotranferase. 
4.5.9  Gene expression profile of high-stage versus low- 
stage tumour samples from both UK and Sri Lankan 
tumours 
SAM supervised analysis identified 12 genes separating “high stage” from “low 
stage” OSCCs of both population groups. Most of genes appeared upregulated in 
high stage tumours and associated with different cancer types and cellular processes 
associated with tumours. 
Most of differentially upregulated genes in high stage tumours exhibited involvement 
in variant biological processes crucial in driven tumour lesion to late stage and 
metastasis with distinct roles in cellular migration, remodelling, outgrowth, invasion, 
differentiation, colony formation, cell cycle progression, activation, proliferation, and 
angiogenesis. 
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Knockdown of SEMA3F (member of semaphorins) cancer cells of breast rescued the 
aggressive phenotypes and tumour invasion by inducing suppressive cell 
microenvironment (Xiong et al., 2012) as well as pancreatic (Matsushita et al., 2007). 
An extensive review explained how Scatter factors and semaphorins, together with 
their receptors, help to orchestrate metastasis programme of neoplastic cells 
(Trusolino and Comoglio, 2002). 
Suswam group (Suswam et al., 2005) noticed that KHSRP involved in IL8 RNA 
stabilization, which plays an integral role in promoting the malignant phenotype in 
breast cancer (Chen et al., 2001, Gherzi et al., 2004). 
Jauliak group identified NFAT5 isoform expressed in invasive human ductal breast 
carcinomas and participate in promoting invasion of human breast and colon 
carcinomas. The transcriptional activity of NFAT5 is induced by alpha-6 and beta-4 
integrin signalling clustering in the presence of chemo-attractants, resulting in 
enhanced cell migration and is involved in promoting carcinoma invasion (Jauliac et 
al., 2002). Further study demonstrated NFAT5 contribution in progression of 
gastrointestinal cancer (Chen et al., 2011b).   
CDC42BPA plays a role in the regulation of cytoskeleton reorganization and cell 
migration (Tan et al., 2008a). It has been demonstrated that invasion can be 
generated by Cdc42-MRCK signalling (Wilkinson et al., 2005) as well as tumour 
progression (Benitah et al., 2004). 




The gene expression profiles of UK and Sri Lankan OSCC compared to normal oral 
mucosa are similar in many respects to other oral cancer expression profiles reported 
in the literature and were mainly similar to each other. Great differences in the 
expression profiles between OSCC and normal tissue than between OSCCs of the 
two populations was observed. However, molecular heterogeneity in each tumour 
populations (such heterogeneity is more marked in UK OSCC, which displays a wide 
range of clinical behaviour). Such molecular heterogeneity may act to reduce 
differences seen in expression profiles of the two populations. Despite that, IPA 
showed common perturbed canonical pathways which indicate that the development 
of OSCCs is mediated, to some extent by similar biological pathways despite the 
differences related to race, ethnicity, lifestyle, and/or exposure to environmental 
carcinogens. 
IPA comparison core analysis of normal as well as tumour samples between the two 
populations displayed highly activated “Cell-mediated Immune Response” processes 
in Sri Lankan normal and tumours relative to UK cohorts which presumably play a 
key role in confrontation of Sri Lankan patients to the invasiveness, metastasis, and 
recurrence of the disease. Sri Lankan consumption of spicy food, including 
Curcumin/Curry in specific (Jayasekera et al., 2004, Pirasath et al., 2010), might 
influence this activation along with downregulation of growth factor receptors 
(EGFR, IGFR, RARA, EPOR, THRA, and NMUR2) that might as well, contributed 
in the phenotypic behaviour of the two tumour groups. The same findings were 
observed in comparison of the tumours from the two population groups which 
confirms the constant existence of the above events between the two populations.  
Smaller number of either elevated or repressed genes in either UK or Sri Lankan 
OSCC but not both contributed to a number of differentially regulated cancer-
associated pathways and specifically to the aggressive behaviour of UK tumours; 
including upregulation of MMP3, POSTN, LAMC2, and downregulation of DUSP1 
and SLPI in UK. Conversely, CD80 upregulation and TWIST1 downregulation, anti-
invasive associated incidents, observed in Sri Lankan tumours. It may be the case 
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that expression differences in key pathways contribute to the observed phenotypic 
differences and so expression differences described here may underpin some of the 
phenotypic differences between UK and Sri Lankan OSCC. Tumour heterogeneity, 
technical variation and data processing may all have an effect on the expression 
profiling data and all such variables should consider when interpreting the results. 
Differences in tumour expression profiles of the two populations highlighted a few 
potentially genes; including lower expression of CDKN1B in UK tumours, a 
phenomenon associated with high-risk tumours only, along with lower expression of 
PSIP1, SAMSN1, CCNG2, and NCOA2 genes which  played a protective role in 
tumorigenic process. Likewise, higher expressions of CCT2 and DHCR24 in UK 
tumours were contributed in rapidly proliferating tumour and melanoma metastases 
respectively.  
Numerous results displayed in this study support the theory that considers cancer as a 
metabolic disorder (Warburg effect) (Galluzzi et al., 2006, Seyfried and Shelton, 
2010, Warburg, 1956). The top perturbed pathways in both populations and each 
separately showed that defects in mitochondrial respiration could be the primary 
reason for induction of tumorigenic transformation reflecting mitochondrial 
dysfunction and oxidative phosphorylation pathways shifted the tumour cell to 
glycolysis pathway affecting Citrate cycle with remarkable dysregulation of fatty 
acids metabolism. As subsequence to the above defects, significant alteration in gene 
expression can be explained as an attempt from the tumour cells to cope with the 
initial disorder, repair, and overcome the fatal causative event(s). Further studies 
with a large size and wide range of populations are required to highlight and validate 
the above phenomena.
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Chapter 5: Biological pathway integration of 
significant metabolomic and transcriptomic 
signatures of OSCC 
5.1 Introduction 
Cancer may be accompanied by the production and release of a substantial number of 
proteins, metabolites and/or hormones into the blood, saliva, and other body fluids 
that could serve as useful markers for assessing prognosis, metastasis, monitoring 
treatment, and detecting malignant disease at an early stage. Metabolic profile of 
variant biofluids, including serum, saliva, urine, and cerebrospinal fluid can be 
changed by different physiological processes following pathophysiological 
provocations, hence, comprehensive perturbation in these profiles may exhibit the 
presence of a specific disease. Metabolomic profiles for early detection as well as 
stages identification of OSCC by employing numerous methods of nuclear magnetic 
spectroscopy and mass spectrometry were reported to provide a coherent outlook of 
the wide-ranging metabolic body response to pathophysiologic effect and genetic 
modification. 
OSCC is a complex disease with a wide heterogeneity involves multiple tissues in 
the oral cavity. Although molecular profiles of the disease from different tissue sites 
remain very similar with common biomarkers, limitation was experienced to find a 
unique signature with a satisfactory specificity and sensitivity of the disease. 
Limitation of both specificity and sensitivity is a consequence of the fact that 
metabolic profile is influenced by various environmental factors and physiological 
status of the body in addition to the biological alteration arisen from the disease. 
The metabolism of OSCC reported to reflect a specific interaction arises from the 
biochemical status of the oral tissue and the biological condition accompanied 
tumourigenesis of OSCC. At present, the lack of metabolic signature required for 
absolute detection of different types of cancer as well as other inflammatory 
conditions, and physiological disorders shrinks the chance of the clinical 
applicability of this signature as a tool to distinguish OSCC from other type of 
cancer. 
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Linking metabolic dysfunctions to altered gene expression profiles can provide new 
insights into the regulatory network underlying the metabolic dysfunctions, enabled 
the assembly of discrete gene expression events into functional pathways. However, 
a major challenge in the integration of ‘omics data (transcriptomics, proteomics, and 
metabolomics) is how best to compare and correlate these large datasets to provide 
the most meaningful biological context. A considerable number of studies attempted 
to address this challenge both at the data level, using statistical and chemometric 
methods, and at the biology level, using pathway analysis (Chou et al., 2003, Coen et 
al., 2003, Martin et al., 2003, Clish et al., 2004, Eerligh et al., 2004, Griffin et al., 
2004, Go et al., 2005, Griffin, 2006, Fan et al., 2006, De Vos et al., 2007, Rezzi et 
al., 2007, Jalanko et al., 2006, Bylesjo et al., 2008, Gomase and Tagore, 2008, 
Phillips and Foster, 2008). The latter approach uses extensive databases of metabolite 
and gene interactions to link known metabolites and genes to relevant pathways and 
phenotypes, i.e. mapping genotype to phenotype. 
5.2 Aims and objectives of the study 
In this review study, an attempt was carried out to gather common differentially 
expressed metabolites across studies which proposed as biomarkers of OSCC. 
Subsequently, integration of the metabolic signature from the review with the 
previously harvested transcriptomic biomarker from the met-analysis study (chapter 
3) was carried out in an attempt to explore more specific signature of OSCC and 
understand the tumorigenic process reflected by the simultaneous perturbed genetic 
and metabolic system using IPA biological tools. The concept behind integration 
approach is that different biological diseases and disorders reflecting same metabolic 
profiles presumably have different transcriptomic profiles. Likewise, those that give 
similar transcriptomic profiles expected to have different metabolic profiles. From 
this insight, merging both metabolic and transcriptomic profiles is carried out (data 
level integration). Furthermore, IPA tools were used to identify the significant 
biological relationships between frequently altered metabolites in OSCC from the 
review study and meta-genes biomarkers of OSCC harvested from chapter 3, while 
the shared cellular biofunctions, functional networks, canonical pathways, and 
upstream regulators differentiating OSCC from normal oral mucosa were identified 
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from the interactive network. Exploring IPA results revealed remarkable synergetic 
and harmonious interaction between altered gene expression during tumourigenesis 
and the subsequent body response coincided in its intermediate and the end product 
metabolites (biological level integration).  
5.3 Materials and Methods 
Published reports of metabolomic expression profiles of OSCC and HNSCC were 
identified using Medline database search. A review of the reports was performed to 
identify metabolites that repeatedly exhibiting altered expression in OSCC and 
HNSCC compared to normal oral mucosa. 
5.3.1 Construction of common metabolites list 
Regularly expressed metabolites in OSCC across the review studies were collected 
and unified in one metabolite identification number using human metabolome 
database (HMDB) (http://www.hmdb.ca/), a freely available electronic database 
containing detailed information about small molecule metabolites existed in the 
human body. 
5.3.2 Biological annotations of the metabolic profile 
Differentially expressed metabolites in OSCCs were subsequently examined using 
available tools from IPA to define the relative canonical pathways, biomarkers, and 
molecular processes that most commonly perturbed in the tumorigenic 
transformation of OSCC and HNSCC, as well as, to inspect the most significant pre-
generated networks associated with the uploaded group of metabolites including 
those related to OSCC development. IPA knowledge base recruits the distinguished 
metabolites that regulated OSCC and HNSCC to generate and highlight the above 
functions. Canonical pathway analysis identified altered pathways from IPA library 
which are most significant to the input data set. The significance of the association 
between the data set and the canonical pathway was determined based on two 
parameters: (1) A ratio of the number of metabolites from the data set that map to the 
pathway divided by the total number of metabolites that map to the canonical 
pathway and (2) A p-value calculated using Fischer's exact test determining the 
  Chapter 5 
196 
 
probability of the association between the metabolites in the data set and the 
canonical pathway is due to chance alone. 
5.3.3 Integrating metabolomic and transcriptomic profiles 
To assist with cross platform integration, IPA “Metabolomics Analysis” was used to 
interpret both metabolomic and transcriptomic data related to OSCC that harvested 
from the metabolic review in this chapter and the meta-analysis study in chapter 3. 
IPA provides biological context to the metabolomic data, links metabolic changes to 
disease-relevant pathways and phenotypes and assists in the selection of a subset of 
metabolomic markers for further study. 
IPA-Metabolomics is powered by the Ingenuity Knowledge Base, a repository of 
molecular interactions, regulatory events, signalling and metabolic pathways, and 
gene to phenotype associations that provide the building blocks for pathway 
construction. IPA contains millions of findings from the full text of the life sciences 
literature that describe relationships between chemicals, proteins, genes, complexes, 
cells, cellular components, tissues, drugs, cellular processes, diseases and clinical 
phenotypes. IPA also has extensive libraries of metabolic and cell signalling 
pathways, an extensive contextual details, including species specificity, localization, 
mutations, epigenetic modifications, and experimental conditions. The structured 
detailed content in the knowledge base enables researchers using IPA to analyse and 
interpret combined ‘omics data’, visualize metabolite and gene interactions, and 
place data in a proper biological and chemical context. 
5.4 Results  
5.4.1 Construction of the metabolic profile set 
From 1996 to 2011, 10 studies recruiting MR spectroscopy, 1HNMR, and MS 
spectral analyses to examine a wide metabolic expression changes associated with 
the development of OSCC and HNSCC were reviewed (Mukherji et al., 1996, 
Mukherji et al., 1997, Adalsteinsson et al., 1998, Star-Lack et al., 2000, El-Sayed et 
al., 2002, Bezabeh et al., 2005, Arias-Mendoza et al., 2006, Yan et al., 2008, Zhou et 
al., 2009, Tiziani et al., 2009, Sugimoto et al., 2010, Wei et al., 2011).  
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Table 5.1: Characteristics of metabolomic studies. 
Studies Sample description Technology used 
Mukherji et al., 1996 18 HNSCC and 13 normal muscle tissue 
specimens.   
In vitro analysis of the 
one-dimensional proton 
MR spectroscopy 
Mukherji et al., 1997 19 HNSCC tissue specimens, 13 normal 
tissue, and 3 metastatic cervical lymph 
nodes 
In vitro 1-D and 2-D 
correlated proton MR 
spectroscopy (11 T)  
 7 HNSCC and 7 healthy controls. In vivo 1-D proton MR 
spectroscopy (1.5 T)  
Star-Lack et al., 2000 14 HNSCC, 6 tissue normal samples 1HNMR 
El-Sayed et al., 2002 85 HNSCC, 50 NORMAL tissue samples ( from 
40 patients) 
1HNMR 
Bezabeh et al., 2005 58 HNSCC and 22 normal tissue samples 1HNMR 
Yan et al., 2008 Saliva samples were obtained from 20 OSCC, 
20 OLP and seven OLK patients, and 11 
healthy donors. 
HPLC/MS analysis 
Zhou et al., 2009 Plasma samples from 32 OSCC patients, 28 
control group 
1HNMR 
Tiziani et al., 2009 Serum samples from 15 OSCC and 10 normal 
healthy controls 
1HNMR 
Sugimoto et al., 2010 Saliva fluid samples from 69 OSCC patients 
and 87 healthy individuals 
CE-TOF-MS 
Wei et al., 2011 Saliva fluid samples from 37 OSCC patients, 
32 oral leukoplakia (OLK) patients, and 34 
healthy individuals 
UPLCQTOFMS 
   
 
A set of 45 differentially expressed metabolites discriminated tumour samples from 
normal oral mucosa and selected for further subsequent analysis (Table 5.2). 
Different methodological techniques were used across studies to extract metabolomic 
signatures for OSCC and HNSCC disease from serum and saliva biofluids. These 
include ¹H and ³¹P nuclear magnetic resonance spectroscopy (¹H and ³¹P- NMR), 
Liquid chromatography–mass spectrometry (HPLC-MS), capillary electrophoresis 
time-of-flight mass spectrometry (CE-TOF-MS), and ultra-performance liquid 
chromatography coupled with quadrupole/time-of-flight mass spectrometry 
analytical methods. The results demonstrated a reasonable separation between the 
samples from healthy controls and patients with OSCC and HNSCC. Certain results 
went further to assign signatures discriminating advanced from early stage (Tiziani et 
al., 2009, Sugimoto et al., 2010, Wei et al., 2011) as well as malignant from benign 
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tumours (Adalsteinsson et al., 1998, Bezabeh et al., 2005, El-Sayed et al., 2002, 
Mukherji et al., 1997, Star-Lack et al., 2000). However, the current review focused 
on metabolic profiles discriminating OSCC from normal oral mucosa in an attempt 
to nominate frequently reported metabolic biomarkers of OSCC and HNSCC for the 
subsequent integration analysis with the transcriptomic biomarkers of the disease that 
will explain later in this chapter.  
Metabolomic analysis of serum samples of OSCC patients was performed by nuclear 
magnetic resonance (NMR) spectroscopy with a satisfactory discrimination between 
OSCC and the healthy controls (Tiziani et al., 2009). Recently, a capillary 
electrophoresis time-of-flight mass spectrometry based salivary metabolomic 
analysis of oral, breast and pancreatic cancer has been performed and a number of 
metabolites related were identified (Sugimoto et al., 2010). Most recent work used an 
advanced version of LC-MS platform, ultra-performance liquid chromatography 
coupled with quadrupole/time-of-flight mass spectrometry (UPLCQTOFMS), to 
study salivary metabolomics of the three groups; OSCC, oral leukoplakia, and 
healthy subjects (Wei et al., 2011). 
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Table 5.2: 45 metabolites with altered expression in OSCC and HNSCC.* 
Metabolite Name Universal ID Expression Metabolite Name Universal ID Expression 
Upregulated in OSCC RELATIVE TO NORMAL  downregulated in OSCC RELATIVE TO NORMAL 
glucose                 HMDB00122 1  Valine HMDB00883 -1 
Ethanol HMDB00108 1  Lactate HMDB01311 -1 
Methanol HMDB01875 1  Alanine HMDB00161 -1 
Acetate HMDB00042 1  Citrate HMDB00094 -1 
Pyruvate HMDB00243 1  Phenylalanine HMDB00159 -1 
Acetone HMDB01659 1  Tyrosine HMDB00158 -1 
Acetoacetate HMDB00060 1  Formaldehyde HMDB01426 -1 
3-hydroxybutyrate HMDB00357 1  formic acid HMDB00142 -1 
 2-hydroxybutyrate HMDB00008 1  Glycine HMDB00123 -1 
Choline HMDB00097 1  Creatine HMDB00064 -1 
Betaine HMDB00043 1  Carnitine HMDB00062 -1 
Dimethylglycine HMDB00092 1  acetyle L-carnitine HMDB00201 -1 
sarcosine   HMDB00271 1  Creatinine HMDB00562 -1 
Asparagine HMDB00168 1  Isoleucine HMDB00172 -1 
Ornithine HMDB00214 1  Leucine HMDB00687 -1 
glutamic acid HMDB00148 1  ү-aminobutyric acid  HMDB00112 -1 
Taurine HMDB00251 1  Threonine HMDB00167 -1 
lactic acid HMDB01311 1  Proline HMDB00162 -1 
Piperidine HMDB34301 1     
Putrescine HMDB01414 1     
Cadaverine HMDB02322 1     
Tryptophan HMDB00929 1     
Phosphocholine HMDB01565 1     
Glycerophosphocholine HMDB00086 1     
Glutathione HMDB00125 1     
Histadine HMDB00177 1     
n-Eicosanoic acid HMDB02212 1     
* +1 and -1 denoted to the elevated and repressed metabolites regardless the magnitude of the 
expressed metabolites.  
5.4.2 Biological interpretation of the expressed metabolites 
To obtain further biological understanding of why expressed metabolites in OSCCs 
are different from normal oral tissue samples, IPA tools was used to examine the 
dysregulated biological pathways, molecular functions, and processes. IPA system 
depends on the knowledge database of selected functional and regulatory interactions 
extracted from the literature and provides integrated graphical representation of the 
biological relationships between metabolites, considering both up- and 
downregulated metabolites from the comparison analysis. 
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5.4.2.1 Functional analysis of the common metabolites  
“Amino Acid Metabolism, Molecular Transport, Small Molecule Biochemistry, Cell 
Cycle, and Protein Synthesis” functions were displayed at the top of the perturbed 
molecular and cellular functions involved in cancer.   
5.4.2.2 Associated network analysis of the common metabolites  
Investigating the biological relationships between genes and gene products, including 
metabolites, was carried out by performing network analysis of the commonly 
altered metabolites. The top molecular network having the highest score (49) among 
other networks was corresponded with “Amino Acid Metabolism, Molecular 
Transport, Small Molecule Biochemistry” functions (Figure 5.1). To visualize more 
comprehensive interactions between the differentially altered metabolites in OSCC, 
the top 4 significantly associated metabolic networks were merged (Figure 5.2). 
Networks 1, 2, 3, and 4 of the altered metabolites were chosen according to the 
highest score value (score = 49, 26, 13, and 2 respectively). The corresponding 
functions of the highest score networks (1, 2, and 3) were “Amino Acid Metabolism, 
Molecular Transport, Small Molecule Biochemistry” and “Cell Cycle, Hepatic 
System Development and Function, Cell-To-Cell Signalling and Interaction” 
respectively. These networks were constructed and merged through the overlapping 
genes (nodes with white colour) suggested from IPA knowledge base as hub nodes 
connecting the uploaded metabolites (Figure 5.2). In both top and master networks 
(Figure 5.1and Figure 5.2), Amino Acid Metabolism and degradation were the 
common detected functions. In addition, a group of metabolites altered in these 
studies and constantly expressed in both networks were observed reflecting common 
functions including “anti-oxidation, free radical scavenging, detoxification of 
xenobiotics and chemicals”. These include metabolites of glutathione, creatine, 
glutamic acid, taurine, glycine, tryptophan, and pyruvic acid. 




Figure 5.1: Top molecular network of the altered metabolites in OSCC. 
The top molecular network identified by IPA tool (version 9.0) from up- and down-regulated metabolomic analysis using overlapping function. The network is 
displayed graphically as nodes (genes/gene products) and edges (the biological relationship between the nodes). The tumours relative to normal overexpressed 
metabolites are shaded in red and underexpressed metabolites in green. White nodes represent gene/gene product suggested by IPA as putative hub nodes connecting 
the uploaded metabolites. The nodes are represented using various shapes that represent the functional class of the gene products. Highly interconnected nodes (‘hub 
genes’) are highlighted with black edges as potential key regulators of the master network. The +2 and -2 are given to the upregulated and downregulated metabolites 
across studies regardless the magnitude of fold change expression.




Figure 5.2: Master molecular network of the altered metabolites in OSCC. 
The master molecular network assembled by merging networks 1, 2, 3, and 4 identified by IPA tool (version 9.0) from up- and down-regulated metabolomic analysis 
using overlapping function. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationship between the nodes). The 
tumours relative to normal overexpressed metabolites are shaded in red and under-expressed metabolites in green. White nodes represent gene/gene product suggested 
by IPA as putative hub nodes connecting the uploaded metabolites. The nodes are represented using various shapes that represent the functional class of the gene 
products. Highly interconnected nodes (‘hub genes’) are highlighted with black edges as potential key regulators of the master network. The +2 and -2 are given to the 
upregulated and downregulated metabolites across studies regardless the magnitude of fold change expression. For clearer view of the network, see supplementary file 
16.
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5.4.2.3 Canonical pathway analysis of the common metabolites 
By utilizing canonical pathway analysis tool, IPA, Glutathione-mediated 
detoxification and Glycine Biosynthesis pathways displayed as the most relative and 
common dysregulated pathway related to the uploaded metabolomic signature. The 
determination of the significant dysregulated pathways is accomplished by 
overlapping the input common metabolites over the pre-generated pathways from 
IPA.  
5.4.2.4 Biomarker analysis of the common metabolites 
In an attempt to find potential biomarkers involved in OSCC and HNSCC from the 
metabolic profile set, a knowledge base of IPA was unable to identify any 
biomarkers. However, 3 biomarkers were identified in relation to cancer disease 
generally (D-glucose, glutathione, and sarcosine). Figure 5.3 displays the diagnostic 
use of each biomarker in different tumour types using “Path Designer” advanced tool 
in IPA. 
 
Figure 5.3: Biomarker analysis of common metabolites involved in cancer. 
Biomarker network built by connecting significant metabolites involved in cancer, identified by 
biomarker filter tool (IPA, version 9.0) from up- and down-regulated common metabolites using 
overlap function of the biomarker analysis. The network is displayed graphically as nodes 
(metabolites) and edges (the biological relationship events between the nodes and the tumour types). 
The tumours relative to normal overexpressed metabolites are shaded in red and under-expressed 
metabolites in green. The +2 is given to the upregulated metabolites across studies regardless the 
magnitude of fold change expression. 
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5.4.3 Integrating metabolomic and transcriptomic profiles 
5.4.3.1 Metabolomic analysis of both meta-genes and the 45 metabolites 
IPA “Metabolomics Analysis” of the combined list of metabolites (the 45 
metabolites harvested from the review study) and genes (the differentially expressed 
genes from the meta-analysis conducted in chapter 3) was performed. The generated 
networks display the interactions between the uploaded metabolites and genes 
(Figure 5.4). 
 
Figure 5.4: Top networks of the interactive meta-genes and metabolites associated with 
significant molecular and cellular functions. 
The top four networks were observed significantly enriched with scores ranging from 30 to 34 where 
the probability for a network to be selected by chance (score ˂ 3) decreasing when its corresponding 
scores value increases. 
Network 1, 3, and 4 exhibited the top and most relative networks to the tumorigenic 
process. Subsequent merging of these 3 networks generated the structure of the 
master network (Figure 5.5) whilst several metabolites involved, glucose symbolized 
a potential hub node of the network whereas HOXA10, AKT, and ERK1/2 
represented the other main hubs structuring the master network. Among the selected 
top 3 networks, several genes and metabolites were associated with OSCC and 
HNSCC, including upregulation of C-X-C chemokines (CXCL1, 3, 5, 6, 9, 11, and 
13), POSTN, TNC, PDPN, glucose, taurine, choline, sarcosine, betaine, and 
acetoacetic acid along with downregulation of PPP1R3C, GABA, creatine, glycine, 
formaldehyde, and acetyl-L-creatinine (Figure 5.5).




Figure 5.5: Master molecular network of meta-genes and metabolites using IPA Metabolomics analysis. 
The master molecular network assembled by merging networks 1, 3, and 4 identified by IPA tool (version 9.0) from up- and down-regulated metabolomic and meta-
analysis transcriptomic analysis using overlapping function. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationship 
between the nodes). The tumours relative to normal overexpressed genes and metabolites are shaded in red and under-expressed metabolites in green. The intensity of 
colours reflects the magnitude of the fold change of the expressed molecule. Grey nodes represent gene/gene product exist in the dataset but don’t reach the fold 
change cut-off criteria. White nodes represent gene/gene product suggested by IPA as putative hub nodes connecting the uploaded dataset molecules. The nodes are 
represented using various shapes that represent the functional class of the gene products. Highly interconnected nodes (‘hub genes’) are highlighted with black edges as 
potential key regulators of the master network. The +2 and -2 are given to the upregulated and downregulated metabolites across studies regardless of the magnitude of 
fold change expression. For clearer view of the network, see supplementary file 17.
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5.4.3.2 Direct integration between the 45 metabolomic profile and the 32 
OSCC and HNSCC transcriptomic biomarkers    
Further interactive network was constructed by direct integration of the 45 metabolite 
set and the 32 transcriptomic biomarkers related to OSCC and HNSCC from the 
meta-analysis study. Using “connect” tool from “build” function of IPA, 14 out of 32 
genes and 15 out of 45 metabolites showed at least one interactive biological relation 
event between transcriptomic and metabolomic profiles according to IPA knowledge 
base. Thorough examination of the interactive networks revealed possible 
interactions between metabolomic markers and several gene biomarkers involved in 
OSCC and HNSCC including upregulated genes with a role in ECM degradation 
(MMP1, MMP3, and MMP9), interleukins (IL1B, IL6, and IL8), collagens 
(COL1A1 and COL4A1), PTGS2, SERPINE1, SLC2A1, and STAT1 along with 
downregulation of CRYAB and CXCL12 (Figure 5.6). Metabolites of glucose, 
ethanol, and glutathione displayed the highest number of interactions with 
transcriptomic biomarkers. Likewise, interleukins, PTGS2, and MMP9 were the 
highest interactive molecules among the OSCC and HNSCC gene biomarkers. 
Glucose appears at the centre of the master network with the highest number of 
interactions. The network displayed elevated SLC2A1, a glucose transporter, which 
considers a common characteristic of human malignancies.  




Figure 5.6: Interactive network between metabolomic profile and the meta-genes biomarkers of OSCC and HNSCC. 
The interactive molecular network assembled by IPA tool (version 9.0) from up- and down-regulated metabolomic profile from the review study (chapter 5) and the 32 
OSCC and HNSCC biomarkers from the meta-analysis study (chapter 3) using connect tool from build function. The network is displayed graphically as nodes 
(genes/gene products) and edges (the biological relationship between the nodes). The tumours relative to normal overexpressed molecules are shaded in red and under-
expressed metabolites in green. The nodes are represented using various shapes that represent the functional class of the gene products. Highly interconnected nodes 
(‘hub genes’) are highlighted with black edges as potential key regulators of the master network. The underlined molecules denoted to the metabolites.
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5.5 Discussion  
5.5.1 Review study of metabolomics 
Reviewing the literature searching for previous work using in vitro NMR and MS 
technologies for diagnosis and monitoring of OSCC and HNSCC, only few studies 
observed comparing to studies used microarray technology observed in the review 
study of chapter 2. Such a metabolomic profile includes aspects of host response as 
well as tumour behaviour. The metabolomic review study specified several 
metabolites and pathways displaying considerably altered expression in cancerous 
versus non-cancerous states across the 12 studies. Among the metabolites identified 
commonly altered in these studies, include several involved in anti-oxidation, free 
radical scavenging, detoxification of xenobiotics and chemicals (glutathione, 
creatine, glutamic acid, taurine, glycine, tryptophan, and pyruvic acid), fatty acid 
metabolism, lipid degradation, and glycolysis. These molecular pathways and 
cellular functions are typical signature of oral cancer and already described by 
previous studies. “Glutathione- mediated detoxification, methylglyoxal 
detoxification” pathways emphasise the crucial role of glutathione which is needed 
for the detoxification of methylglyoxal, a toxin produced as a by-product of 
metabolism. 
Several of the observed metabolite markers were involved in associated network 
function (Figure 5.2), signalling and metabolic pathways (5.4.2.3), and biomarker 
analysis (Figure 5.3) representing glucose and glutathione metabolites as hub nodes 
associated with detoxification process, glycolysis, energy production and amino acid 
metabolism. Biomarker analysis identified both glucose and glutathione over-
expression as verified biomarkers of other types of cancer along with sarcosine 
metabolite Figure 5.3. 
Elevated glucose level along with significantly increased fatty acids metabolism may 
be linked to the unique behaviour of oral cancer. This represents a typical signature 
in cancer patients, and it has been previously linked to “Warburg effect” (Galluzzi et 
al., 2006, Seyfried and Shelton, 2010, Warburg, 1956), which assumes that tumours 
rely on glycolysis as a main source of energy, even in the presence of oxygen. Many 
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solid tumours showed an increase glycolytic metabolism, which has, in the case of 
OSCC, been associated with the over-expression of glucose transporters, especially 
Glut-1 (SLC2A1) (Kunkel et al., 2003), which showed an elevation in the current 
study as well. 
Glutathione-S-transferase (GST) is considered a useful aid in early diagnosis, 
predicting tumour extent, and determining parameters of treatment efficacy and 
prognosis of oral cancer. Elevated GST was also detected in the sera of patients with 
cancers of oesophagus, gastrointestinal tract, liver, bile duct, pancreas, uterine cervix, 
colon, and lung (Hirata et al., 1992). A higher immune-activity and more affinity of 
GST in squamous cell carcinoma among cancers of various types of histological 
findings suggested GST a possible useful marker in oral cancer and cervical cancer 
because both have substantial involvement by squamous cell carcinoma (Eimoto et 
al., 1988). Further results indicated glutathione level of oral tissues may be a useful 
marker for oral cancer, which is in agreement with findings from lung squamous cell 
carcinoma, cervical squamous cell carcinoma and other squamous cell carcinomas 
(Wong et al., 1994). 
Glutathione transferases (GSTs) are enzymes that catalyse the conjugation of 
glutathione to a variety of electrophilic substances. Their best known role is as cell 
housekeepers engaged in the detoxification of xenobiotics (redox reactions, in which 
portion of cell membranes protects against peroxidation) (Scholz et al., 1989). 
Recently, GSTs have also been shown to act as modulators of signal transduction 
pathways controlling cell proliferation and cell death. Their participation in tumour 
cell growth and differentiation, and in the development of resistance to anticancer 
agents, has made them attractive drug targets (Laborde, 2010). IPA canonical 
pathway analysis of the current study displayed Glutathione-mediated detoxification, 
Methylglyoxal detoxification, Glutathione-mediated formaldehyde oxidation II, 
Glycine Biosynthesis, and several amino acids metabolism pathways exhibited the 
top, carcinogenic related, dysregulated pathway that the uploaded set of metabolic 
profile involved in. Previous studies extensively described the role of these pathways 
during tumour transformation. Through this essential detoxification mechanism, 
glutathione binds to electrophilic chemicals, forming conjugates which exported 
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from the cell. These conjugation reactions have been demonstrated for a multitude of 
foreign chemicals, as well as endogenous reactive intermediates (Wang and 
Ballatori, 1998). The breakdown products of the glutathione -toxin conjugates 
(glutamate and glycine) are reabsorbed and can be used for glutathione synthesis 
(Boyland and Chasseau.Lf, 1969). The results of current study also showed glycine 
regularly repressed along with perturbed level of glutamic acid which confirm the 
detoxification abundance. 
Over-expression of ethanol in tumour samples has critical relation with glutathione in 
tumourigenesis. Chronic alcohol consumption has been reported to decrease 
glutathione levels and enhances the susceptibility of the liver towards alcohol related 
peroxidative damage (Lieber, 1994a, Lieber, 1994b). 
A pivotal relation between higher consumption of alcohol and OSCC and carcinoma 
of the pharynx, Larynx, and oesophagus has been distinguished since the mid1950s 
(1988). Alcohol may influence the proliferative cells by both intracellular (e.g., 
endocytosis) and intercellular (permeability) pathways. The carcinogenic exposure of 
the proliferating stem cells in the basal layer may be regulated through these 
pathways (Ogden, 2005). Ethanol can induce oxidative DNA damage in human 
peripheral lymphocytes in vitro, and its mechanism may be associated with the 
metabolism of ethanol by the ADH1B/ALDH2 pathway (Yan et al., 2011). Alcohol 
dehydrogenase 3 (ADH3) converts ethanol to acetaldehyde, which is a suspected oral 
carcinogen (Schwartz et al., 2001). 
Ethanol consumption induces changes in lipid metabolism. This might be reflected 
locally as an alteration in the epithelial lipid barrier. The parallel changes between 
lipid metabolism and permeability suggests that one effect of ingested alcohol is to 
alter the lipid-containing permeability barrier of stratified squamous epithelium 
(Squier et al., 2003). 
Exposure to ethanol and environmental tobacco smoke induced high increase in 
cytochrome P450 2E1 (CYP2E1), an enzyme involved in the metabolism of 
xenobiotics, and inducible nitric oxide synthase (iNOS) protein. It also increased 3-
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nitrotyrosine, mtDNA damage, decreased cytochrome c oxidase protein as well as 
increasing HIF1alpha expression (Bailey et al., 2009). 
Several evidences of elevated glutamate and interaction between inflammatory 
cytokines and glutamate receptors may play a role in initiating certain cancers. 
Additionally, recent studies demonstrated an interaction between inflammation and 
glutamate receptors that may enhance tumour invasion and metastasis by affecting a 
number of cell-signalling mechanisms. Chronic inflammation appears as a major 
initiating mechanism in most human cancers, involving cell-signalling pathways, 
which responsible for cell cycling, cancer cell migration, invasion, tumour 
aggressiveness, and angiogenesis (Blaylock, 2013). 
The excessive growth of a tumour requires high rates of glucose uptake and 
glycolysis and continuous recruitment of new blood vessels. Pyruvic acid, the end 
product of glycolysis, exhibits strong angiogenic activity. Additionally, mRNA 
expression of fibroblast growth factor receptor-2 (FGFR2) and vascular endothelial 
growth factor (VEGF) was enhanced by pyruvic acid suggesting important role of 
pyruvic acid in angiogenesis of tumour growth and metastasis (Lee et al., 2001). 
Further study showed pyruvate suppressed the expression of inflammatory mediators 
such as IL1α, IL1β, IL6 and COX2 in a culture media. In addition, pyruvate 
suggested inhibiting inflammatory response by inhibiting the p38 MAPK activation 
(Aoki-Yoshida et al., 2013). 
It has been known that cancer cells produce excessive amounts of lactic acid. 
Researchers believe that without sufficient oxygen, cancer cells must revert to 
fermentation for their energy supply and this is what causes them to produce 
excessive lactic acid. Controversial hypothesis suggested cancer cells have 
dysfunctional mitochondria, which prevent their use of citric acid or Krebs cycle. 
Consequently, pyruvic acid, the end product of glycolysis, which normally would 
enter the mitochondria for its total combustion into energy, is instead converted to 
lactic acid. Evidence exists to support this hypothesis which, when acknowledged, 
could dynamically impact both cancer research and the treatment of all forms of 
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cancer (John, 2001). Recent results showed that lactic acid functions as an intrinsic 
inflammatory mediator that activates IL23-dependent and -independent pathways, 
resulting in the promotion of chronic inflammation in tumour microenvironments 
(Yabu et al., 2011). Lastly, Taurine and lysine can increase both GABA synthesis 
and effects, while aspartic acid and glutamic acid probably inhibit GABA effects 
(Nisijima and Ishiguro, 1995). 
Although a promising progress of metabolomic diagnostic profiles, the sensitivity 
and specificity cannot meet the demands of being a clinical useful tool for 
monitoring disease. The multifactorial nature of oncogenesis and the heterogeneity in 
oncogenic pathways make detection of all cancer of a particular organ implausible to 
be detected when using a single biomarker with high specificity and sensitivity. 
Therefore, prediction models to identify combinations of biomarkers that can identify 
OSCC patients among all the samples can improve the task. 
5.5.2 Metabolomics analysis of both meta-genes and the 45 
metabolites 
The corresponding functions of the highest score networks were; energy production, 
lipid and fatty acid metabolism and degradation processes emphasizing the 
significant metabolic activity of tumour relying on glycolysis as a main source of 
energy alternative to normal mitochondrial respiration and it has been previously 
linked to “Warburg effect” (Galluzzi et al., 2006, Seyfried and Shelton, 2010, 
Warburg, 1956) while lipid degradation and amino acid metabolism provide the 
sufficient fuel and environment for glycolysis.  
5.5.3 Direct integration between the 45 metabolomic profile 
and the 32 transcriptomic biomarkers of OSCC and 
HNSCC  
5.5.3.1 Glucose and gene biomarkers of OSCC and HNSCC 
Elevated levels of glucose transporters, especially of Glut-1 (SLC2A1), considers a 
common characteristic of human malignancies, including OSCC where both glucose 
transport and its metabolism might play a key role in the progression of OSCC. Both 
glucose transport and glucose metabolism determine the glycolytic tumour 
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phenotype, which considers a significant negative biomarker of prognosis and overall 
survival in patients with OSCC (Kunkel et al., 2003). This probably due to the 
enhanced glycolytic metabolism of more aggressive neoplastic cells (Rojas Ayala et 
al., 2010). Both GLUTI and GLUT3 reported an involvement in basal glucose uptake 
of extracranial head and neck tumours. The increased expression of these high-
affinity GLUT isoforms may be related to the growth maintenance of tumour tissue 
in cases of inadequate supply of substrate e.g., in poorly vascularized tumour areas 
(Mellanen et al., 1994). 
Glucose induces the upregulation of Pro-renin receptor (PRR) and its ligands, 
leading to increased IL1B and COX2 production via the angiotensin II-dependent 
pathway (Huang and Siragy, 2009). Further study demonstrated that high glucose in 
vitro might directly upregulate the expression of the inflammatory PTGS2 gene in 
pancreatic islets (Shanmugam et al., 2006). High glucose also reported significantly 
increasing reactive oxygen species (ROS) production, IL6 secretion, intercellular 
adhesion molecule-1 (ICAM-1) expression, and endothelial adhesiveness to 
monocytes (Chen et al., 2012). Similarly, results of ELISA showed the release of IL6 
and IL8 can be inhibited by high glucose. High glucose may decrease the innate 
immunity through relation to toll-like receptor TLR2 and TLR4 in cornea epithelium 
(Ni et al., 2011). Furthermore, D-Glucose in culture medium increased the release of 
human IL6 protein in fibroblasts from human skin that mediated by adenosine 
triphosphate (Solini et al., 2000). Moreover study report concluded that IL1B-
induced nitric oxide production in the presence of glucose is signalled by the p38 
pathway (Sprinkel et al., 2001).  
In human mesangial cells, D-Glucose indicated an increase expression of human 
SERPINE1 gene (Murphy et al., 1999, Jeong et al., 2011, Chen et al., 1998). 
Additional results specified stimulation of SERPINE1 promoter by both high glucose 
and glucosamine and that the hexosamine pathway may be involved in the regulation 
of gene expression by high glucose in glomerular mesangial cells (Goldberg et al., 
2000). 
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The production of MMP9 and collagen IV alpha protein can be regulated by high 
glucose, and the extracellular signal-regulated kinase ERK1/2 transduction pathway 
mediates such regulation (Bai et al., 2005). Further study suggested mechanism of 
redox-sensitive MMP9 expression by hyperglycaemia which may provide a rationale 
for antioxidant therapy to modulate diabetic vascular complications (Uemura et al., 
2001). In addition, a study reported that high glucose, IL6, and lipopolysaccharide 
act in concert to stimulate MMP1 expression. A study proposed that hyperglycaemia-
induced elevation in p38 MAPK activity and Activating transcription factor-2 (ATF-
2) phosphorylation which contribute to cyclic adenosine monophosphate (cAMP) 
response element activation and modulation of c-Jun and collagen I expression in 
osteoblasts (Zayzafoon et al., 2002). An attempt to elucidate underlying mechanisms, 
ERK and c-Jun N-terminal kinase (JNK) pathways were required for stimulation of 
MMP1 by IL6 and high glucose. Moreover IL6 and high glucose stimulated the 
expression of c-Jun, a key subunit of AP1 known essential for MMP1 transcription 
(Li et al., 2010). In cultured human endothelial cells, high glucose-induced 
overexpression of fibronectin and collagen IV were detected (Roy et al., 1990). 
Exposure of human renal fibroblasts to hyperglycaemic conditions resulted in the 
upregulation of the mRNA expression of both COL1A1and COL3A1where the 
increased transcription of COL1A1 mRNA by high glucose and exogenous TGF-β1 
was reflected by an increase in COL1A1 protein secretion (Lam et al., 2003).  
5.5.3.2 Ethanol and gene biomarkers of OSCC and HNSCC 
Recently, some studies have demonstrated that ethanol and its metabolites, including 
acetaldehyde, can induce the production of matrix metalloproteinases (MMPs) or 
inhibit the tissue inhibitors of metalloproteinases (TIMPs) in the liver (Arthur, 2000, 
Friedman, 2004, Purohit and Brenner, 2006). Ethanol and acetaldehyde directly 
stimulate the production of transforming growth factor beta-1 (TGFβ-1) and several 
extracellular matrix (ECM) constituents and also alter TIMPs/MMPs regulation by 
direct activation of hepatic stellate cells (HSCs), inducing liver fibrosis (Friedman, 
2004, Purohit and Brenner, 2006). In fact, acetaldehyde is a fibrogenic agent to the 
liver inducing the expression of type-1 and type-3 collagen genes in HSCs (Purohit 
and Brenner, 2006). In fibrotic liver, elevated level of TIMPs which play a 
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significant role in the regulation of MMPs activities, including the gelatinases 2 and 
9, stimulates both proliferation and migration (Pires et al., 2008). 
Additional findings on human breast cancer exhibited a higher amount of active 
MMP2 and MMP9 in their culture medium when exposed to ethanol giving new 
insights into the effects of alcohol on cell migration in breast cancer which might not 
due solely to an oestrogen-like activity of alcohol (Etique et al., 2006).  
The ability of ethanol and arachidonic acid (AA), as inducers of oxidative stress and 
key factors in alcoholic liver disease, to upregulate COL1A2 gene expression was 
identified where the oxidant stress derived from metabolism of ethanol or AA was 
found directly fibrogenic. Mechanistic studies reveal a critical role for H2O2 in the 
upregulation of COL1A2 expression by ethanol and AA. Moreover, COX-2 mediates 
the AA-mediated induction of COL1A2 expression (Nieto et al., 2000). Ethanol and 
acetaldehyde, also induced production of type I collagen (Masamune et al., 2010). 
Low doses of alcohol have been shown to alter the expression of the genes encoding 
tissue plasminogen activator (PLAT) and SERPINE1(Booyse et al., 1999), an OSCC 
biomarker, which play a critical role in oral cancer. 
5.5.3.2.1 Ethanol and pro-inflammatory cytokines (IL1B, IL6, and IL8) 
Increased serum levels of IL6, IL10 and, to a lesser extent IL8, declined in the few 
days after alcohol abstinence in patients with alcohol withdrawal syndrome. whilst 
serum IL8 level increased after alcohol intake in healthy subjects (Gonzalez-Quintela 
et al., 2000). Further study demonstrated that endotoxin-induced IL8 release is 
mediated by TNF alpha (Vandeventer et al., 1993). However, several studies 
reported acute alcohol, in vivo as well as in vitro, attenuating monocyte-derived 
chemokine production in response to a subsequent immune challenge. Hence, 
impaired IL8 induction upon an immune challenge is likely to contribute to 
compromised host defence after acute alcohol consumption (Szabo et al., 1999, 
Taieb et al., 2002, Mas et al., 2010). Additional results demonstrated that acute 
ethanol exposure can impair macrophage IL6 production and indicated that this 
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effect may result from ethanol-induced alterations in intracellular signalling through 
p38 and ERK1/2 (Goral et al., 2004, Norkina et al., 2008). 
The abovementioned variable levels of chemokine in relation to alcohol can be 
explained by a study findings represented that high concentrations of ethanol inhibit 
IL6-activated anti-apoptotic signal, though increasing the concentrations of IL6 can 
overcome such inhibitory effect. These findings suggest that elevated serum IL6 
levels in alcoholic liver disease may overcome the inhibitory effect of ethanol on 
IL6-mediated anti-apoptotic signals (Hong et al., 2002).  
Moreover, a study revealed that acute alcohol treatment activated STAT1/3 
signalling pathways, a significant cancer indicator, and induced suppressors of 
cytokine signalling levels in monocytes (Norkina et al., 2008), which support the 
evidence of alcohol consumption as a major risk factor in oral cancer. 
5.5.3.3 Glutathione and gene biomarkers of OSCC and HNSCC 
Glutathione (GSH) has multidisciplinary mechanisms in cancer. Oxidative stress 
may cause glutathione increased activation of pro-MMPs (pro-MMP1, 8, and 9) 
(Springman et al., 1990, Okamoto et al., 2001). Additional result suggested a 
developed synthetic Organoselenium compound, a glutathione conjugate, that 
inhibited colon carcinogenesis and COX1 and COX2 activities (Rao et al., 2001). 
Other study showed depletion of GSH increased expression of mouse IL1B mRNA, 
an OSCC biomarker, in mouse liver (Llacuna et al., 2009). Moreover, in fibroblasts 
from human lung, glutathione decreased expression of human IL6 mRNA that 
increased by human TGFB protein (Junn et al., 2000). Recent study demonstrated 
identification of IL6 as a tumour-derived molecule promoting GSH efflux in 
hepatocytes (Obrador et al., 2011). 
Additionally, glutathione reported to decrease transcription of SERPINE1 mRNA 
that is increased by oxidative stress of cells (Vulin and Stanley, 2004). Moreover, the 
regulation of SERPINE1 expression induced by cyclosporine A might be critically 
related with the intracellular glutathione and the ERK-MAPK pathway (Ho et al., 
2010). Further study demonstrated that STAT1 inhibition by prostaglandin 
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metabolite was abolished by N-acetylcysteine, glutathione, superoxide dismutase, 
and catalase (Chen et al., 2003). In addition, a glutathione reduction supposed to be 
necessary for antioxidant activity of CRYAB protein (Arrigo et al., 2007). 
5.5.3.4 Taurine and gene biomarkers of OSCC and HNSCC 
Anticancer effects of taurine, 2-aminoethanesulfonic acid, on cancer cells remain 
poorly understood. However, the protective properties of taurine have been attributed 
to taurine acting as a detoxifying agent against hypochloric acid by forming the 
stable and less toxic taurine chloramine (Quinn et al., 1996). Taurine diminished the 
induction of COX2 (Warskulat et al., 1997) and reduced mRNA of pro-inflammatory 
mediators encoding MMP9, fibronectin and the protein expression of COX2 (Song et 
al., 2011). Recent study reported a role of taurine in reduction of cell proliferation by 
apoptosis induction (Kim and Kim, 2013). 
Furthermore, taurine chloramine reported inhibition of superoxide anion, IL6 and 
IL8 in activated human leukocytes (Park et al., 1998), and from rheumatoid arthritis 
patients (Park et al., 2002, Chorazy-Massalska et al., 2004)  which attributed to the 
ability of this compound to diminish the activity of the major transcriptional 
regulators (NFκB and activator protein 1), which subsequently reduced the 
transcription of these cytokine genes (Kontny et al., 2000). 
Recently, results suggested that the anti-inflammatory effect of the taurine 
conjugated 5-aminosalicylic acid on experimental colitis is attributed to the 
inhibition of the IL1B-mediated NFκB activation and the taurine effect is through 
taurine chloramine potentiating the ability of 5-aminosalicylic acid to inhibit IL1B 
dependent NFκB activation (Joo et al., 2009). 
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5.5.3.5 Tryptophan and gene biomarkers of OSCC and HNSCC 
L-Tryptophan reduced the oxidative stress and expression of the TNF-α, IL6, IFN-γ, 
IL12p40, IL1B, IL17, IL8, and intracellular adhesion molecule-1, as well as 
increased expression of apoptosis initiators caspase-8 and BAX (Kim et al., 2010). 
Inversely, IL1B protein in cerebral ventricles has been increased the quantity of 
tryptophan in rat hippocampus (Song and Horrobin, 2004). 
5.5.3.6 Glutamate and gene biomarkers of OSCC and HNSCC 
Glutamate reported a significant reduction by IL1B protein (Kelly et al., 2001). IL6 
has been also shown to inhibit glutamate release in the cerebral cortex (D'Arcangelo 
et al., 2000). Further study, demonstrated IL6, IL11, and OSM cytokines, partially 
inhibited glutamate-induced neuronal death that mediated by STAT3 activation (Park 
et al., 2012). 
Neuronal COX2 expression was reported an elevation following brain insults via 
glutamatergic and inflammatory mechanisms (Strauss and Marini, 2002) and the 
elevation was reduced by 2-Arachidonoylglycerol (Zhang and Chen, 2008).  
5.5.3.7 GABA and gene biomarkers of OSCC and HNSCC 
GABA reported to decrease production of IL1B protein in plasma from diabetic 
mouse (Soltani et al., 2011). It also decreased expression of COX2 protein (Hou, 
2011). However, GABA increased expression of human MMP3 and MMP9 proteins 
where the influence of GABA stimulation on in vitro MMP production and the 
invasive ability of cancer cells was investigated using human prostate cancer cell line 
indicating the involvement of MMP activity in GABA-induced cancer cell invasion 
(Azuma et al., 2003). As a final point, CXCL12 was reported to enhance the effects 
of GABA (Luo et al., 2008, Bhattacharyya et al., 2008). 
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5.5.3.8 Choline, Creatine, Creatinine, Tyrosine, and Lactic acid 
interactions with genetic biomarkers of OSCC and HNSCC 
Choline reported to upregulate the expression of COX2 (Zhao et al., 2010) which 
increase the level of creatinine in blood (Norwood et al., 2000). Furthermore, mutant 
mouse IL6 gene (knockout) reported to decrease quantity of creatinine in mouse 
serum that is increased by ischemia reperfusion of kidney (Kielar et al., 2005). 
Additionally, human IL6 suggested to increase phosphorylation of L-tyrosine (Yin 
and Yang, 1994). To end with lactic acid/ MMPs interactions, extracellular matrix 
remodelling involving matrix metalloproteinases and wound lactate accumulation are 
considered as essential elements of tissue repair (Weinreich et al., 2011). 
Altogether, metabolites perform a complex interaction pattern with transcriptomic 
biomarkers of OSCC and HNSCC and supposed to be more complex when 
attempting to include all altered genes related to cancer disease generally (rather than 
only OSCC and HNSCC biomarkers) from the differentially expressed genes 
discriminating tumour from normal samples of the meta-analysis. However, certain 
biological pathways and cellular processes appear constantly dysregulated among the 
vast interactions, including lipid and amino acid metabolism, molecular transport, 
cell-to-cell signalling interaction, cellular movement, and immune cell trafficking. 




Metabolomic signature recruited NMR and MS spectral technologies to study the 
body end products in reflecting the behaviour of oral cancer and body response 
against it. The current review enriched our knowledge via better understanding of the 
characteristic behaviour of oral cancer and the alteration of system biology in 
response to the tumorigenic assault at metabolic level. Diagnostic tool biomarker 
from metabolomic signature of OSCC is under improving progress. 
“Metabolomics Analysis” tool from IPA, provided the common molecular pathways 
and cellular functions related to both metabolomic candidates harvested from the 
review study (45 metabolites) and the differential transcriptomic profile from the 
meta-analysis study conducted in chapter 3 (8995 genes). The corresponding 
pathways and functions of the networks revealed energy production, lipid and fatty 
acid metabolism and degradation processes highlighting the significant metabolic 
activity of oral cancer relying on glycolysis as a main source of energy alternative to 
normal mitochondrial respiration.   
Considering the transcriptional and metabolic changes that accompanied 
carcinogenic exposure during OSCC, direct biological integration highlighted 
ethanol, a major risk factor in oral cancer, created essential hub molecule in the 
interactive network. Acute alcohol intake suggested attenuating monocyte-derived 
chemokine production which responds to a subsequent immune challenge (Szabo et 
al., 1999, Taieb et al., 2002, Mas et al., 2010). Ethanol may influence proliferative 
cells, inducing oxidative DNA damage, altering the lipid-containing permeability 
barrier of stratified squamous epithelium, and can increase mitochondrial DNA 
damage (Ogden, 2005). It also induced the production of matrix metalloproteinases, 
stimulated both proliferation and migration or inhibited the tissue inhibitors of 
metalloproteinases (TIMPs) (Pires et al., 2008) as well as activation of STAT1/3 
signalling pathways , a significant cancer indicator (Norkina et al., 2008), as well as 
elevation of COL1A2 (Nieto et al., 2000), and SERPINE1 (Booyse et al., 1999). 
Moreover, ethanol decreased glutathione and cytochrome c oxidase protein level, the 
essential detoxifying agents, (Bailey et al., 2009). 
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Glucose, the highest interacting metabolite with correlative transcriptomic 
biomarkers, denoted to glycolysis, the unique cancer behaviour including oral cancer. 
Elevated level of glucose with its transporters, especially SLC2A1, considers a 
common characteristic of human malignancies, including HNSCC where both 
glucose transport and its metabolism may play a key role in the progression of OSCC 
(Kunkel et al., 2003). Glucose also increased IL1B, COX2 (Huang and Siragy, 
2009), production of reactive oxygen species (ROS) (Chen et al., 2012), IL6 
secretion (Solini et al., 2000), expression of human SERPINE1 (Murphy et al., 1999, 
Jeong et al., 2011, Chen et al., 1998), as well as the production of MMP1 (Zayzafoon 
et al., 2002), MMP9 (Bai et al., 2005), fibronectin, COL1A1, and COL4A1 (Lam et 
al., 2003). 
Elevation of glutathione, taurine, tryptophan, and L-glutamic acid levels constitute 
the main antioxidant and detoxification system essential to neutralise and remove the 
toxic by-products that produced during tumourigenesis. Best known role of 
glutathione enzymes is as cell housekeepers in the detoxification of xenobiotics 
(Scholz et al., 1989). Glutathione inhibited COX1 and COX2 activities (Rao et al., 
2001), decreased transcription of SERPINE1 mRNA that increased by oxidative 
stress of cells (Vulin and Stanley, 2004), decreased expression of human IL6 and 
IL1B mRNA (Junn et al., 2000, Llacuna et al., 2009). Taurine acts as a detoxifying 
agent against hypochloric acid by forming the stable and less toxic taurine 
chloramine (Quinn et al., 1996). Taurine also diminished the induction of COX2 
(Warskulat et al., 1997), reduced mRNA of pro-inflammatory mediators encoding 
MMP9, and fibronectin (Song et al., 2011), as well as inhibited the production of 
IL6, IL8, and IL1B (Park et al., 1998, Joo et al., 2009). L-Tryptophan established a 
reduction of oxidative stress and the expression of interleukins IL6, IL1B and IL8 
(Kim et al., 2010). Similarly, glutamic acid  exhibited a declination by IL1B protein 
(Kelly et al., 2001) and IL6 (D'Arcangelo et al., 2000). 
Comprehensive reading of the aforementioned simultaneous transcriptional and 
metabolic interactive changes that accompanied tumourigenesis of OSCC revealed 
an intimate relation between genetic and metabolic system biology during 
carcinogenic transformation. To obtain meaningful and comprehensive 
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understanding, more efforts required to identify additional key players of a larger 
interactive network with a larger review study and validation to confirm the role of 
each player in this complex context. However, the current analysis already 
highlighted interleukins, MMPs, COX2, SERPINE1, and STAT1 as major key 
players represented the transcriptomic platform transecting specific players from the 
platform of metabolome which include; ethanol and its metabolites establishing the 
carcinogenic factor, glucose and its relative metabolites as representative by-products 
of OSCC, glutathione, creatine, glutamic acid, taurine, glycine, tryptophan, and 
pyruvic acid as a reparative antioxidant and detoxifying elements against 
tumorigenic assault of OSCC (Figure 5.6).     
Such an interactive pattern may represent a clinically useful surrogate of the presence 
of OSCC and can be used to form the basis of diagnostic device of OSCC. Further 
investigation of the interactive network is required. Additionally, to get more 
comprehensive and complete story, further expanding of the interactive network is 
required by including all altered genes involved in cancer disease from the meta-
analysis study (401genes rather than only 32 OSCC and HNSCC biomarkers that 
included in the current analysis) for integration with the 45 metabolomic OSCC 
biomarkers (biological level integration). 
Clinical application of the current interactive signature as diagnostic tool can also 
carried out by simple cross-correlation of both metabolomic and transcriptomic 
candidate biomarkers in the interactive model across the examined samples (data 
level integration). A combination of part or all transcriptomic and metabolomic 
molecules of the interactive network in figure 5.6 can be applied on clinical 
independent samples to validate it’s efficacy as discriminative tool of OSCC. 
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Chapter 6: Summary and Discussion 
6.1 Rational and objectives of the project 
The pathogenic pathways that contribute to OSCC remain poorly characterised and 
the critical factor in the lack of prognostic improvement is that a significant 
proportion of cancers initially are asymptomatic lesions and are not diagnosed or 
treated until they reach an advanced stage. Hence, a clinically applicable gene 
expression signature is in high demand and improved characterization of the OSCC 
gene expression profile would constitute a substantial progress. For OSCC, possible 
themes that might be addressed using microarray data include distinguishing the 
disease from normal at the molecular  level; determining whether specific biomarkers 
or profiles are predictive for tumour behaviour; and  identifying  biological pathways 
necessarily altered in tumourigenesis, potentially illuminating novel therapeutic 
targets. However, OSCC is a heterogeneous disease, making diagnostic biomarker 
development difficult. Although this phenotypic variation is striking when one 
compares OSCC from different geographic locales, little is known about the 
underpinning biological mechanisms. 
The primary aim of this thesis is to investigate metabolomic and transcriptomic 
profiles using multiple bioinformatics approaches and biological annotation tools in 
an attempt to identify specific biomarkers and prediction models for OSCC from 
each profile as well as from the interface outcomes of integrating the two platforms. 
Additional aims of the thesis go further to identify the mechanisms underlying the 
biological changes during tumorigenic transformation of OSCC, as well as to 
determine the biological processes underpinning the heterogeneity of the disease 
among populations. 
OSCCs of UK and Sri Lanka have different aetiological factors and clinical 
phenotypes. One aim of this project is to identify gene expression differences 
between the two groups of tumours as a preparatory point to understand their 
biological diversity. The availability and free access of the wide range bioinformatics 
packages from Bioconductor in R along with the existence of IPA tools as a powerful 
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biological annotation tools, provide a great enhancement to analyse the raw data 
available from both countries.  
Furthermore, to investigate the interactive networks created by merging metabolomic 
and transcriptomic profiles to highlight the significant molecular and cellular 
biofunctions, pathways, and biomarkers distinguishing OSCC from normal oral 
mucosa. The pattern may represent a clinically useful surrogate for the presence of 
OSCC which might help in deciphering some of the obscure multifaceted 
mechanisms underlying carcinogenesis of OSCC which emerged from dysregulated 
genetic and metabolic system of the body.   
6.2 Summary of the findings 
This thesis has described findings from genome wide expression analysis, recruiting 
various bioinformatics approaches and biological annotation tools for the analysis of 
molecular behaviour of OSCC. The study reported the discovery of a number of 
potential candidate genes, metabolites, and a comprehensive integrative approach for 
further research. This final chapter presents a summary of the findings, how they 
relate to the molecular field of OSCC diagnosis, and a possible direction for future 
work based on these findings. 
6.2.1 Common gene expression profiling reveals biological 
alterations involved in early tumourigenesis of oral 
squamous cell carcinomas (Chapter 2) 
The review study specified several genes and pathways exhibiting 
substantially altered expression in cancerous versus non-cancerous states 
across studies. Figure 2.4 displayed 76 (over 20% of the total common genes) 
genes associated with OSCC and HNSCC where 27 of them are verified biomarkers 
(Figure 2.6). Notably, some of these changes, although identified in multiple studies, 
may also present in other sample studies which are not identified, basically due to the 
absence of probes for these genes in the platforms used for these studies. Arrays used 
by various studies contained probes for as few as 384 genes to as many as over 
47,000 transcripts (Table 2.1). These results were encouraging considering the 
heterogeneity of the studies where the samples are collected. 
  Chapter 6 
225 
 
The current review pointed out a popular significant inaccuracy among the studies 
using microarray technologies reflected by the underestimation of the tumour origin 
of HNSCC during sample collection. A study used microarray design demonstrated 
that HNSCCs originating from different anatomic locations can exhibit various 
behaviours which gave a conclusion that HNSCC originating from different 
anatomic sites share consistent changes in gene expression when comparing primary 
tumours to normal adjacent mucosa, where these common changes most likely 
reflect alterations required for tumour development. In contrast, once a tumour has 
developed, tumour-host interactions at different anatomical sites are likely 
responsible for the site-specific signatures associated with aggressive versus non-
aggressive disease. Hence, predictions of outcomes based on gene expression 
profiling are therefore heavily influenced by the anatomical site of the primary 
tumour (Belbin et al., 2008). 
The top differentially expressed gene in 11 out of 28 studies is considered a poor 
outcome as a unique identifier/s for OSCC. The weakness of the tumour profiling of 
the list of common genes originates primarily from limited sample sizes and 
heterogeneity in experimental design and execution as well as the differences in the 
size of the final set of genes published by the individual studies. 
Published data from such studies should not viewed as endpoints of research 
accomplishments, but rather as screening tools for identifying potential genes for 
validation and further investigation. Nevertheless, the capability to measure the 
expression of thousands of genes simultaneously gives researchers a powerful 
method to analyse global genetic events responsible for HNSCC progression (Choi 
and Chen, 2005). 
This review did not access the expression raw data of most of the studies, and 
therefore did not consider how different fold changes in gene expression might 
impact different clinical outcomes or biological pathways. Ideally, all published 
studies containing DNA microarray analyses should deposit their raw expression 
data in publically accessible repositories (e.g., NCBI GEO, Array express, others), to 
permit accomplishment of systematic and comprehensive meta-analysis. For this 
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reason, additional attempt was carried out (chapter 3) to perform meta-analysis 
profiling OSCCs relative to normal mucosa by recruiting the same bioinformatics 
approach on multiple raw data sets. 
Conclusion of the current review suggests not only relying on the final set of genes 
that published by the individual studies, but to access the raw data of each study and 
start subsequent analysis from that stage using unified bioinformatics approaches to 
acquire useful and complete understanding of the systems biology and to identify the 
subsequent dysregulated biological pathways, molecular functions, and processes. 
6.2.2 Detection of a robust gene signature for oral squamous 
cell carcinoma by integrating multiple microarray 
datasets (Chapter 3) 
The successful discriminative results of bioinformatics approaches highlight the 
advantage of meta-analysis (employed large and wide range samples from different 
research centres) in creating more robust and comprehensive predictive signature. 
The results proved that SAM tool (siggenes package) is capable to elect the top 
discriminatory genes beyond level of FDR value = 0, with a model consisted of 8 
genes showed the best discriminating power among the prediction models. Further 
validations of the model of 8 genes with additional external datasets are required to 
confirm it’s specificity in discriminating OSCC from other tumour types of the body 
as well as other molecularly similar inflammatory processes (e.g., Atherosclerosis 
and periodontitis). If this model proves its ability in providing a unique signature of 
OSCC, a novel discovery will be reported for this analysis in the diagnosis of OSCC 
with emerging of new potential therapeutic targets.    
The variability in the number of genes forming the final set of discriminating model 
following adjustment of specific criteria highlighted the impact of using different 
selected criteria and bioinformatics approaches in formulating the final set of gene 
discriminators. Hence, the result of current study suggests dealing with fold change 
as cut-off criteria with caution, especially in determining the final set of genes and 
identifying the subsequent dysregulated biological pathways, molecular functions, 
and processes, since molecular relationships in the system biology comprise not only 
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activation or inhibition of expression, but also protein-protein interactions, DNA-
protein interactions and activation, localization, and inhibition of the corresponding 
proteins (Debily et al., 2009), and it is not surprising that microarrays results 
(especially those with a high fold change cut-off value criteria) may fail to identify 
some of the hub genes as significantly differentially expressed among the tumour 
versus normal samples. These genes might play a major role through protein 
activation, for instance. Instead, their modulations may be very subtle and below the 
threshold for reliable detection of differences of the microarray platform despite its 
high sensitivity (Debily et al., 2009). Alternatively, study suggestion is to consider 
comprehensive inclusion of the whole expressed genes, accompanied with using a 
Biological Annotation tool (like; IPA, KEGG, STRING, etc.) in an attempt to obtain 
a true and complete understanding of the biological concept of the system biology 
from which the sample extracted during collection, considering the fact that genes 
are highly interchangeable. However, setting a low threshold for a significant 
correlation between genes will result in the inclusion of many spurious links, 
whereas a high threshold will control the false-positive rate at the expense of 
omitting many genuine edges. For this reason, the suggestion of this study is the 
production of two separate sets; the one with less stringent criteria including large 
amount of genes is recruited for the purposes of subsequent biological annotation 
(like for identifying the dysregulated pathways and the affected transcriptional 
regulators), after which selection of a specific disease and its relative pathways will 
be focused on. Whilst the second set comprising a small number of genes can be 
recruited for the identification and monitoring of a specific tumour state (models of 
diagnostic, assessment, and prognostic biomarker). 
Both common genes of the review study and the meta-genes of the meta-analysis 
study presented a significant common gene alteration. Among the differentially 
expressed genes, several potential diagnostic biomarkers were identified which have 
previously been reported in OSCC and HNSCC (Table 3.6). Notably, elevation of 
seven members of collagens (COL1A2, COL1A1, COL4A1, COL5A2, COL4A2, 
COL5A1, and COL11A1), six members of MMPS (MMP1, MMP3, MMP9, 
MMP10, MMP12, and MMP13), and five members of C-X-C motif chemokines 
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(CXCL1, CXCL6, CXCL9, CXCL10, and CXCL11) were elevated which 
accompanied with three keratins repression (KRT4, KRT13, and KRT15). Additional 
potential tumour key players, including elevation of SPP1, LAMC2, IL8, IFI6, 
ISG15, MYO1B, SERPINE1, BS2, AIM2, and PTHLH along with repression of 
CRNN, MAL, TGM3, EMP1, CRISP3, PPP1R3C, ECM1, IL1RN, SCEL, SPINK5, 
TGFBR3, CEACAM5, CEACAM7, TGM1, and TYRP1 genes were observed in 
tumour relative to normal cohorts. 
6.2.3 Gene expression profiling reveals biological pathways 
responsible for phenotypic heterogeneity between UK 
and Sri Lankan oral squamous cell carcinomas 
(Chapter 4) 
The gene expression profiles of UK and Sri Lankan OSCC compared to normal oral 
mucosa are similar in many respects to other oral cancer expression profiles reported 
in the literature and were mainly similar to each other. Great differences in the 
expression profiles between OSCC and normal tissue than between OSCCs of the 
two populations were observed. However, molecular heterogeneity in each tumour 
populations (such heterogeneity is more marked in UK OSCC, which displays a wide 
range of clinical behaviour). Such molecular heterogeneity may act to reduce 
differences seen in expression profiles of the two populations. Despite that, IPA 
showed common perturbed canonical pathways which indicate that the development 
of OSCCs is mediated, to some extent by similar biological pathways despite the 
differences related to race, ethnicity, lifestyle, and/or exposure to environmental 
carcinogens. 
IPA comparison core analysis of normal as well as tumour samples between the two 
populations displayed highly activated “Cell-mediated Immune Response” processes 
in Sri Lankan normal and tumours relative to UK cohorts which presumably play a 
key role in resistance of Sri Lankan patients to the invasiveness, metastasis, and 
recurrence of the disease. Sri Lankan consumption of spicy food, including 
curcumin/curry in specific, might be responsible for this activation along with 
downregulation of growth factor receptors (EGFR, IGFR, RARA, EPOR, THRA, 
and NMUR2) that might as well, contributed in the phenotypic behaviour of the two 
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tumour groups. The same findings were observed comparing tumours from the two 
population groups which confirms constant existence of the events between the two 
populations.  
Smaller number of either elevated or repressed genes in either UK or Sri Lankan 
OSCC but not both contributed to a number of differentially regulated cancer-
associated pathways and specifically to the aggressive behaviour of UK tumours; 
Including upregulation of MMP3, POSTN, LAMC2, and downregulation of DUSP1 
and SLPI in UK. Conversely, CD80 upregulation and TWIST1 downregulation, anti-
invasive associated incidents, observed in Sri Lankan tumours. It may be the case 
that expression differences in key pathways contribute to the observed phenotypic 
differences and so expression differences described here may underpin some of the 
phenotypic differences between UK and Sri Lankan OSCC. Tumour heterogeneity, 
technical variation and data processing may all have an effect on the expression 
profiling data and all such variables should consider when interpreting the results. 
Differences in tumour expression profiles of the two populations highlighted a few 
potentially genes; including lower expression of CDKN1B in UK tumours, a 
phenomenon associated with high-risk tumours only, along with lower expression of 
PSIP1, SAMSN1, CCNG2, and NCOA2 genes which  played a protective role in 
tumorigenic process. Likewise, higher expressions of CCT2 and DHCR24 in UK 
tumours were contributed in rapidly proliferating tumour and melanoma metastases 
respectively.  
6.2.4 Evidences support theory that cancer is a metabolic 
disease 
Numerous results displayed in this study support the theory considering cancer as a 
metabolic disorder (Warburg effect) (Galluzzi et al., 2006, Seyfried and Shelton, 
2010, Warburg, 1956). The top dysregulated pathways in each and both UK and Sri 
Lankan populations (Chapter 4) showed that defects in mitochondrial respiration 
could be the primary reason for induction of tumorigenic transformation reflected in 
dysregulation of oxidative phosphorylation and mitochondrial dysfunction pathways, 
shifted tumour cells to glycolysis affecting citrate cycle with remarkable 
  Chapter 6 
230 
 
dysregulation of fatty acids metabolism. As consequent to the above defects, 
significant alteration in gene expression can be explained as an attempt from the 
tumour cells to cope with the initial disorder, repair, and overcome the fatal causative 
event(s). Further studies with a large size and wide range of populations are required 
to highlight and validate the above phenomena. 
The review study of metabolic profile (Chapter 5) showed elevated glucose level 
along with significantly increased fatty acids metabolism which has been previously 
linked to “Warburg effect” (Galluzzi et al., 2006, Seyfried and Shelton, 2010, 
Warburg, 1956), and assumes that tumours are relied on glycolysis as a main source 
of energy, even in the presence of oxygen. Many solid tumours show an increased 
glycolytic metabolism, which has, for OSCC, been associated with the over-
expression of glucose transporters especially Glut-1 (SLC2A1) (Kunkel et al., 2003), 
which showed an elevation in the current study as well. 
Furthermore, IPA “Metabolomics Analysis” of combined meta-genes and the 45 
metabolites (Chapter 5) displayed energy production, lipid and fatty acid metabolism 
and degradation processes among the corresponding functions of the highest score 
networks emphasizing the significant metabolic activity of tumour relying on 
glycolysis as a main source of energy alternative to normal mitochondrial respiration 
which has been previously linked to “Warburg effect” (Galluzzi et al., 2006, Seyfried 
and Shelton, 2010, Warburg, 1956) while lipid degradation and amino acid 
metabolism provide the sufficient fuel and environment for glycolysis. 
6.2.5 Gene expression profile of perineural invasive versus 
non- invasive tumour samples from UK 
Three genes appeared over-expressed in perineural invasive tumours of UK group; 
PGM1, ENO2, and ILK. ENO2 (enolase2) reported  a prognostic biomarker in 
metastatic, high grade, and invasiveness of various types of cancer, including breast, 
lung, bladder, renal, prostate, colorectal cancer, and OSCC (Abba et al., 2005, van 
Zandwijk et al., 1992, Di Carlo et al., 1990, Vandepol et al., 1994, Buzaid et al., 
1994, Rasmuson et al., 1993, Jacobsen et al., 1990, Nishihara et al., 2009, Zufferey et 
al., 2001, Famulski et al., 2001). ILK has been associated with multiple cellular 
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functions including cell migration, proliferation, and signal transduction. Recent 
studies reported ILK as a biomarker associated with laryngeal, lung, colon, ovarian 
cancer as well as metastatic behaviour of gastric carcinoma (Ito et al., 2003, Wu et 
al., 2006, Takanami, 2005, Bravou et al., 2006, Du et al., 2008, Loessner et al., 
2009).  
GO term (Gene Ontology, www.geneontology.org/) showed both PGM1 and ENO2 
enzymes involved in magnesium ion binding whereas the all three genes involved in 
phosphorylation and interconversion activities of certain proteins and amino acids 
like phosphopyruvate hydratase, lyase, phosphoglucomutase, isomerase, and 
phosphotranferase.  
6.2.6 Gene expression profile of high-stage versus early and 
low- stage tumour samples from both UK and Sri 
Lankan tumours 
SAM supervised analysis identified 12 genes separating “high stage” from “low and 
early stage” OSCCs of both population groups. Most of genes appeared over-
expressed in high stage tumours and associated with different cancer types and 
cellular processes associated with tumours. 
Most of differentially upregulated genes in high stage tumours exhibited involvement 
in variant biological processes crucial in driven tumour lesion to late stage and 
metastasis with distinct roles in cellular migration, remodelling, outgrowth, invasion, 
differentiation, colony formation, cell cycle progression, activation, proliferation, and 
angiogenesis. 
Knockdown of SEMA3F (member of semaphorins) cancer cells of breast rescued the 
aggressive phenotypes and tumour invasion by inducing suppressive cell 
microenvironment (Xiong et al., 2012) as well as pancreatic (Matsushita et al., 2007). 
An extensive review explained how Scatter factors and semaphorins, together with 
their receptors, help to orchestrate metastasis programme of neoplastic cells 
(Trusolino and Comoglio, 2002).  
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Suswam group (Suswam et al., 2005) noticed that KHSRP involved in IL8 RNA 
stabilization, which plays an integral role in promoting the malignant phenotype in 
breast cancer (Chen et al., 2001, Gherzi et al., 2004). 
Jauliak group identified NFAT5 isoform expressed in invasive human ductal breast 
carcinomas and participate in promoting invasion of human breast and colon 
carcinomas. The transcriptional activity of NFAT5 is induced by alpha-6 and beta-4 
integrin signalling clustering in the presence of chemo-attractants, resulting in 
enhanced cell migration and is involved in promoting carcinoma invasion (Jauliac et 
al., 2002). Further study demonstrated NFAT5 contribution in progression of 
gastrointestinal cancer (Chen et al., 2011b).   
CDC42BPA plays a role in the regulation of cytoskeleton reorganization and cell 
migration (Tan et al., 2008a). It has been demonstrated that invasion can be 
generated by Cdc42-MRCK signalling (Wilkinson et al., 2005) as well as tumour 
progression (Benitah et al., 2004). 
6.2.7 Review study of metabolic profile  
Metabolomic signature recruited NMR and MS spectral technologies to study the 
body end products in reflecting the behaviour of oral cancer and body response 
against it. The current review enriched our knowledge via better understanding the 
characteristic behaviour of oral cancer and the alteration of system biology 
responding to tumorigenic assault at metabolic level. Diagnostic tool biomarker from 
metabolic signature of OSCC is continuously under improving progress. 
Among the metabolites identified commonly altered in the studies of review, include 
several involved in anti-oxidation, free radical scavenging, detoxification of 
xenobiotics and chemicals, (glutathione, creatine, glutamic acid, taurine, glycine, 
tryptophan, and pyruvic acid), fatty acid metabolism, lipid degradation, and 
glycolysis. These molecular pathways and cellular functions are typical signature for 
oral cancer and already described by previous studies. Glutathione- mediated 
detoxification, methylglyoxal detoxification pathways emphasise the crucial role of 
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glutathione which also needed for the detoxification of methylglyoxal, a toxin 
produced as a by-product of metabolism. 
Several detected metabolic markers were involved in associated network function 
(Figure 5.2), signalling and metabolic pathways (5.4.2.3), and biomarker analysis 
(Figure 5.3) representing glucose and glutathione metabolites as hub nodes 
associated with detoxification process, glycolysis, energy production, and amino acid 
metabolism. Biomarker analysis identified both glucose and glutathione over-
expression as verified biomarkers of other types of cancer along with sarcosine 
metabolite (Figure 5.3). 
Elevated glucose level along with significantly increased fatty acids metabolism may 
be linked to the unique behaviour of oral cancer. This represents a typical signature 
in cancer patients, and it has been previously linked to “Warburg effect” (Galluzzi et 
al., 2006, Seyfried and Shelton, 2010, Warburg, 1956), which assumes that tumours 
are relied on glycolysis as a main source of energy, even in the presence of oxygen. 
Many solid tumours show an increased glycolytic metabolism, which has, for OSCC, 
been associated with the over-expression of glucose transporters, especially Glut-1 
(SLC2A1) (Kunkel et al., 2003), which showed an elevation in the current study as 
well. 
The multifactorial nature of oncogenesis and the heterogeneity in oncogenic 
pathways make detection of all cancers of a particular organ unlikely detected when 
using a single biomarker with high specificity and sensitivity. Therefore, prediction 
models to identify combinations of biomarkers that can identify OSCC patients 
among all the samples can improve the task. 
6.2.8 IPA metabolomics analysis of both meta-genes and the 
45 metabolites 
“Metabolomics Analysis” tool from IPA, provided the common molecular pathways 
and cellular functions related to both metabolomic candidates harvested from the 
review study (45 metabolites) and the differential transcriptomic profile from the 
meta-analysis study conducted in chapter 3 (8995 genes). The corresponding 
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pathways and functions of the networks revealed energy production, lipid and fatty 
acid metabolism and degradation processes highlighting the significant metabolic 
activity of oral cancer relying on glycolysis as a main source of energy alternative to 
normal mitochondrial respiration. 
6.2.9 Direct integration between the 45 metabolomic profile 
and the 32 OSCC and HNSCC transcriptomic 
biomarkers 
Considering the transcriptional and metabolic changes that accompanied 
carcinogenic exposure during OSCC, direct biological integration highlighted 
ethanol, a major risk factor in oral cancer, created essential hub molecule in the 
interactive network. Acute alcohol intake suggested attenuating monocyte-derived 
chemokine production responding to a subsequent immune challenge (Szabo et al., 
1999, Taieb et al., 2002, Mas et al., 2010). Ethanol may influence proliferative cells, 
inducing oxidative DNA damage, altering the lipid-containing permeability barrier of 
stratified squamous epithelium, and can increase mitochondrial DNA damage 
(Ogden, 2005). It also induced the production of matrix metalloproteinases, 
stimulated both proliferation and migration or inhibited the tissue inhibitors of 
metalloproteinases (TIMPs) (Pires et al., 2008) as well as activation of STAT1/3 
signalling pathways , a significant cancer indicator (Norkina et al., 2008), as well as 
elevation of COL1A2 (Nieto et al., 2000), and SERPINE1 (Booyse et al., 1999). 
Moreover, ethanol decreased glutathione and cytochrome c oxidase protein level, the 
essential detoxifying agents, (Bailey et al., 2009). 
Glucose, the highest interacting metabolite with correlative transcriptomic 
biomarkers, denoted to glycolysis, the unique cancer behaviour including oral cancer. 
Elevated level of glucose with its transporters, especially SLC2A1, considers a 
common characteristic of human malignancies, including HNSCC where both 
glucose transport and its metabolism may play a key role in the progression of OSCC 
(Kunkel et al., 2003). Glucose also increased IL1B, COX2 (Huang and Siragy, 
2009), production of reactive oxygen species (ROS) (Chen et al., 2012), IL6 
secretion (Solini et al., 2000), expression of human SERPINE1 (Murphy et al., 1999, 
Jeong et al., 2011, Chen et al., 1998), as well as the production of MMP1 (Zayzafoon 
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et al., 2002), MMP9 (Bai et al., 2005), fibronectin, COL1A1, and COL4A1 (Lam et 
al., 2003). 
Elevation of glutathione, taurine, tryptophan, and L-glutamic acid levels constitute 
the main antioxidant and detoxification system essential to neutralise and remove the 
toxic by-products that produced during tumourigenesis. Best known role of 
glutathione enzymes is as cell housekeepers in the detoxification of xenobiotics 
(Scholz et al., 1989). Glutathione inhibited COX1 and COX2 activities (Rao et al., 
2001), decreased transcription of SERPINE1 mRNA that increased by oxidative 
stress of cells (Vulin and Stanley, 2004), decreased expression of human IL6 and 
IL1B mRNA (Junn et al., 2000, Llacuna et al., 2009). Taurine acts as a detoxifying 
agent against hypochloric acid by forming the stable and less toxic taurine 
chloramine (Quinn et al., 1996). Taurine also diminished the induction of COX2 
(Warskulat et al., 1997), reduced mRNA of pro-inflammatory mediators encoding 
MMP9, and fibronectin (Song et al., 2011), as well as inhibited the production of 
IL6, IL8, and IL1B (Park et al., 1998, Joo et al., 2009). L-Tryptophan established a 
reduction of oxidative stress and the expression of interleukins IL6, IL1B and IL8 
(Kim et al., 2010). Similarly, glutamic acid  exhibited a declination by IL1B protein 
(Kelly et al., 2001) and IL6 (D'Arcangelo et al., 2000). 
Profound reading of the simultaneous transcriptional and metabolic interactive 
changes that accompanied tumourigenesis of OSCC revealed an intimate relation 
between genetic and metabolic system biology during carcinogenic transformation. 
To obtain meaningful and comprehensive understanding, more efforts required to 
identify additional key players from a larger interactive network alongside larger 
review study and validation to confirm the role of each player in this complex 
context. However, the current analysis already highlighted interleukins, MMPs, 
COX2, SERPINE1, and STAT1 as major key players from transcriptomic profile 
platform transecting specific players from the platform of metabolome which 
include; ethanol and its metabolites establishing the carcinogenic factor, glucose and 
its relative metabolites as representative by-products of OSCC, glutathione, creatine, 
glutamic acid, taurine, glycine, tryptophan, and pyruvic acid as a reparative 
  Chapter 6 
236 
 
antioxidant and detoxifying elements against tumorigenic assault of OSCC (Figure 
5.6).   
Such an interactive pattern may represent a clinically useful surrogate of the presence 
of OSCC and can be employed to form the basis of diagnostic device of OSCC. 
Further investigation of the interactive network is required. Additionally, to get more 
comprehensive and complete story, further expanding of the interactive network is 
required by including all altered genes involved in cancer disease from the meta-
analysis study (401genes rather than only 32 OSCC and HNSCC biomarkers that 
included in the current analysis) for integration with the 45 metabolomic OSCC 
biomarkers (biological level integration). Clinical application of the current 
interactive signature as diagnostic tool can also carried out by simple cross-
correlation of both metabolomic and transcriptomic candidate biomarkers in the 
interactive model across the examined samples (data level integration). 
6.3 Suggestion for the future work 
The various findings of this investigation have also raised new questions which 
should be addressed in the future studies to fully understand the mechanisms 
involved in the tumorigenic transformation of OSCC, as well as to improve the 
predictive models for diagnosis, assessment, and prognosis of the disease. Some of 
the suggestions are listed below: 
1- Development of a new meta-analysis study through implementation of a larger 
number of samples as well as establishment and investigation of the signatures 
responsible for the invasion, recurrence, and metastasis of OSCC. 
2- Further validation of the predictive models (especially the models consisting of 
the 8 and 38 genes) using different methods to prepare for their employment as 
diagnostic tool for OSCC. 
3- Additional assessment and validation of the harvested gene expression models 
responsible for the discrimination of perineural invasion from non- or lesser-invasive 
OSCC. 
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4- Additional comprehensive investigation of the interactive networks correlating 
metabolic and transcriptomic profiles to improve and further understand the 
interactive signature of what can represent a clinically useful surrogate of the 
presence of OSCC and can be employed to form the basis of the diagnostic device of 
the disease. 
5- Collection of additional wide range samples from Indo-Asian and Western 
countries to validate the results defining the heterogenic phenotypic behaviours of 
OSCC across distinct populations. 
6- Establishment of a new meta-analysis study differentiating gene expression profile 
of LCM samples and those harvested from tumour bulk samples of OSCC in an 
attempt to understand the tumour-stromal interaction of the disease. 
7- As various results in the current work suggested a defect in mitochondrial function 
which might be responsible, or even, the primary cause of tumour, further studies 
required to measure gene expression profiles of tumour patients who receive a 
therapeutic dietary supplement accompanied with a periodic fasting. 
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